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Afferent chemoreceptor activity was recorded from the peripheral
cut end of the carotid sinus nerve in pentobarbitone anaesthetized
cats. The effects of purines, peptides and ouabain on chemosensory
activity were studied.
Purines. It was found that intracarotid injections of adenosine;
AMP; ADP; ATP; CoA; the adenosine analogues: N6-methyladenosine,
2'-chloroadenosine, 3'-deoxyadenosine but not 2'-deoxyadenosine; cyclic
AMP; dibutyryl cyclic AMP increased spontaneous chemoreceptor
discharge. The ATP analogues, crg-methylene ATP decreased spon¬
taneous chemoreceptor discharge, whereas the g-y-methylene ATP
caused a slight increase in discharge. Adenine and the purine nucleo¬
sides inosine and guanosine had little or no effect on the discharge.
The pyrimidine nucleosides cytidine and uridine were also studied and
had little or no effect on spontaneous chemoreceptor discharge.
Intracarotid injection of theophylline transiently depressed spontaneous
chemosensory activity and potentiated the action of adenosine.
Intracarotid injection of dipyridamole increased spontaneous chemoreceptor
discharge and the chemoexcitation evoked by low doses of adenosine
and ATP was potentiated whereas that caused by high doses was
inhibited and associated with a decrease in arterial blood pressure.
Dipyridamole administered intravenously increased the chemoexcitatory
actions of both low and high doses of adenosine. Responses evoked by
sodium cyanide were slightly and variably modified during an adenosine
infusion and those evoked by acetylcholine and dopamine were increased.
It is concluded that adenosine increases chemoreceptor activity by acting
on an extraeellularly located receptor, which is theophylline-insensitive
and probably of the R-site type.
X.
Peptides. The opioid peptides, methionine-enkephalin, leucine-
enkephalin and B-endorphin inhibited spontaneous chemoreceptor dis¬
charge. B-endorphin was a less potent inhibitor and the inhibition it
evoked was very similar to that of morphine. Chemoinhibition induced
by B-endorphin was greatly reduced by naloxone; the inhibition
associated with the enkephalins was also decreased, although not so
markedly. Vasoactive intestinal polypeptide in low doses decreased
spontaneous chemoreceptor activity whereas higher doses of the same
substance increased chemoreceptor activity as did cholecystokinin
octapeptide. Substance P was unable to overcome the chemoinhibitory
effect of methionine-enkephalin. It is concluded that peptides such
as methionine-enkephalin, leucine-enkephalin and vasoactive intestinal
polypeptide, known to be present in the carotid body as well as
others present in the brain, such as B-endorphin and cholecystokinin
octapeptide, influence carotid body chemoreceptor activity. The
opioid peptides act via naloxone-sensitive receptors.
Ouabain. Ouabain increased spontaneous chemoreceptor activity.
During infusions the excitation was followed by a decline in discharge
to frequencies near the control level. During the excitation the
stimulatory action of sodium cyanide, carbon dioxide-equilibrated Locke
solution and acetylcholine were potentiated, as was the chemoinhibition
induced by dopamine. During the post-excitatory phase the responses
evoked by these substances were reduced or abolished. It appears that
ouabain has two distinct actions on the carotid body chemosensory
activity, a 'sensitizing' followed by a 'desensitizing' phase.
The possibility that the various substances investigated act via
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s.e. mean standard error of mean
SIF small intensively fluorescent
SP substance P
Torr torr




This thesis explores the actions of purines, neuropeptides and
ouabain on the cat carotid body chemoreceptors using electro¬
physiological techniques to record chemoreceptor action potentials
from the carotid sinus nerve in order to provide a measure of chemo¬
receptor activity.
The carotid body is a sensory organ (De Castro, 1928, 1940)
and its chemoreceptor function definitively proven (Heymans, Bouckaert
and Dautrebande, 1930; Schmidt, 1932). One of the properties of
its chemoreceptors is the capacity to generate afferent impulses at a
frequency dependent on the P02, PC02 and the pH of the blood
perfusing it, and so to initiate the necessary cardiovascular and
respiratory reflexes to correct any changes observed in those factors.
For example, stimulation of the carotid body chemoreceptors causes
(1) increase in the tidal volume, frequency and minute volume of
breathing (Heymans, Bouckaert and Dautrebande, 1930; Heymans
and Bouckaert, 1933); (2) systemic vasoconstriction (Daly and Ungar,
1966) and bradycardia (Daly and Scott, 1958); (3) increase in
bronchiolar tone (Daly and Schweitzer, 1951); (4) increase in the
pulmonary vascular resistance (Daly and Daly, 1959); (5) increase
in secretion of the adrenal medulla and cortex (Anichkov, Malyghina,
Poskalenko and Ryzhenkov, 1960); (6) increase in activity of the motor
cortex, leading to convulsions (Schmidt and Comroe, 1940).
Chemoreceptors are activated by a fall in Pa02 or pH and by an
increase in PaC02, with the main natural stimulus being hypoxia: the
lower the local tissue Pa02 at the receptor, the greater the chemo¬
receptor stimulation (Biscoe, Purves and Sampson, 1970).
In the usual laboratory animals (e.g. dogs, cats, rabbits, rats)
the carotid body is a small structure located bilaterally on the root of
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the occipital artery or on the common trunk of the occipital and
ascending pharyngeal arteries from which receives the blood supply
(see Adams, 1958) (see also Figure 2.1).
1.1 Historical
The progress in the knowledge of the carotid body has been
associated with the vicissitudes of the progress of biological sciences.
A comprehensive history of the carotid body told through the
eyes of a morphologist was written by Adams (1958). Interesting
controversies can be detected since the discovery of the carotid body
in 1742 by Berckelmann (cit. by Adams, 1958) who was pupil of Haller.
For an account on the history of the discovery of the carotid body see
also Pick (1959).
In the early literature, carotid body nomenclature was related to
the interpretation of the putative function of the organ. For example,
ganglion minuten (Taube, 1743 cit. by Pick, 1959), ganglion exigum
(Haller, 1762 cit. by Adams, 1958 and Pick, 1959), ganglion parvum
(Neubauer, 1772 cit. by Adams, 1958); ganglion intercaroticum
(Andersh, 1797; Mayer, 1833; Valentin, 1833 all these authors cit.
by Adams, 1958 and Pick, 1959) were related to the interpretation that
the carotid body was a sympathetic-like ganglion. In 1862 Luschka
(cit. by Adams, 1958 and Pick, 1959) considered the carotid body as a
"nerve-gland" like the adrenal gland, the anterior pituitary or the
coccygeal gland and named it glandula carotica. Three years later,
Arnold (1865) stressed its vascular richess and suggested the name
glomeruliarteriosi intercarotici. In 1892, Stilling (cit. by Adams, 1958)
proposes a reconciliation between the "gland" school and the "vascular"
school and suggested the name paraganglion. Paraganglion inter¬
caroticum was the name adopted by Kohn ( 1900), Vincent (1922) who
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considered it as a gland of internal secretion, and De Castro (1926).
Another term was suggested still later by Celestino da Costa (1939,
1940, 1954) that of metaneurogonia on the grounds that the carotid
body is composed of "elements neuraux ... qui s'y differencient assez
peu eu regie" and that some of the cells may have similarities with
Schwann cells.
Basically, the controversy was between the carotid body being a
sympathetic-like ganglion as its neighbours, the superior cervical
ganglion or the nodose ganglion or alternatively, a kind of endocrine
gland similar to the adrenal medulla. In the polemics the embryological
nature of the carotid body, ectodermic or mesodermic (see e.g. Adams,
1958; Kondo, 1975) was frequently invoked either to support the
"ganglion" or the "gland" schools or whenever attempts were made to
reach a compromise between both schools. The basis of the compromise
was that the carotid body shares properties of both neural ganglia
and the adrenal medulla. Recently the same notion has been revived
in the Amine Precursor Uptake and Decarboxylation (APUD) (Pearse,
1969) and the paraneurone (Fujita, 1977, 1980) concepts. The carotid
body type I cells can be classified as being members of both groups.
Both theories seek to break down the barriers that exist between nerve
and gland cells which as the poetic expression of Fujita and Kobayashi
(1979) says, "neurones and paraneurones are continuous like the colours
of the rainbow". The central dogma of the paraneurone concept, as
Kobayashi and Fujita (1981) pointed out recently, is the 'continuity' of
neurones and endocrine/sensory cells. These cells are considered as
forming a continuous spectrum with regard to structure (neurosecretion-
like and/or synapse-like granules), products (peptides, amines and
adenine nucleotide secretion common to or closely related to neurohormones
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and neurosecretions) and function (recepto-secretory). Carotid body
type I cells are of the 'closed' type because they are closed in the
internal environment and receive their main stimulation from the blood
stream.
The APUD concept was advanced by Pearse (1969) to draw
together under the same umbrella endocrine and nerve cells. According
to a recent account (Pearse, 1978), the APUD concept is now expressed
in the following terms: "the cells of the APUD series, producing
peptides active as hormones or as neurotransmitters, are all derived
from neuroendocrine-programmed cells originating from the ectoblast.
They constitute a third (endocrine or neuroendocrine) division of the
nervous system whose cells act as third-line effectors to support,
modulate or amplify the actions of neurones in the somatic and autonomic
divisions, and possibly as tropins to both neuronal and non-neuronal
cells". The author divided the functions of the APUD cells into six
categories according to the site where they secrete (1) neurocrine
(into neurones), (2) neuroendocrine (via axons), (3) endocrine (into
the bloodstream), (4) paracrine (into intercellular space), (5) epicrine
(into somatic cells), (6) exocrine (to the externum). The SIF and
carotid body type I cells are neurocrine.
1.2 Structure and function
Much of what is known about the morphology of the carotid body
stems from discoveries by De Castro (1926, 1928) who established that
the main innervation of the carotid body has its origin from the glosso¬
pharyngeal nerve and not from the sympathetic. De Castro (1928)
was the first to demonstrate the sensory innervation and the sensory
function, but it was Heymans and colleagues (see Heymans and Neil,
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1958 and references therein) who extensively studied the reflexes
arising from the carotid bifurcation and identified the chemoreceptor
reflexes associated with the carotid body.
It is generally accepted that in all mammals studied to date the
parenchyma of the carotid body includes a glomus complex containing
type I and type II cells, nerve endings terminating on glomus cells
and blood vessels (see Figure 1.1). Connective tissue exists between
and around the glomus complexes. Myelinated (A) and unmyelinated (C)
fibres from the carotid sinus nerve are also present. Myelinated fibres
(dimaters of 1-10 |im, conduct at 4-53 m/s) represent about two-thirds
of the total number of chemoreceptor fibres, the other third being
unmyelinated (0.1-1.3 jam diameter, 0.5-2.0 m/s) (Fidone and Sato,
1969; see also Eyzaguirre and Fidone, 1980). A single sensory fibre
usually branches extensively to innervate between 10 and 20 type I
cells, and according to Eyzaguirre and Gallego (1975) and Kondo (1976)
this may constitute the sensory unit. The existence of myelinated and
non-myelinated fibres may be related to conduction of different informa¬
tion (see Biscoe, 1971). For a review of recent controversies on the
carotid body morphology including its inherent semantic problems see
Biscoe (1971).
Assigning function to morphology, one can say in a rather con¬
densed way:
7.2. 7 Type / cells
The type I cells seem to operate as chemoreceptor cells. By
this interpretation carotid body chemoreceptors have traditionally been
considered to be composite or secondary receptors, i.e. receptors
where a non-neural element is the primary target or receptor of the
stimulus. This implies that a sensory or afferent synapse should operate
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FIGURE 1.1
Schematic representation of the main structural components of the
carotid body according to De Castro (1951), Torrance (1968) and
Nishi (1976). Note that in De Castro's representation based on light
microscopy the nerve endings penetrate the glomus cells, and in
Torrance's scheme that type II cell envelops the carotid sinus nerve
axon as it leaves its sheath to its termination in contact with type I
cell also surrounded by the type II cell. In the Nishi's scheme all
structural components of the carotid body are contemplated: type I
cells (GC), type II cells (SC), carotid sinus nerve endings (NE)
and fibres (nf), capillaries (c), nerve endings presumably of
sympathetic origin (n) and Schwann cells enveloping both carotid sinus
nerve and presumably sympathetic fibres (Sch).
The type I ceils contain catecholamines (dopamine, noradrenaline,
adrenaline), 5-HT and perhaps ACh. They also contain neuropeptides
(met-ENK, leu-ENK, SP and VIP) and ATP.
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between the type I cell and the sensory nerve endings. The type I
cells are ovoid cells about 10 urn diameter with large nuclei, well-
developed mitochondria, endoplasmic reticulum, Golgi apparatus and
numerous dense-core vesicles (30 - 120 nm) which are similar to but
smaller than those present in the adrenal medulla (e.g. Lever, Lewis
and Boyd, 1959; Hellstrom, 1975; Verna, 1979); they occur in groups
of two or three surrounded by a type II cell (see Figure 1.1).
Fluorescence microscopy, electron microscopy, immunohistochemistry
and chemical analysis have revealed the presence of catecholamines
(dopamine, noradrenaline, adrenaline) and 5-hydroxytryptamine
(Chiocchio, Biscardi and Tramezzani, 1966; 1967), neuropeptides:
methionine-enkephalin (met-ENK), leucine-enkephalin (leu-ENK), vaso¬
active intestinal polypeptide (VIP), substance P (SP) (Lundberg,
Hokfelt, Fahrenkrug, Nilsson and Terenius, 1979; Cuello and McQueen,
1980; Wharton, Polak, Pearse, McGregor, Bryant, Bloom, Emson,
Bisgard and Will, 1980; Fitzgerald, Raff, Garger, Fechter, Anand and
Said, 1981) and ATP (Bock, 1980). Using a bioassay method, i.e.
injecting carotid body extracts and measuring the arterial blood pressure
in cats Eyzaguirre, Koyano and Taylor (1965) detected a high level of
ACh-like material in the cat carotid body; this amount has been reduced
to one-tenth of the bioassay measurement by using chromatography/mass
fragmentometry ( -12 nmol/g tissue ~ 12 pmol/organ) (Fidone, Weintraub
and Stavinoha, 1976). However, there is still no direct evidence
that the ACh detected is stored in type I cells. In spite of the lack
of unequivocal morphological evidence to support the existence of
two or more varieties of type I cell (see Biscoe, 1971) the recent
observations that type I cells can contain ATP and a number of neuro¬
peptides as well as catecholamines, 5-HT and possibly ACh and that all
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these substances may be contained in vesicles make it plausible that
different type I cells may exist with different combinations of those
substances. The presence of some non-innervated type I cells (see
Eyzaguirre and Fidone, 1980) may be related to a different function
for these cells with respect to type I innervated cells.
7. 2. 2 Type II cells
The type II cells are supporting or sustentacular cells similar to
the Schwann cells of the motoneurones or the glial cells. They support
the type I cells and surround the carotid sinus nerve axon in its
passage from its sheath to its termination on the surface of the type I
cell (see Comroe, 1964) (see Figure 1.1). The type II cells contain
a nucleus and the usual cytoplasmic inclusions (Golgi apparatus, endo¬
plasmic reticulum, mitochondria and fibrils). It is possible that ACh
is stored in these cells (Biscoe, 1971; Eyzaguirre and Fidone, 1980)
as has been shown to be the case in the Schwann cells of the motor
neurones of denervated preparations (Birks, Katz and Miledi, 1960;
Miledi and Slater, 1968). Schwann end-plate potentials and Schwann
miniature end-plate potentials follow Poisson statistics, i.e. random
release characteristics (Bevan, Grampp and Miledi, 1976) are blocked by
curare and are independent of Ca2+ (Dennis and Miledi, 1974).
7. 2. 3 Nerve endings
Carotid sinus nerve fibres terminate on glomus cells in a variety
of nerve-ending formations, including calices, boutons, and a number of
intermediate forms. Some of the nerve endings are relatively large
(up to 15 urn diameter). A nerve filament may branch from one ending
to innervate a type I cell, with a second ending terminating as a calyx,
a bouton, or an intermediate form on another type I cell (De Castro,
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1940; Nishi, 1976). The carotid sinus nerve endings can be divided
into afferent (sensory) and efferent (motor). The zones of apposition
between endings and cells are separated by a cleft of 20 - 30 nm and
a number of a small (30 - 40 nm) clear-core vesicles are present in the
nerve endings and sometimes in the glomus cells as well. Synaptic-like
membrane densifications have been detected on one or both sides of
the junction. According to the location of these electron-dense zones
and accumulations of vesicles, the nerve endings have been classified
as presynaptic, postsynaptic or reciprocally synaptic to the type I
cells. This picture varies with different species (see Eyzaguirre and
Fidone, 1980) and much may depend on the methods used for preparing
the tissues. The presence of efferent synapses between pre- or post¬
ganglionic sympathetic fibres (from the superior cervical ganglion)
and the glomus cells, has also been reported (e.g. Verna, 1971;
McDonald and Mitchell, 1975).
Since chemosensory activity is depressed when the carotid sinus
nerve is stimulated electrically it has been suggested that an efferent
pathway exists in the nerve (see Biscoe and Sampson, 1968; Neil,
and O'Regan, 1971). Sympathetic nerve endings and fibres
(most of them unmyelinated - Eyzaguirre and Uchizono, 1961) from the
superior cervical ganglion are also present in the carotid body and
they appear to be involved in regulating blood flow. In the cat with
the carotid body sympathetically denervated the blood flow is about
38 mm3/min compared with its value (82 mm3/min) before ganglionectomy
(Daly, Lambertsen and Schweitzer, 1954). The existence and function
of fibres coursing from the vagus nerve or from the nodose ganglion to
the carotid body has yet to be established (see Biscoe, 1971).
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7. 2. 4 Blood vessels
The arteries divide into fenestrated capillaries which are in close
contact with type I cells, and supply the blood to be 'tasted' (see
Torrance, 1968) by the chemoreceptors for its Pa02, PaC02 and pH;
the veins draining carotid body pass either directly into the jugular
vein or into the transverse vein and then into the external or internal
jugular veins (see Comroe, 1964). Blood flow through the carotid body
is very high (about 2 1/100 g of carotid body tissue/min) (Daly,
Lambertsen and Schweitzer, 1954), the total venous outflow from the
carotid body arises from the tissue vascular bed plus that which is
diverted through an arteriovenous shunt whenever this is present
(De Castro, 1951; Seidl, 1975).
Despite type I cell being regarded as a chemoreceptor cell,
existence at the nerve endings of a regenerative region which is
sensitive to a number of stimuli, e.g. NaCN, ACh, has also been
proposed (see Paintal, 1977). So the possibility of fine nerve endings
being chemoreceptors as proposed by Biscoe (1971) partly on the basis
of experimental evidence (the chemoreceptor afferent fibres have a
discharge pattern which is compatible with a Poisson process) but
mainly on theoretical grounds (fibre dimensions and geometry; K +
depolarization calculated by the Nernst equation; ATP productions
either taking place near the pumping (Na + , K+-ATPase) site or diffusing
rapidly to that site; oxygen consumption and high energy phosphate
bonds formation; localization of a low-affinity cytochrome as a source
of energy bypassing ATP), has been sustained experimentally by others.
For instance, neuromas of the sinus nerve (without glomus type I or
II cells) respond to low Pa02 and high PaC02 (Kienecher, Knoche and
Bingmann, 1978; Tan, Pallot and Purves, 1981). A compromise may be
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that both glomus cells and nerve endings function as chemoreceptors,
their relative importance being dependent upon the type of stimulation.
The information carried centripetally may also depend on the type of
fibre (A or C) used.
1. 3 Methods of studying the carotid body chemoreceptor pharmacology
Information about the effects of drugs on chemoreceptors can be
obtained by studying the cardiovascular and respiratory reflexes
originated in the carotid body or in a more direct way by recording
bioelectrical activity from the carotid sinus nerve. The latter can be
performed in vivo or in vitro.
7. 3. 7 Reflex studies
These include effects on respiratory and cardiovascular reflexes
obtained by stimulating the chemoreceptors following administration of
drugs in the whole animal.
The methods used in early studies provide only limited information
about the action of drugs on carotid body chemoreceptors. For example,
secondary actions (e.g. in blood gas tensions, lung inflation reflex,
arterial blood pressure) which can modify the primary chemoreceptor
reflex might mask the chemoreceptor action of the drug. Moreover,
integration in the central nervous system makes it difficult to relate
output (reflex change) to input (drug action on chemoreceptors).
The main advantages of the method are: (1) it is easy to perform;
(2) it provides some information concerning the actions of drugs and
physiological stimuli on the whole intact receptor populations (see
Heymans and Neil, 1958; Anichkov and Belen'Kii, 1963).
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I. 3. 2 Electrophysiological studies
The use of electrophysiological techniques have as their main
advantages: (1) the possibility of directly measuring the electrical
activity of neurones; (2) they have a high temporal resolution which
helps to relate cause and effect; (3) they can be used to provide
quantitative data.
i. 3. 2. I In vivo recordings:
The advantages of this technique are: (1) the cells are more or
less close to their milieu interieur; (2) if anaesthesia and other
experimental factors such as B.P., blood gases (Pa02 and PaC02)
and pH are controlled then the action of drugs may be studied in the
carotid body under relatively physiological conditions. The most used
technique consists in obtaining recordings from the carotid sinus nerve
previously cut near the point where it joins the glossopharyngeal nerve.
By this method it is possible to eliminate any efferent activity of the
carotid sinus nerve (see e.g. Bogue and Stella, 1935; Heymans and
Neil, 1958; McQueen, 1977). A refinement of this technique is to
record from a single chemoreceptor unit since in this condition there
is no doubt when a unit dies, as pointed out by Biscoe (1971). Another
technique consists of obtaining recordings from the petrosal ganglion;
this allows one to maintain carotid sinus nerve efferent influence to
the carotid body (see Vidruk and Dempsey, 1980).
In both methods it is possible to eliminate the ganglioglomerular
(sympathetic) activity. The limitations of these methods arise from the
fact that it is not possible to know where within the receptor complex
a drug is acting and the sample of fibres studied is limited. Vascular
effects of drugs may complicate interpretation of results.
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1.3.2.2 In vitro recordings:
These techniques include extracellular and intracellular recordings
and offer the advantage of permitting the application of drugs in
precisely known concentrations, and avoiding vascular complications.
Other advantages are the exclusion of anaesthesia and the possibility
of elucidating the ionic mechanisms involved in responses. The main
disadvantages in relation to the carotid body are the absence of blood,
the drugs take longer to act, and their effects last longer which
contrasts with the dynamic characteristics for the carotid chemoreceptors
in vivo.
- Extracellular recordings:
This technique hss been largely used by Eyzaguirre's group
(see e.g. Eyzaguirre and Lewin, 1961; Eyzaguirre and Zapata, 1968a;
Eyzaguirre and Nishi, 1974). The technique allows the recording of
chemoreceptor discharge as in vivo or the recording of the mass
receptor potential which is taken as a cumulative measure of the
polarization of sensory nerve endings in the carotid body (see Eyzaguirre
and Nishi, 1974).
- Intracellular recordings:
This technique improves the proximity to the receptor and
creates the possibility of administering drugs into cells. However,
the membrane potentials recorded (10-60 mV with a mean of 20 mV)
are much lower than those reported for excitable tissues (Gallego and
Eyzaguirre, 1978). The main disadvantage of intracellular recordings
is that damage to cells is caused by the relatively gross microelectrodes
commonly used. Sample bias arises because it is more likely that
larger rather than smaller cells and nerve fibres will be impaled by the
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microelectrodes (see Eyzaguirre and Fidone, 1980). Another difficulty-
arises from the fact that many type I cells are covered by processes
of type II cells and so the information obtained may be a combination
of effects involving the membranes of both cells.
7. 3. 3 Various methods
These include tissue culture technique which enables a correlation
of microelectrophysiological and biochemical experiments on a relatively
homogeneous population of cells (see e.g. Acker and Pietruschka, 1977).
Other methods are related to bioassay, biochemistry, immuno-
histochemistry, histofluorescence, electron microscopy, the use of
gas-chromatography - mass-spectrometry and binding studies.
1.4 Pharmacology
Carotid body chemoreceptors can be stimulated by a large number
of chemical substances - about 70 compounds were listed by Heymans
and Neil (1958). This kind of 'omnireceptor' (Eyzaguirre and Fidone,
1978) can be stimulated by (1) chemicals known to modify utilization
of oxygen in tissues by interfering with cytochrome oxidase. Sodium
cyanide is the best example and the most frequently used; (2) chemicals
known as nicotinic agonists. This group includes nicotine, ACh, DMPP;
(3) miscellaneous substances including ATP, veratridine, papaverine,
potassium ions (see Heymans, 1955; Comroe, 1964).
The role of substances present in the carotid body which are
capable of modifying chemoreceptor activity when exogenously applied
to the carotid body, such as ACh and catecholamines, has been
investigated in recent years. Despite lack of definitive evidence that
chemical transmission of sensory impulses occurs in the carotid body
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(see reviews by Torrance, 1968; Bisooe, 1971; Eyzaguirre and
Fidone, 1980) ACh and catecholamines (in particular dopamine) fulfill
some of the requirements of putative carotid body transmitters.
A brief review of some of the evidence follows.
7. 4. 7 Acetylcholine and catecholamines
- Acetylcholine
The discovery of ACh chemoreceptor stimulatory properties led
to the idea that the substance might be an excitatory transmitter in
the carotid body. This was first suggested by Schweitzer and Wright
(1938) on the grounds that the anticholinesterase neostigmine increased
chemoreflex stimulation of respiration in cats and that the effect of
intracarotid injection of ACh was enhanced by anticholinesterases.
These findings were confirmed by a number of authors using reflex
studies (see e.g. Heymans and Neil, 1958). The introduction of electro¬
physiological techniques confirmed the excitatory action of ACh
(Landgren, Liljestrand and Zotterman, 1952). Some authors using
cats and dogs noted that this excitatory action of ACh was correlated
to the nicotinic properties (e.g. Mercier, Rizzo and Delphaut, 1934;
Anichkov, 1937; Philippot, 1937; Comroe and Schmidt, 1938),
whereas substances that possess muscarinic rather than nicotinic
properties such as the derivatives of g-methylcholine had little or no
effect (Comroe and Starr, 1933; Philippot, 1937; Comroe and Schmidt,
1938). Methacholine initially considered as a muscarinic stimulant also
stimulates chemoreceptors (De Wispelaere, 1937), but this effect was
later clarified as inconclusive by McQueen (1978) who showed that the
stimulant effect was a result of a weak nicotinic action of methacholine.
Other arguments supporting ACh as a transmitter in the carotid
body include its release from the structure (Eyzaguirre, Koyano and
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Taylor, 1965; Fidone, Weintraub and Stavinoha, 1976), the presence
of acetylcholinesterases identified histochemically (e.g. Hollinshead
and Sawyer, 1945; Koelle, 1951; Biscoe and Silver, 1966). Choline
acetylase is also present in the carotid body but in small amounts
(Hebb, 1968; Jones, 1975). However, some of these findings have
been regarded as equivocal (see e.g. Douglas, 1954; Biscoe, 1971;
Sampson, 1971; McQueen, 1977). Moreover, mecamylamine (an ACh
antagonist) does not antagonize chemoreceptor excitation induced either
by hypoxia or hypercapnia (McQueen, 1977) and in the rabbit ACh
inhibits chemoreceptor discharge (Docherty and McQueen, 1979).
The possibility of ACh being the transmitter of an efferent synapse
involving carotid sinus nerve fibres and type I cells as suggested by
Neil and O'Regan (1971) and Osborne and Butler ( 1975) has been
questioned by Goldberg, Lentz and Fitzgerald (1978) who measured
the ACh content of the carotid sinus nerve and found that the amount
measured was too small (0.05 ± 0.02 pmol ACh/|ig protein) compared
with the amounts detected in cholinergic nerves, e.g. vagus (1.03 ±
0.42 pmol ACh/|ig protein). So they concluded that the chemoreceptor
fibres that synapse with type I cells are not cholinergic. Furthermore,
levels of ACh present in the carotid body are virtually unchanged after
chronic carotid body denervation (Fidone, Weintraub and Stavinoha, 1976;
Hellstrom, 1977). Kinetic studies of choline uptake by the carotid body,
and the autoradiographic localization of the high affinity component of
this uptake have shown similarities with other putative cholinergic
systems (see e.g. Yamamura and Snyder, 1973). The chronic total
denervation of the carotid body (carotid sinus and ganglioglomerular
nerves cut) for 1 week to 3 months does not reduce the high-affinity
component of choline uptake. This further supports the notion that
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the carotid sinus nerve is not cholinergic (see Eyzaguirre and Fidone,
1980). However, it remains to be explained whether ACh is stored, in
type I, type II, or in both kinds of glomus cells.
Despite these inconsistencies, interesting observations made with
the use of microelectrophysiological techniques have been reported by
Hayashida and Eyzaguirre (1979). These observations indirectly
support the presence in the carotid body of an excitatory transmitter.
They detected the presence of random electrical noise which might be
the equivalent of the miniature end-plate potentials recorded from
muscle fibres. According to Eyzaguirre, a main protagonist of the ACh
transmitter hypothesis in the carotid body (see Eyzaguirre and Fidone,
1978) the present state of the art can be summarized as follows:
"our present view of the processes of chemoreceptor excitation would
suggest that stimuli affect the resting state of the glomus cells, which
in turn release a 'transmitter' or 'generator' substance (possibly ACh)
into the enclosed synaptic cleft to depolarize the terminals. Ending
depolarization would in turn initiate the sensory discharge by acting,
presumably, on the first node of the myelinated sensory fibres".
- Catecholamines
The presence of chromaffin tissue in the carotid body (e.g.
Ross, 1959) prompted studies on the involvement of catecholamines in
the carotid body. The findings supporting the importance of catechol¬
amines are: (1) the presence of dopamine, noradrenaline and adrenaline
in yesicles of the type I cells (e.g. Chiocchio, Biscardi and
Tramezzani, 1966; Dearnaley, Fillenz and Woods, 1968; Zapata,
Hess, Bliss and Eyzaguirre, 1969; Mills, Smith, Slotkin and Breese,
1978); (2) the enzymes required to synthetize catecholamines, specially
tyrosine-hydroxylase, the rate-limiting enzyme is present in Type I
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cells (Hanbauer, Lovenberg and Costa, 1977). Monoamine oxidase,
which is an important enzyme in the catabolism of monoamines is also
present in the carotid body (Lee and Mattenheimer, 1964); (3) the
depletion of dopamine-containing vesicles by anoxia in the rat (e.g.
Hanbauer and Hellstrom, 1978); (4) the presence of both a- (Sampson,
Aminoff, Jaffe and Vidruk, 1976) and 3- (Biscoe, 1965; Folgering,
Ponte and Purves, 1980) receptors; (5) administration of dopamine
close-arterial to the carotid body inhibits chemoreceptor discharge in
cats (Sampson, 1972; Zapata, 1975; Docherty and McQueen, 1978)
and noradrenaline and adrenaline cause small inhibition followed by an
excitation (see Eyzaguirre and Fidone, 1980).
ACh and catecholamines are present in the glomus cells of the
carotid body and release of these substances increases during stimula¬
tion by hypoxia or interruption of flow in vitro, and by pharmacologic
stimuli (see Eyzaguirre and Fidone, 1980; Fidone, Gonzalez and
Yoshizaki, 1980). The response of carotid body chemoreceptors to
these substances varies among the mammalian species studied so far.
For example, ACh increases the discharge of cat chemoreceptors through
nicotinic mechanisms (Eyzaguirre and Koyano, 1965; McQueen, 1977;
1978; Monti-Bloch and Eyzaguirre, 1980) and muscarinic agonists are
practically without effect. On the other hand, ACh depresses the
discharge of rabbit chemoreceptors through muscarinic actions (Docherty
and McQueen, 1979; Monti-Bloch and Eyzaguirre, 1980). As Eyzaguirre
and Fidone (1980) pointed out recently, "it appears then that, in the
rabbit, the depressant muscarinic effect of ACh predominates over the
stimulatory nicotinic action of ACh". Opposite actions for dopamine
have also been described, in cats and dogs the response is predominantly
inhibitory whereas in rabbits both excitatory and inhibitory receptive
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sites for dopamine appear to exist (see Eyzaguirre and Fidone, 1980).
In rabbits in vivo dopamine inhibits chemoreeeptor discharge (Docherty
and McQueen, 197 9) whereas in vitro it increases the discharge
(Monti-Bloch and Eyzaguirre, 1980).
In spite of cholinergic and dopaminergic antagonists blocking or
decreasing the effects of ACh or dopamine, they do not appreciably
affect the spontaneously occurring discharge or the increase induced
by natural (low Pa02; high PaC02; low pH) or chemical (e.g. NaCN)
stimuli (see e.g. Eyzaguirre and Fidone, 1980). It might be that
natural stimulation releases other agents such as neuropeptides that
interfere with the action of ACh and/or dopamine and, hence, make
the effect of cholinergic and dopaminergic blockers less effective.
Alternatively, as Eyzaguirre and Fidone (1980) suggested, one should
consider the possibility of electrical coupling between glomus cells and
nerve endings. These authors also consider that since ACh and
catecholamines are vasoactive substances these substances can influence
chemoreceptor discharge by interfering with the local carotid body
blood flow.
1.5 Ouabain
Despite extensive studies on the actions of cardiac glycosides
on the nervous system (for a recent review see Gillis and Quest,
1980), little is known about the effects of these substances on carotid
body chemoreceptors.
Ouabain is a glycoside used in the treatment of cardiac insufficiency.
A property of this group of substances is that they affect Na + , K+-
ATPase (see e.g. Akera and Brody, 1978). The integrity of this
enzymatic system seems essential for the process of normal activation
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of. excitable cells. This has been demonstrated in nerve and muscle
(skeletal, smooth or cardiac muscle) cells. The recognition that
cardiac glycosides affect the Na+, K+-ATPase (Schatzmann, 1953)
and that via this mechanism they can trigger a number of subsequent
ionic processes involved in the excitability of the cells, i,e. modify
Na+, K+ and Ca2 + concentrations inside and outside the cells, has
been a result of extensive studies (for reviews, see e.g. Skou, 1965;
Thorp and Cobbin, 1967; Lee and Klaus, 1971; Akera and Brody,
1978; Gillis and Quest, 1980).
Transmission at the autonomic ganglia in anaesthetized cats
can be enhanced by cardiac glycosides (digitoxin, lanatoside-C, K-
strophantoside) and this effect is followed by an inhibition of trans¬
mission. These substances also increase the ganglionic responses
to ACh (Konzett and Rothlin, 1952). Confirmation of these results
was obtained by Perry and Reinert (1954) who used ouabain.
Neurophysiological studies also performed in vivo suggest that
cardiac glycosides facilitate ganglionic transmission (Pace and Gillis,
1976; Weaver, Akera and Brody, 1976). It has been shown in cats
and dogs in vivo that high doses of cardiac glycosides increase
catecholamine release from the adrenal medulla (Richards and Wood,
1915). This has been confirmed in vitro by Banks ( 1967) who reported
that ouabain increases both spontaneous and evoked (carbachol-
induced) release of catecholamines by the isolated perfused adrenal
gland of the cow, and by others using adrenals from dogs, cats and
rats (Roy and Chatterjee, 1970; Gascon, 1977; Garcia, Hernandez,
Horga and Sanchez-Garcia, 1980). It has been frequently suggested
that the excitatory effect of cardiac glycosides in neural tissue is related
to their action on the Na+, K+-ATPase (see e.g. Gillis and Quest, 1980).
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The presence of this ATPase has been identified in small nerve fibres
(Rang and Ritchie, 1968). Thus inhibition of this ATPase by cardiac
glycosides could explain the excitatory action in efferent autonomic
nerves (Ten Eick and Hoffman, 1969) and ganglia (Libet, Tanaka and
Tosaka, 1977; Smith and Weight, 1977). Myelinated fibres such as
motor nerve fibres are also excited by cardiac glycosides either in
vivo (Levitt, Raines, Sohn, Standaert and Hirshfeld, 1970) or in
vitro (Birks, 1963) and the glycosides also stimulate these fibres,
probably by inhibition of the sodium pump.
There is evidence that chemosensory receptors in the region of
the carotid bifurcation can be affected by cardiac glycosides. Schmitt,
Guth and Muller-Limmroth (1958) were the first to show that digitalis
can act on carotid body chemoreceptors. They described that as a
consequence of injecting digitalis (digipurat and K-strophanthin)
intravenously in cats the frequency of action potentials recorded from
chemoreceptor fibres increases. Their identification of chemoreceptors
was based on the localization of the recording electrodes in the carotid
body, and that increasing PC02 in the ventilating air increased
spontaneous chemoreceptor discharge. More recently, McLain (1970)
described how ouabain injections (i.m. or i.v.) in cats anaesthetized
with chloralose increase neural traffic (baroreceptor and chemoreceptor
activity) recorded from the carotid sinus nerve, and Joels and Neil
(1968) reported that ouabain (10-10M) inhibits chemoreceptor activity
evoked by nitrogenated Krebs-Hensleit solution and in a concentration
of 10~8M can also reduce the discharge evoked by ACh in vascularly
isolated carotid bodies. According to these authors the effect of
ouabain on ACh responses might suggest that ouabain has some action
on the chemosensory endings. Studies performed in vitro by Eyzaguirre,
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Baron and Gallego (1977) have shown that ouabain (5 x 1CT5M) induces
cell depolarization of the type I cells at normal temperature and this
effect was potentiated by lowering the temperature of the perfusion
fluid. More indirect observations also indicate that cardiotonic glycosides
can activate chemoreceptors. For example, Heymans, Bouckaert and
Re"gniers ( 1932) and Zipf and Ehrlicher (1951) reported that digitalis
can activate carotid sinus receptors. However, it is not possibLe to
ascertain whether these effects were exerted on baroreceptors, chemo¬
receptors or both, since selective discrimination between the different
sensory receptors was not attempted. It has been found that in
decerebrate cats in which the carotid bodies were destroyed by acetic
acid, intracarotid acetylstrophanthidin caused a smaller effect on
carotid sinus nerve activity as compared with the responses obtained
before destruction (Quest and Gillis, 1971). Another glycoside,
scillaren A injected close-arterial to the carotid body in dogs enhanced
the reflex respiratory excitatory responses to ACh and nicotine
(Carpi, Konzett and Cerletti, 1957). In an investigation performed by
Viana (1973) digoxin (2 |ig/kg/min i.v.) potentiated the respiratory
stimulant effects of NaCN (i.e.) and ACh (i.e.). Furthermore, digoxin
(2 ug/kg/min i.v.) no longer caused respiratory stimulation after
surgically removing both carotid bodies in dogs (Viana, 1974). The
relative contribution of chemoreceptors as opposed to baroreceptors
cannot be ascertained from these studies.
In the present thesis the effects of ouabain on arterial chemo¬
receptors have been studied in order to clarify its action on spontaneous
chemoreceptor discharge and its interaction with evoked responses.
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1.6 Adenosine triphosphate
It is well-known that the chemical, mechanical and osmotic work
of the cells depends upon the chemical energy supplied by ATP (see
e.g. Lehninger, 1965). According to this, therefore, ATP should
affect the carotid body, and a. theory for the activation of the carotid
body based on the interruption of its ATP production has been developed.
This theory has been advanced on the grounds that anoxia and metabolic
inhibitors increase chemoreceptor discharge (see e.g. Krylov and
Anichkov, 1968; Torrance, 1968). The action of anoxia or of metabolic
inhibitors on cells is to interfere with the energy supply to the Na+
pump (Hodgkin and Keynes, 1955) and to the Ca2+ pump (for a review
see e.g. Carafoli and Crompton, 1978). All this information comes from
indirect evidence. As Loewenstein and Rose (1978) pointed out, it is
possible to cause closure of Ca2+ channel in condition in which the cells
are poisoned with cyanide, but there is no way of knowing whether in
this condition all ATP was actually depleted. ATP can restore and
enhance the responsiveness of the carotid body when this has been
reduced by prolonged perfusion with poisons (e.g. cyanide) (see
Anichkov and Belen'Kii, 1963). Also Joels and Neil (1968) found that
in vascularly isolated perfused cat carotid body ATP reduces the
responses to cyanide or dinitrophenol, which seems to support the ATP
depletion theory. The results of the Russian school seem to imply that
ATP exogenously applied can restore chemoreceptor activity when it is
exhausted, whereas Joels and Neil (1968) suggest that ATP protects
against metabolic inhibitors. Although subscribing the same theory,
i.e. relying on ATP depletion for chemoreceptor activation, their
results come from different observations. The Russian school reported
that the nucleotide is ineffective in low concentrations but in high
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concentrations excites chemoreceptors, whereas Joels and Neil (1968)
found that ATP (l(T5w/v) reduced chemoreceptor responses evoked
by cyanide or dinitrophenol; this implies that chemoreceptor activity
is reduced during normal production of ATP. AMP and ADP lacked the
effects of ATP (Joels and Neil, 1968), Although the observations of
these authors fit well the ATP-metabolic chemoreceptor activation,
their results appear to be rather a matter of coincidence than to serve
as real support to the theory, since (1) ATP hardly crosses cell
membranes from outside to inside the cells (see e.g. Glynn, 1968),
and this is theoretically supported by knowing that the normal con¬
centration of ATP inside the cells (1-5 mM) is much higher than outside
(see Lehninger, 1965); (2) the enzymatic machinery quickly metabolizes
ATP into ADP, AMP, adenosine, adenine, inosine and hypoxanthine.
Roumy and Leitner ( 1977) have been able to reproduce the results of
Krylov and Anichkov (1968) but not those reported by Joels and Neil
(1968); they proposed that calcium is involved in the process of
chemoreceptor activation on the grounds, firstly that transmitter release
from the type I cells during hypoxia is a function of the cytoplasmic
calcium concentration, and secondly that the concentration of cytoplasmic
calcium is regulated by the mitochondria which has an ATP-dependent
calcium pump (see e.g. Carafoli and Crompton, 1978). Similar inter¬
pretations have been used to explain the increased release of trans¬
mitter at the neuromuscular junction in the presence of metabolic
inhibitors (see e.g. Alnaes and Rahaminoff, 1975) as well as to explain
the decrease in the spontaneous release of the transmitter at the neuro¬
muscular junction caused by both adenosine and ATP (Ribeiro and
Dominguez, 1978). So when less ATP is present in the cell more calcium
is free in the cytoplasm to promote transmitter release, because the
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mitochondrial ATPase (the calcium pump) cannot pump calcium into
the mitochondria in the absence of ATP. Mimicking
the intracellular ATP by using exogenous ATP appears, therefore,
difficult to achieve, but even if it were possible to do this the ATP
would be expected to decrease rather than increase chemoreceptor
activity. The analysis of the above information seems to indicate that
ATP activates chemoreceptors via a site located outside the membrane.
A theory concerning the role of ATP in the process of impulse generation
has been proposed by Duncan (1965, 1967). According to this, the
mechanism underlying the generator process at sensory nerve endings
is similar to that used by amoeba in sensing mechanical stimuli, i.e.
there is an enzyme (ATPase) located on the membrane which contacts
with the substrate and triggers the activation (Duncan, 1967).
Despite the discovery that ATP is the main energy supplier for
the work of the cells, which created conditions to advance metabolic
theories of nerve activation and release of transmitters, ATP, related
nucleotides and adenosine have been progressively implicated in
neurotransmission quite independently of their direct metabolic roles
as part of the cellular energy supply system.
It is nearly 30 years since Holton and Holton (1953, 1954) suggested
that ATP might be released as a neurotransmitter from both peripheral
and central endings of sensory fibres. Since then a great deal of effort
has gone into attempts to unravel the role of adenosine and adenine
nucleotides on neurotransmission. Torrance ( 1968) pointed out the
interest of the excitatory action of ATP reported by Anichkov and
Belen'Kii (1963) in view of the report of Douglas and Poisner (1966)
that ATP is released with catecholamines from the adrenal medulla and
since catecholamines have their supporters for the office of transmitter
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in the carotid body, ATP may act synergically (cotransmitter function)
with an amine at the nerve endings.
The actions of adenosine and related nucleotides on neuro¬
transmission have been a matter of intensive research in the last ten
years (for reviews see e.g. Burnstock, 1972; Mcllwain, 1972; Arch
and Newsholme, 1978; Ribeiro, 1978; Fredholm and Hedqvist, 1980;
Daly, Bruns and Snyder, 1981; Phillis and Wu, 1981; Stone, 1981).
There are in principle, two distinct actions of adenosine and
related nucleotides at synapses. One is the postsynaptic action - ATP
can behave as a neurotransmitter and/or as a cotransmitter. The role
of ATP as a neurotransmitter has been extensively characterized by
Burnstock (1972, 1978) under the concept of purinergic transmission.
For a recent account of the steps which led to the formulation of the
purinergic hypothesis, the recent monograph Purinergic Receptors
(Burnstock, 1981) should be consulted.
The function of ATP and/or adenosine as cotransmitters is poorly
understood, but basically corresponds to their capacity to sensitize
the post-synaptic membrane to the effects of the classical neurotrans¬
mitters such as ACh or noradrenaline (see e.g^ Ribeiro, 1978).
The other action of adenosine and related nucleotides at synapses
is presynaptic and manifest by a reduction in transmitter release. This
was first detected electrophysiologically by Ginsborg and Hirst (1971;
1972) in the rat-diaphragm, and further confirmed in the same laboratory
by Ribeiro and Walker ( 1973; 1975) in both rat-diaphragm and the frog-
sartorius preparations. There is now an extensive literature on the
presynaptic action of adenosine and adenine nucleotides (e.g. Ribeiro,
1979; Burnstock, 1980; Fredholm and Hedqvist, 1980; Paton, 1981;
Stone, 1981).
28.
In spite of these achievements more direct evidence for the
presence of ATP in the carotid body was produced in 1972 by Nada and
Ulano, who detected histochemically and by electron microscopy
adenosine triphosphatase activity in the carotid body. However, its
localization to vesicles and, hence in a releasable state, was only
recently reported by Bock (1980). This author used fluorescence
microscopy (labelling with quinacrine) and electron microscopy
(uranaffin reaction) and concluded that ATP is stored within specific
granules in addition to catecholamines and proteins in the carotid body
type I cells. Part of his work was prompted by (1) previous descriptions
concerning the storage mechanisms of catecholamines in dense-core
vesicles of sympathetic terminals and in adrenomedullary chromaffin
granules (Smith and Winkler, 1972); and (2) by the prediction that
paraneurones (Fujita and Kobayashi, 1979) should contain amines,
peptides and ATP.
ATP is effective on sensory systems. For example, perfusion of
frog taste buds, via the lingual artery, with ATP initiates a discharge
in the afferent nerve (Duncan, 1964); ATP excites sensory nerve
endings of trigeminal (Juan and Lembeck, 1974). Adenosine compounds
excite pain receptors (Bleehen and Keele, 1977) and their action on
afferent nerve terminals resemble other known algogenic substances
such as potassium, ACh, 5-HT and bradykinin. The adenine compounds
were comparatively less potent than ACh, 5-HT or bradykinin, but
had greater potency than potassium (Bleehen, 1978).
In the perfused superior cervical ganglion of the cat phosphate
compounds such as ATP stimulate ganglionic transmission (Feldberg
and Hebb, 1948). In isolated spinal cord preparations in which synaptic
transmission had been abolished by perfusing with a Ca2+_free solution
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containing 10 mM Mg2+, ATP had a depolarizing action on dorsal root
terminals but did not affect motoneuronal membrane potentials. It is
likely that these compounds have a direct effect on afferent terminals
(Phillis, Kastopoulos, Edstrom and Ellis, 1979).
Of more direct interest to the present work are the observations
of Jarisch, Landgren, Neil and Zotterman ( 1952) who found that ATP
increases chemoreceptor discharge when injected i.e. The effect was
interpreted as a result of stimulating the sensory nerve endings, and
compared to that observed by Jarisch and Zotterman (1948) who demon¬
strated that ATP can stimulate cardiac receptors, and is also comparable
with the stimulation of pulmonary nerve endings (Emmelin and Feldberg,
1948). Dontas (1955) also found that ATP injected i.e. causes chemo¬
receptor excitation, and that the effect is probably on the membrane
surface. Furthermore, he concluded that inactivation of phosphorylation
should not be responsible for chemoexcitation, since some inhibitors
such as thiopentone and pentobarbitone depressed chemoreceptor
activity.
Some of the above authors concentrated on studying the effects
of ATP but concluded that ADP and AMP were also effective, although
only in much higher doses. So far there have been no reports on the
effects of adenosine.
The first hint that adenosine modifies physiological processes
came in 1929 when Drury and Szent-Gyorgi observed that injection of
adenosine into mammals lowered the arterial blood pressure, dilated
the coronary arterioles, induced sleep and inhibited movements of the
small intestine.
As Arch and Newsholme (1978) pointed out, during the thirty
years that followed the observations of Drury and Szent-Gyorgi (1929),
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more attention was given to the pharmacological effects of adenine
nucleotides than those of adenosine. In particular, attention was
centred on ATP. Upon injection, high doses of ATP produce a state
of shock with lowered blood pressure, lowered body temperature, renal
dysfunction, mobilization of glycogen from liver and muscle and
elevated blood levels of glucose, lactate and pyruvate. This suggested
that the release of ATP from damaged tissues contributed to traumatic
shock (Green and Stoner, 1950). Although adenosine produced similar
effects to ATP, as Arch and Newsholme (1978) pointed out, the tissue
content of adenosine was considerably less than that of ATP so that it
was considered to be less important. According to Arch and Newsholme
(1978) if the rapidity of the breakdown of extracellular ATP to adenosine
had been appreciated, the nucleoside might have assumed a greater
importance in these early studies.
ATP is present in the carotid body type I cells but there is
conflicting evidence regarding its action on the chemoreceptors.
Recent ideas about the importance of other purines, in particular
adenosine, on neurotransmission led to the present investigation
concerning the effects of these substances on arterial chemoreceptors.
1.7 Peptides
As a result of recent progress in understanding the nervous
system a number of neuropeptides emerged as fulfilling a number of
criteria classically required of neurotransmitters namely on synthesis,
storage, release, inactivation in tissues and effectiveness when
exogenously applied (for reviews see e.g. Lord, VVaterfield, Hughes
and Kosterlitz, 1977; Iversen, 1979; Hokfelt, Johansson, Liungdahl,
Lundberg and Schultzberg, 1980; Snyder, 1980). Their importance
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has been stressed in terms of their ambivalence, i.e. being either
neurotransmitters, hormones or having both roles according to the
circumstances. As mentioned previously ideological support for these
roles has been provided by the APUD and paraneurone concepts.
Using immunohistochemical techniques such as the indirect immuno¬
fluorescence technique of Coons (1958) (Lundberg, Hokfelt, Fahrenkrug,
Nilsson and Terenius, 1979; Cuello and McQueen, 1980; Fitzgerald,
Raff, Garger, Fechter, Anand and Said, 1981) or combining immuno-
histochemistry and radioimmunoassay (Wharton, Polak, Pearse, McGregor,
Bryant, Bloom, Emson, Bisgard and Will, 1980) it has proved possible
to distinguish enkephalin-, substance P- and VIP-like immunoreactivity
in the carotid body.
As Hokfelt, Johansson, Ljungdahl, Lundberg and Schultzberg
(1980) pointed out any substance can be traced using immunohisto-
chemistry providing that (1) the substance is available in pure form,
(2) it is immunogenic (or can be rendered immunogenic by conjugation
to carrier protein) and (3) it can be retained in tissue sections during
processing for immunohistochemistry.
Apart from limitations of sensitivity, and the limited ability of
the antibodies to penetrate the intracellular storage sites, the major
problem is the specificity of the immunological reaction. Thus, an
antiserum may not only react with the proper antigen but also cross-
react with structurally similar peptides.
Important characteristics of peptides are that they can consist
of up to 30 or more amino acids and high molecular weight (M.W. -3000)
compared with the classical neurotransmitters (M.W. - 200).
One feature that is common to several classes of peptide neurone
is the large granular vesicle (Goldsmith, 1977) compared with 'pure'
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cholinergic and adrenergic neurones containing small granular vesicles
(see Burnstock, Hokfelt, Gershon, Iversen, Kosterlitz and Szurszewski,
1979). The method of replenishment of peptide neurotransmitter at
nerve endings seems to differ from that of classical neurotransmitters.
For example, intraneuronal noradrenaline levels are kept fairly constant
by the efficient replacement of released transmitter by (1) enzymatic
synthesis in the nerve endings, (2) re-uptake from the extraneuronal
(synaptic) space through an active membrane mechanism and (3) supply
of amine in storage vesicles (or their precursors) from the cell body via
axonal transport (Iversen, 1967).
Peptides, on the other hand, are probably produced only on the
ribosomes of the cell soma, possibly in the form of a larger precursor
molecule (Gainer, Loh and Same, 1977) without local synthesis in nerve
endings. As no reuptake mechanisms seem to operate for peptides in
nerve endings, every single peptide molecule released from a nerve
ending must be replaced by axonal transport. This comparatively
inefficient and slow mechanism should be reflected in the dynamics of
synaptic events at peptide synapses (Bloom, 1977).
Table 1.1 summarizes main similarities and differences between
classical small neurotransmitters and putative peptide transmitters
that should be kept in mind, according to Hokfelt (1979), in order to
understand potential mechanisms of action involved in the effects of
both groups of substances.
7. 7. 7 Opioid peptides: methionine-, leucine-enkephalin and g-endorphin
Hughes (1975) showed that brain extracts can mimic morphine's
effects on electrically induced contractions of smooth muscle and that
this is blocked by naloxone. A morphine-like substance from the brain
of pigs was isolated and shown to consist of two pentapeptides,
TABLE1.1:Differencesbetweenclassicalsmalneurotransmittersdput tiveep de transmitters(Hokf lt,1979) Molecularweight Synthesis Principle Localization Storage Supplyforrelease InactivationClassicalPutativepeptid transmitterstransmitters -200-30001 Enzymatic Nerveendings (cellbody,axon) Vesicles Localsynthesis Reuptake (Axonaltransport) Reuptake Enzymatic Diffusion
Ribosomal Cellbody Vesicles Axonaltransport Cleavagefromprecursor Enzymatic Diffusion
1Exceptionsarethnkephalinswithmolecularweig tsabout600.
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met-ENK and leu-ENK (see Figure 1.2) which differ only in having
methionine or leucine at the carboxyl terminal. The same two peptides
were also isolated from calf brain (Simantov and Snyder, 1976). By
using radioreceptor assay it was shown that the enkephalins were
localized in nerve endings (Simantov, Snowman and Snyder, 1976),
this being consistent with a neurotransmitter role, and in the monkey
brain their regional distribution closely parallels that of opiate receptors.
Moreover, it was described that the enkephalins are released in a
calcium-dependent manner with brain depolarization (e.g. Smith, Hughes,
Kosterlitz and Sosa, 1976; Iversen, Iversen, Bloom, Vargo and
Guillemin, 1978).
The five amino acids (residues) constituting met-ENK are contained
within the 91 amino acids of the peptide g-lipotropin isolated from the
pituitary by Li (1964). Several groups of investigators showed that
a variety of lipotropin fragments, all incorporating the met-ENK possess
opiate activity (e.g. Ling, Burgus and Guillemin, 1976). Within the
pituitary most opiate-like activity can be accounted for by g-endorphin,
the 31 amino acid peptide at the carboxyl terminal portion of g-lipotropin
(Goldstein, Tachibana, Lowney, Hunkapiller and Hood, 1979).
g-lipotropin itself derives from a 31,000 dalton precursor peptide which
also incorporates the sequence of ACTH, and hence is referred to as
31K ACTH (e.g. Mains, Eipper and Ling, 1977). g-endorphin occurs
in the brain in specific neuronal systems (e.g. Rossier, Vargo, Minick,
Ling, Bloom and Guillemin, 1977).
As Hughes ( 1978) pointed out recently, g-endorphin
may be considered as the prototype opioid peptide interacting equally
well with several or perhaps all opiate receptors. Met- and leu-ENK
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Composition of the neuropeptides studied in the present work.
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specific receptors. According to these authors, 6-endorphin should
be considered as having mainly a neuroendocrine function whereas the
enkephalins may have a neurotransmitter function.
Vasoactive intestinal polypeptide
VIP was identified in extracts of the gut as a vasodilator. It
was isolated as a 28 amino acid peptide (see Figure 1.2) with many
similarities in amino acid sequence and biological activity to the
intestinal peptides secretin and glucagon, namely stimulates the
conversion of glycogen to glucose, increases lypolysis and insulin
secretion, decreases the production of gastric acid, and stimulates
secretion by the pancreas and small intestine (Said and Mutt, 1970;
Mutt and Said, 1974). VIP was also found in the brain, the highest
levels occur in the cerebral cortex (Bryant, Polak, Modlin, Bloom,
Albuquerque and Pearse, 1976; Said and Rosenberg, 1976). The
VIP neurones are bipolar and oriented perpendicular to the surface
of the cerebral cortex. This makes them ideally suited to activate and
synchronize neuronal activity within the vertical columns of cerebral
cortical cells. VIP is a potent and rapid neuronal excitant in the hippo¬
campus, is stored in vesicles and is released with neuronal depolariza¬
tion (see Snyder, 1980).
It is interesting to note that the concentrations of VIP in the
carotid bodies and in the carotid sinus nerves from the cat are relatively
close (carotid body/carotid sinus nerve = 1.46). This contrasts with
the striking difference in relation to ACh (carotid body/carotid sinus
nerve = 3-4 or 30-40 depending on how ACh is determined - see above).
VIP infused close arterial to the carotid body increases chemoreceptor
activity (Fitzgerald, Raff, Garger, Fechter, Anand and Said, 1981).
This is statistically significantly different from the control at 15 and 20 s
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intervals. The doses of 5 or 25 |ig in 0.5 ml in six experiments each
caused similar effects, i.e. about 50% increase in relation to the pre-
injection period. Arterial pressure dropped in a dose-dependent manner
with the diastolic pressure being most affected, a characteristic response
to VIP.
Cholecystokinin octapeptide
CCK was originally isolated from the duodenum as a substance
that contracted the gall bladder. It is a 33 amino acid peptide (Mutt
and Jorpes, 1968) and is identical to pancreozymin. Whereas intestinal
CCK largely consists of the 33 amino acid residue peptide, the major
CCK entity in the brain is the COOH-terminal octapeptide (CCK-8)
(see Figure 1.2) with a lesser amount of the COOH-terminal tetrapeptide
and very little CCK-33 (Muller, Straus and Yalow, 1977; Rehfeld, 1978).
CCK is present in the cerebral cortex and with VIP are the only
brain peptides with cells in the cerebral cortex (see Snyder, 1980).
The concentration of CCK in total brain is about 1-2 mg in humans, far
greater than that of any other peptide (see Snyder, 1980). CCK-8 is
a quick and potent excitant of cerebral cortical cell firing with a fast
onset than ACh (Dodd and Kelly, 1979).
Like SP, CCK occurs in sensory fibres with cell bodies in dorsal
root ganglia and terminals in the dorsal grey matter of the spinal cord.
As with SP, neurotensin and the enkephalins CCK cells are abundant
in the hypothalamus, whereas the central nucleus of the amygdala has
a dense collection of CCK fibres but not cells (see Snyder, 1980). Like VIP
neurones CCK neurones are positioned in a similar way in the cerebral
cortex and hence similar function has been postulated for both substances




Next to the enkephalins, SP (see Figure 1.2) is the most
studied brain peptide. The role of SP as a sensory transmitter in
the pain reflex pathway has been extensively supported. It occurs
in 20% of dorsal root ganglia cells with some processes extending to
the skin and others entering the spinal cord and giving rise to terminals
in the substantia gelatinosa (see Hokfelt, Johansson, Ljungdahl,
Lundberg and Schultzberg, 1980). SP has been associated with sensory
nerves. For example, removal of the tooth pulp, which contains only
pain-sensitive sensory fibres, causes a loss of nerve endings that
contain SP in the trigeminal nucleus of the brainstem, where sensory
fibres terminate (Gobel and Binck, 1977).
Since SP is a 'pain' transmitter, the demonstrated blockade of
its release in spinal cord by opiates (Jessel and Iversen, 1977; Mudge,
Leeman and Fishbach, 1979) may account in part for opiate analgesia.
Interactions between the enkephalins and SP may occur in the central
nervous system, since neurones containing the two peptides are juxta¬
posed in such areas as the raphe nuclei, the ventral tegmental area,
the septum and the amygdala (see Hokfelt, Johansson, Ljungdahl,
Lundberg and Schultzberg, 1980).
The effects of SP on carotid chemoreceptor activity in the cat
have been studied by McQueen (1980) who found that SP causes a
delayed increase in spontaneous chemoreceptor activity.
The coexistence of peptides with classical transmitters and ATP
is now largely accepted (see e.g. the Neurosciences Research Program
edited by Burnstock, Hokfelt, Gershon, Iversen, Kosterlitz and
Szurszewski, 1979). In many tissues coexistence of receptors for
classical neurotransmitters such as ACh and catecholamines, for peptides
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such as the opioid peptides (met-, leu-ENK and 8-endorphin) and
for ATP and/or its metabolite adenosine, has been reported. Co¬
existence of substances has been found in the adrenal medullary cells
(Schultzberg, Lundberg, Hokfelt, Terenius, Brandt, Elde and Goldstein,
1978) and in the carotid body (Lundberg, Hokfelt, Fahrenkrug, Nilsson
and Terenius, 1979). The neurones that innervate exocrine glands,
including sweat and salivary glands and glands in the nasal mucosa and
tongue are innervated by cholinergic neurones, which contain a VIP-
like peptide (Lundberg, Hokfelt, Schultzberg, Uvnas-Wallenstein,
Kohler and Said, 1979). This is based on techniques that identified
in the same sections the existence of ACh-esterase rich neurones
containing VIP. This suggests that these neurones may release two
putative transmitters, ACh and VIP (Fahrenkrug, Haglund, Jodal,
Lundgren, Olbe and Schaffalitzky de Muckadell, 1978). For instance,
it has been postulated that ACh and VIP can be released from the same
nerve endings to participate in the secretory process: ACh mainly
causing secretion and VIP vasodilatation (see Hokfelt, Johansson,
Ljungaahl, Lundberg and Schultzberg, 1980). The VIP response is
atropine-resistant (e.g. Anga&ra, 1974). In the salivary gland
simultaneous infusion of VIP and ACh causes a marked potentiation of
both vasodilatary and secretory responses (Lundberg, Angaard,
Fahrenkrug, Hokfelt and Mutt, 1980).
The presence of neuropeptides in the carotid body together with
their apparent importance in neurotransmission in other parts of
the nervous system prompted the present interest on the investigation




Experiments were performed on 71 cats of either sex (26 females
and 45 males) weighing between 1.7 and 4.4 kg (mean 3.03 ± 0.05 kg).
In 2 cats no data were obtained: from the other 69 cats, 21 recordings
were from single chemoreceptor units and 48 from multiple units.
Anaesthesia
The animals were anaesthetized with pentobarbitone sodium,
42 mg/kg i.p., supplemented approximately every 1-2 hr during the
experiment by 10% of the initial dose administered i.v.
General
A cannula was inserted into the trachea low in the neck. Both
femoral arteries were cannulated, one catheter being connected to a
B.P. transducer (Bell and Howell, 4-442) and the other used for
withdrawing blood samples for gas analysis. The signal from the
pressure transducer was displayed on a pen-recorder (Ectromed, Mx 6)
and recorded on one channel of an FM tape recorder (Tandberg, 100;
frequency response d.c. to 1250 Hz). Arterial blood pH, P02 and
PC02 were measured at hourly intervals using a Radiometer gas monitor
(BMS 3 with PHM 71 meter). A femoral vein was cannulated and used
for drug administration. Rectal temperature was monitored and
maintained at 38 ± 0.5°C by an electric blanket.
The carotid bifurcation region was exposed and dissected free of
surrounding tissue. A cannula was inserted into the lingual artery
until its tip lay in the common carotid artery 1.5-2.0 cm caudal to the
carotid bifurcation. In some experiments a second catheter was
positioned in the same common carotid artery via the superior thyroid
artery about 3 cm caudal to the tip of the lingual catheter. The
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catheter dead-space was 0.3 ml. In the experiments in' which recordings
were made from both carotid sinus nerves another catheter was similarly
positioned in the other common carotid artery. The catheters were
used for both injections (0.1 ml) or infusions of drug solutions (0.1-0.5
ml/min using a Unita pump, Braua^ .
Respiration
The animals were artificially ventilated with room air by a respiratory
pump (S.R.I.), operating at 18 rev/min. End-tidal C02 was con¬
tinuously monitored by an infra-red C02 analyser (med 1A; Grubb
Parsons) and maintained at about 5% by appropriate adjustment of the
pump stroke volume. Hypoxic stimulation was achieved by ventilating
the animal with 10-15% 02 : 90-85% N2 or 100% N2. Adequate proportion
of the ventilating gases was achieved with flow meters.
Gallamine
The animals were paralysed during the experiment with gallamine
triethiodide (3 mg/kg i.v.), the dose being repeated as required, usually
every 1- 1.5 hr, when supplementing the anaesthesia. This neuro¬
muscular blocking drug was given to prevent muscle contractions,
either spontaneous or caused by the close-arterial injections of ACh,
from moving the nerve on the recording electrodes, and also to suppress
spontaneous respiratory movements which are associated with fluctuations
in end-tidal C02 and B.P. According to McQueen (1977) chemoreceptor
discharge obtained with the animal artificially ventilated and paralysed
is very similar to that observed when it was breathing spontaneously,
and remains relatively constant throughout the experiment. Gallamine
does not appreciably affect chemoreceptor activity evoked by NaCN or
ACh (see McQueen, 1977).
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Recording of sinus nerve activity
The sinus nerve was identified and sectioned central to its
junction with the glossopharyngeal nerve. Exposed tissues were
covered with warm (37°C) mineral oil. The outer sheath of the nerve
was removed and small filaments were dissected from the peripheral
end of the nerve trunk. Electrical activity from single or multiple
chemoreceptor units was recorded from the filaments using bipolar
platinum-iridium electrodes. Sensory nerve discharge was amplified
by an A.C. amplifier (Neurolog, Digitimer), displayed on an oscilloscope
(Tektronix 5103N) and recorded on one channel of the tape recorder
(see Figure 2.1).
Chemoreceptor units were identified by their random discharge,
their increase in discharge frequency following injection of NaCN
(usually 5 ug) into the ipsilateral common carotid artery, their increase
in discharge in response to hypoxia, and by the depression of sponta¬
neous discharge in response to hyperoxia (breathing 100% 02).
In the majority of the experiments, the ganglioglomerular nerves
(two to three sympathetic nerves from the superior cervical ganglion
to the carotid sinus region) were cut in order to eliminate reflex effects
of sympathetic activity on chemosensory discharge (Floyd and Neil,
1952; Eyzaguirre and Lewin, 1961).
Single-chemoreceptor units were identified from the constant shape
and amplitude of the action potential, and by delay of at least 7 ms
between successive spikes (Biscoe and Taylor, 1963). In most of the
multi-unit recordings it was found that a high dose of stimulant evoked
a maximum discharge which remained fairly constant during the course
of an experiment. If a unit was recruited, or another ceased responding,
the maximum discharge changed and this provided a quick method for
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Schematic representation of the recording, monitoring and drug
administering systems. The monitoring system includes: rectal tem¬
perature; electrocardiogram (ECG); femoral arterial blood pressure
(B.P.); femoral arterial blood samples for determining pH, Pa02,
PaC02 (B.SAMPLES); end-tidal C02. The recording system includes
aheadstage, A.C. pre-amplifier, A.C. amplifier, an audio-amplifier
and a tape-recorder. The drug administering system includes: intra-
carotid injections or infusions through catheters inserted via the lingual
or superior thyroid arteries (I.C. INJ./INF.) and intravenous injections
(I.V. INJ.) via a femoral vein. Different gas mixtures could be
administered through the respiratory pump.
In the upper left of the figure the anatomy of the region (right side)
is represented. The carotid sinus nerve (sn) from which the recordings
were obtained can be seen, as can the relative positions of the lingual
(la) and superior thyroid (sta) arteries in relation to the carotid body
(cb). The figure also shows the ganglioglomerular (sympathetic) nerves
which course between the superior cervical ganglion (scg) and the
carotid body.
monitoring units and was used in conjunction with visual checking of
the action potentials on the oscilloscope (see McQueen, 1977). Analysis
was performed only if the number of units being examined, usually
2-3, remained constant throughout the experiment.
Drug administration
Intracarotid injections
Intracarotid injections were generally made in a volume of 0.1 ml
into the common carotid artery and washed in with 0.2 ml Locke
modified solution which had been bubbled with 5% C02 : 95% air in a
water bath at 37°C. Injections were made at the peak of the inspiratory
phase of the respiratory cycle and generally completed within one
respiratory cycle, usually within 2 s. A period of 3 - 5 min was
allowed between injections of test drugs, unless otherwise indicated
in the text. Drugs were injected intravenously in a volume of 0.2-1.0
ml and the catheter flushed with 0.5 ml 0.9% w/v aqueous sodium chloride
(saline). Responses of the chemoreceptors to C02 were obtained by
i.e. injection of 0.1-0.3 ml Locke solution equilibrated with 100% C02.
Control injections of modified Locke, i.e. 0.1 ml Locke equilibrated
with room air, were administered i.e. and the catheter flushed with
0.2 ml Locke bubbled with 5% C02 in air, in every experiment.
Data analysis
Data were analysed according to McQueen ( 1977). The output of
the tape channel containing the action potentials passed through a
filter module (DC - 10 KHz with 50 Hz notch) and fed to a pulse height
discriminator (WPI mod. 120) and information relating to the number of
pulses occurring in 0.1sbins was processed by a PET 32K microcomputer
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(Commodore, 303 series). The data were stored on a dual drive floppy
disk (3040 series) and subsequently analysed with the aid of the micro¬
computer (see Figure 2.2).
Average discharge (x) in the pre-stimulus (injection or infusion)
or 'control' period, generally 20 - 50 s, unless otherwise indicated in
the text, was computed from data stored on the floppy disk. The
average and total counts (Ix) were calculated for each response after
its duration (t s) had been determined by the computer. Responses
were expressed as increments above the control level by subtracting
the appropriate values, i.e.:
Ax = x (response) - x (control)
A Ex - Ex (response) - Ex (control)
where Zx(control) = x (control) x t (response duration, s).
Data are expressed in this way since measurement of A Ex takes into
account any variation in t as well as any change in x (see McQueen,
1977), and control experiments showed that control x does not vary
appreciably over 10- 20 min periods.
Dose-response data and presentation of data
Data from more than one experiment were usually pooled and
expressed as the mean ± s.e. mean. In order to determine whether
changes observed were statistically significant, particularly when they
were small, responses to particular drug doses in the different experi¬
ments were compared with the corresponding responses to the drug
vehicle in the same experiments using either the Wilcoxon signed ranks
test (when the number of pairs 7) or Student's paired ^test (for ^ 6
pairs, and assuming Gaussian distribution) (see Colquhoun, 1971).
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FIGURE 2.2
Schematic representation of the system used to analyse data. The
information (chemoreceptor discharge) stored on a FM tape was fed
a PET 32K microcomputer and then stored on a floppy disk for sub¬
sequent analysis.
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The null hypothesis was rejected if P <0.05 and the difference between
groups considered to be statistically significant.
Whenever possible, responses to a range of doses of test drug
were obtained and AZX plotted against log10 dose. The portion of the
dose-response curve over which the relationship between dose and
response was approximately linear was determined and a straight line
was fitted to the points using the method of least squares.
Linearly related dose-response data was obtained whenever
possible. However, owing to the limited and somewhat unpredictable
duration of a given recording it was considered expedient, in some
cases, to administer test drugs in single doses before and after
administration of another drug. The usefulness of data derived from
single dose studies of this type was limited inasmuch as subtle changes
in responsiveness were difficult to detect and dose-ratios could not be
calculated. Nevertheless data of this type was considered a useful
supplement to linearly-related dose-response data obtained for other
drugs in the same experiment.
Drugs
Drugs were prepared in modified Locke solution (NaCl 6.0 g;
KC1 0.42 g; CaCl2 0.24 g; Tris base 6.0 g; N-HC1 39 ml; distilled
water to 1.0 1; pH 7.41 at 37°C , 295 m osmoles) or 0. 9% w/v aqueous
sodium chloride solution (297 m osmoles). Exceptions were dipyridamole
which was initially dissolved in polyethyleneglycol 200, and 8-endorphin
in 0.5% aqueous bovine serum albumin solution, then both were diluted
with saline. Doses referred to are those of the salts.
The drugs used in this work were: pentobarbitone sodium,
gallamine triethiodide, morphine sulphate (May & Baker), acetylcholine
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iodide, atropine sulphate, physostigmine salicylate, sodium cyanide
(B.D.H.), dopamine hydrochloride (Koch Light), a(cis)-flupenthixol
dihydrocnloride (Lundbeck & Co.), mecamylamine hydrochloride
(M.S.D.), naloxone hydrochloride (Endo), adenosine, adenosine
5'-monophosphate , adenosine 5'-diphosphate , adenosine 5'-triphosphate,
coenzyme A, a-g-methylene adenosine 5'-triphosphate , g-y-methylene
adenosine 5'-triphosphate, cyclic AMP, dibutyryl-cyclic AMP, adenine,
inosine , guanosine , cytidine , uridine, N6-methyladenosine , 2'-chloro-
adenosine, 3'-deoxyadenosine , 2'-deoxyadenosine , theophylline,
aminophylline, imidazole, methionine-enkephalin, leucine-enkephalin,
substance P, ouabain octahydrate (Sigma), cholecystokinin octapeptide
non-sulphated (Peninsula Labs), human g-endorphin (Aalton Bio Reagents,
Dublin), porcine g-endorphin (kindly supplied by Dr. D. Smyth, National
Institute for Medical Research, London), vasoactive intestinal polypeptide
(kindly supplied by Dr. S.I . Said, University of Texas Health Science
Center, Dallas, U.S.A.), dihydro-ouabain (Boheringer Manheim),
dipyridamole (Boheringer Ingelheim).
SECTION III
The Effects of Purines
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INTRODUCTION
It has been shown that ATP is present in the carotid body
(Nada and Ulano, 1972) and high concentrations of the nucleotide were
found within specific granules of the type I cells stored together with
catecholamines and proteins (Bock, 1980).
In view of the suggestions that ATP and adenosine, a metabolite
of ATP, may play roles in neurotransmission (see e.g. Burnstock,
1972; Ribeiro, 1978), the opportunity was taken to investigate the
action of adenosine and ATP on the carotid body chemoreceptors.
Adenosine antagonists such as theophylline and aminophylline, adenosine
uptake blockers such as dipyridamole, ATP, and adenosine analogues
were also studied in order to characterize the purine receptors involved.
Cyclic AMP and dibutyryl cyclic AMP were used to provide some





The effects of intracarotid injection of different doses of adenosine
on spontaneous chemoreceptor discharge are illustrated in Figure 3.1.
Discharge for each test was averaged over 10 s periods commencing 10 s
before and continuing for 60 s after the injection. As can be seen from
either the neurograms or the averaged discharge, the main effect was
a dose-dependent increase in the frequency of discharge. No tachy¬
phylaxis to the action of adenosine was observed. Thus, when injected
at intervals of 5 min over a period of 1 h, there was no diminution of
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FIGURE 3.1
Effects of intracarotid (i.e.) injections of adenosine on the frequency of
spontaneous chemoreceptor discharge. A. a) Neurograms taken from
one experiment show the increase in the discharge of a single unit
(insert, i) caused by injecting (arrow) adenosine 0.1 and. 1 ug; in (i)
the duration of the action potential is shown, the trace being of 10
consecutive superimposed spikes, b) Responses of the chemoreceptor
unit to i.e. injection of 0.1 ml of the Locke solution flushed in by 0.2 ml
of Locke solution (total Locke solution injected 0.3 ml), and to adenosine:
0.001 ug; 0.1 ug and 1 ug. B. Responses of three chemoreceptor units
to adenosine: 1 ug; 10 ug and" 100 ug.
The graphs show the intensity and duration of the responses averaged
over 10 s periods following the injections.
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Low doses of adenosine (0.001-0.01 ug) caused a decrease in
chemoreceptor discharge during the first 10 s following the injection
(see Figure 3.1), an effect which appeared to be most pronounced for
the lowest dose. However, a slight inhibition of spontaneous discharge
was also usually associated with injection of the same volume of drug
vehicle, Locke solution (see Figures 3.1 and 3.2), so responses to the
low doses of adenosine were studied (see Figure 3.2) and compared with
responses to injections of Locke solution (0.3 ml). There was no
significant difference (P >0.05) between the responses to adenosine and
Locke solution in these experiments.
Data obtained from ten experiments were averaged over 5 s
periods for 30 s after the injection, pooled and plotted against time
(Figure 3.2). This quantitative evidence confirmed that the increases
in discharge were dose-related. The peak of the discharge occurred
between 5 and 10 s after the injections for all doses (0.1- 100 ug),
although that caused by 0.1 |ig was not significantly different from that
caused by the highest dose studied, 100 ug (P >0.05). The increase
caused by adenosine (1- 100 pg) was significantly different from the
control (P <0.05) in the first 5 s following the injections. The threshold
dose for the adenosine excitatory action is thus between 10 and 100 ng.
Injections of Locke solution were also made in these experiments and the
results obtained summarized in Figure 3.2. They confirm the transient
inhibitory effect of Locke solution illustrated in Figure 3.1. A significant
decrease in discharge occurred during the first 5 s following the
injection (P <0.05, compared with the pre-injection averaged discharge).
This was much less marked and not statistically significantly different
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FIGURE 3.2
Effects on spontaneous chemoreceptor discharge (ct/s) of injecting
Locke solution (0.3 ml, see legend of Figure 3.1) and adenosine (0.001;
0.01; 0.1; 1; 10; 50 and 100 ug). Discharge was averaged over 5 s
periods following the injection. Data obtained from ten cats were
pooled and presented as the mean with vertical bars indicating s.e.
mean. The panel on the right shows an arterial blood pressure (B.P.)
trace after injecting (arrow) 100 |ig of adenosine in one experiment.
B.P. calibration, 0-100-200 mmHg.
* P <0.05 compared with Locke solution injections.
** P <0.05 compared with pre-injection (control) period.
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Results from four experiments in which both average discharge
and maximum discharge, expressed as ct/s, were obtained in response
to different doses of adenosine are compared and summarized in
Table 3.1. The average spontaneous chemoreceptor discharge was
determined in the 15 s pre-injection control period immediately preceding
each injection and in the 15 s post-control period commencing 45 s
after the injections. Responses to adenosine were evaluated by deter¬
mining the average discharge in the period during which discharge was
increased above control frequency. Apart from increasing the average
discharge, adenosine also increased the maximum discharge frequency.
This latter increase, however, was not so marked as that averaged over
the whole period, showing that the overall increase in discharge caused
by adenosine resulted from a sustained increase throughout the response
rather than from a sudden transient increase, such as occurs with
ACh (cf. McQueen, 1977). The duration of the adenosine response was
dose-dependent, and the delay to onset of the response was inversely
related to dose.
The effects obtained were not related to changes in systemic
blood pressure since adenosine in the doses studied did not cause any
consistent or substantial changes in arterial blood pressure, as can be
seen from Figure 3.2. Neither were changes in arterial blood gas
tensions nor pH observed following administration of adenosine.
Infusions of adenosine
Adenosine was infused at a rate of 50 pg/min for 2 min; six
infusions were performed in two cats. A sustained increase in chemo¬
receptor discharge occurred, which returned to pre-infusion control
levels within 30 s of stopping the infusion (Figure 3.3). The peak
response was significantly different from the control, whether this was
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taken as the pre-infusion discharge or the discharge averaged during
an infusion of the same volume of the vehicle Locke solution (0.1 ml/
min). The infusion of Locke solution had no appreciable effect on
spontaneous discharge (Figure 3.3). Adenosine infusions were not
associated with changes in systemic blood pressure, as can be seen
from Figure 3.3, or with marked changes in arterial blood gas tensions
or pH (see legend of Figure 3.3).
Adenosine triphosphate
ATP (1- 100 |ig i.e.) increased the spontaneous chemoreceptor
discharge (see Figures 3.4 and 3.5). Data obtained from six experi¬
ments were pooled and expressed in ct/s ± s.e. mean and plotted as a
function of time during the 50 s period following the injections (Figure
3.5). Control injections of Locke solution (0.3 ml) were carried out
in all experiments; they caused a slight decrease in spontaneous
chemoreceptor discharge in the first 10 s after injection followed by
slight oscillations (increases and decreases) in the discharge.
Statistical analysis of the results was carried out by comparing the
frequency of the discharge averaged in 5 s periods after injecting ATP
with that averaged during the same periods following injection of Locke
solution. The comparison using Student's paired T-test showed that
ATP significantly increased the discharge between 5 and 10 s, after
injecting ATP 10 pg, and between 5 and 15 s after ATP 100 ag (P <0.05)
(Figure 3.5). The effect was dose-dependent and the response lasted
25 to 30 s for the higher dose. Recovery to the control levels occurred
for the higher dose in the next 20 s, i.e. in 50 s after the injection.
No tachyphylaxis to the action of ATP was observed, thus when
injected at intervals of 5 min over a period of 1 hr, there was no






























Pooled data from 6 infusions of adenosine (50 |ig/min i.e.) in two cats
showing the effect on spontaneous chemoreceptor discharge. The
broken line represents the typical discharge during an infusion of
Locke solution (0.1 ml/min). The horizontal bar indicates the duration
of infusions. The upper panel shows a blood pressure trace recorded
during one of the adenosine infusions. B.P. calibration is 0-100-200
mmHg. Arterial blood samples taken during an adenosine infusion
gave values of pH 7.36, Pa02 105 Torr, PaC02 30 Torr, compared with
pre-infusion sample values of pH 7.35, Pa02 105 Torr, PaC02 30 Torr.
* P <0.05 paired t-test, compared with pre-infusion control period.
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The effect was not associated with changes in the arterial blood
pressure as can be seen from a blood pressure trace illustrated in
Figure 3.10.
Comparison between the effects of ATP, ADP, AMP and adenosine
A close comparison between the effects of ATP and adenosine was
carried out in six cats. The results from these experiments are
summarized in Figure 3.6, chemoreceptor responses were expressed
as the increase in the discharge in the 30 s immediately following
injections. Discharge, expressed as AEx, was plotted against dose
expressed in moles. The results show that both substances caused
similar quantitative effects when compared on a molar basis adenosine
(m.w. = 267), ATP (m.w. = 507). However, the effect of adenosine had
a faster onset, for example, adenosine (1- 100 |ig) caused increases in
chemoreceptor discharge statistically significantly different from the
Locke solutions in the first 5 s after injection (Figure 3.2), whereas
although ATP caused a significant increase, it occurred only in the
period between 5 and 10 s following the injection for the doses of
10-100 ug (Figure 3.5).
The effects of ADP and AMP were also investigated in two cats
and compared with those of adenosine and ATP (Figure 3.7). All
four substances (1- 100 pg i.e.) caused a dose-related increase in
spontaneous chemoreceptor discharge but the effects of lower doses of
ATP, ADP and AMP were smaller than those obtained with adenosine.
However, if those doses are expressed in moles the substances appear
to have an activity which is very similar to that of adenosine.
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FIGURE 3.4
Recording of a single chemoreceptor unit illustrating the response of
ATP (1 ug i.e.). Panel shows from above downwards: action
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FIGURE 3.5
Effects on spontaneous chemoreceptor discharge (ct/s) of injecting
Locke solution (0.3 ml, 0.1 ml + 0.2 ml to flush in, see legend of
Figure 3.1) and ATP 1 ug, 10 |ig and 100 yg i.e. Discharge was
averaged over 5 s periods following the injections. Data obtained
from tests in six cats were pooled and presented as the mean ± s.e.
mean.
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FIGURE 3.6
Comparison of ATP with adenosine on spontaneous chemoreceptor
activity. Each point is the average ± s.e. mean of six experiments
expressed as the increase on spontaneous discharge occurring in the
30 s and following the injections. The broken lines are extrapolations.
Lines were fitted to the data by the method of least squares. Averaged
values ± s.e. mean (ct/s) for the pre-injection (15 s) control periods
are as follows: adenosine 2 x 10 moles 3.7 ±0.9; 20 x 10~7 moles
4.2 + 0.9 and 200 x 10~7 3.9 ± 1.2; ATP 4 x 10" 7 moles 3.2 + 0.8, 40 x 10"7
2.7 + 0.6 and 400 x 10~7 moles 3.2+0.9. Chemoreceptor responses are
expressed as the mean AZx(see Section II, Methods and Materials)





































Comparison between the effects of ATP, ADP, AMP and adenosine
on spontaneous chemoreceptor discharge in two cats (recordings from
a total of 2 - 3 chemoreceptor units). Averaged values (ct/s) for the
pre-injection (15 s) control periods are as follows: ATP 1 pg 1.1,
10 pg 3.2, 100 pg 1.7; ADP 1 pg 5.1, 10 pg 3.3, 100 pg 3.6;




In view of the suggestion that coenzyme A ( CoA), a naturally
occurring adenine compound, could play a role in neurotransmission
(Cook, Hamilton and Okwuasaba, 1978), an investigation was under¬
taken to determine whether CoA affected carotid body cnemoreceptor
activity and to compare its effects with those of ATP and adenosine
in the same animal.
Results from one of the experiments in which CoA was studied
(1- 100 |ig i.e.) are illustrated in Figure 3.8. CoA increased chemo-
receptor discharge in a dose-dependent manner and its effect was
similar to that caused by both adenosine and ATP.
Since the effect of CoA was not markedly different from that of
ATP or adenosine its activity is probably related to the adenine
nucleotide portion of the molecule.
ATP in the presence of adenosine and adenosine in the
presence of ATP
In order to test whether ATP acted in the same way as adenosine
an experiment was performed in which ATP (100 |ig) was injected i.e.
during an infusion of adenosine (5 ug/min i.e.). As can be seen in
Figure 3.9, the presence of adenosine reduced the full chemoreceptor
response to ATP, such was obtained before starting the infusion of
adenosine.
In another experiment adenosine (50 ug i.e.) was injected 20 min
after starting an ATP infusion (10 ug/min i.e.). The excitatory response
to adenosine was reduced from AEx = 55 counts before starting the ATP






































Effects of coenzyme A (CoA) on chemoreceptor activity and its
comparison with ATP and adenosine in a cat (recordings from 3-4
chemoreceptor units). Values (ct/s) for the pre-injection (15 s)
control period are as follows: ATP 1 |ig 1.5, 10 ug 1.8, 100 ug 2.0;
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FIGURE 3.9
Effect of ATP on chemosensory discharge (recordings from 2-3
chemoreceptor units) in the presence of an adenosine infusion. The
upper panel shows from left to right the responses to ATP (100 pg
i.e.) obtained immediately before starting the infusion and at 25 and
35 min. The lower panel shows the increase in spontaneous chemo¬
receptor discharge observed after starting adenosine infusion (5 pg/
min i.e.). The horizontal bar indicates the duration of the infusion.
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ATP analogues: a- g-methylene ATP and g-y-methylene ATP
The bigger delay to onset of response seen with ATP, in
comparison with adenosine (see Figures 3.2 and 3.5) suggests that the
effect of ATP might result from it being hydrolysed to adenosine.
To test this further the effects of the non-hydrolysable ATP analogues:
a- g-methylene ATP and g-y-methylene ATP were investigated. The
effects of these substances were compared with ATP in four cats and
the results are summarized in Figure 3.10. In contrast to the effects
of ATP, a~6-methylene ATP (100 ug i.e.) caused a decrease in
spontaneous chemoreceptor discharge; the effect was associated with
an increase in arterial blood pressure. The effect of g-y-methylene
ATP (100 ug i.e.) was not so clear-cut since in one experiment it
caused an effect similar to that of ATP itself while in another three
experiments it caused a smaller increase in discharge. Averaging the
four experiments the mean increase was not statistically significantly
different either from the Locke solution injections or from the pre-
injection discharge (P >0.05).
Dipyridamole
The effect on spontaneous chemoreceptor discharge of infusing
dipyridamole (50 ng/min i.e.) is illustrated in Figure 3.11. The
substance increased the discharge during the period of infusion (20
min), discharge returning to control values 10 min after stopping the
infusion.
The effects of lower doses (1 ug i.e.) of both adenosine and
ATP were potentiated during dipyridamole infusion (50 ug/min i.e.)
but the effects induced by higher doses (100 jjg i.e.) were reduced and
the chemoexcitation caused by adenosine was converted into a biphasic
response with an early inhibitory component (see Figure 3.12).
68.












0 20 40 60
n = A
0 20 40 60
n = A
J L
0 20 40 60
Time (s) after injection
FIGURE 3.10
Comparison of the effects of non-hydrolysable ATP analogues,
a-6-methylene ATP and 8-y-methylene ATP with ATP on spontaneous
chemoreceptor discharge (ct/s). The upper panel shows the effects
on arterial blood pressure (B.P.) and of injecting ATP, a-6-methylene
ATP and 6-y-methylene ATP on spontaneous discharge in the same cat
(recordings from 3-4 chemoreceptor units). The lower panel shows










Effect of dipyridamole on spontaneous chemoreceptor discharge (ct/s).
Horizontal bar indicates duration of infusion. The black rectangle
indicates the average discharge in the 2 min that preceded the infusion.
Recordings from 3-4 chemoreceptor units.
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FIGURE 3.12
Effects of adenosine (i.e.) and ATP (i.e.) on spontaneous chemo-
receptor discharge (ct/s) (recordings from 3-4 chemoreceptor units)
A) before, and B) in the presence of dipyridamole (50 pg/min i.e.).
Above each graph is shown the B.P. trace recorded after injecting
the substances. B.P. calibration 0-100-200 mmHg.
Dose-response curves to adenosine ( 1- 400 |jg i.e.) were
obtained before and after dipyridamole (50 |ig/min i.v.) (Figure 3.13).
As can be seen dipyridamole itself administered intravenously caused
a slight increase in spontaneous chemoreceptor discharge during the
period of infusion (10 min) and dose-response curves to adenosine
were shifted upwards and to the left during dipyridamole intravenous
infusion (Figure 3.13).
Specificity for adenosine
A number of neucleosides have actions on neurotransmission
(e.g. Phillis, Edstrom, Kostopoulos and Kirkpatrick, 1979). So it was
considered of interest to evaluate the effect of some of those substances
on the carotid body chemoreceptor activity in order to explore the
specificity of the adenosine receptor. Figure 3.14 summarizes results
from two experiments in which adenine, the purine nucleosides
inosine and guanosine, and the pyrimiaine nucleosides cytidine and
uridine were tested. The effects were compared with those of adenosine
itself. As can be seen neither adenine (10- 100 |ig) nor the nucleosides,
inosine, guanosine, cytidine or uridine, caused any substantial changes
in the spontaneous chemoreceptor discharge, whereas adenosine caused
the usual increase in discharge.
Evoked responses
Figure 3.15 shows responses to single doses of NaCN (5 |ig i.e.),
C02-equilibrated Locke solution (0.3 ml i.e.) ACh (50 ug i.e.) and
dopamine (5 jig i.e.) obtained before and after (5-20 min) injections
of adenosine (100 ug i.e.). The chemoexcitatory responses evoked by
both NaCN and C02 were decreased after adenosine, the chemo-
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FIGURE 3.13
The upper part of the figure shows the effect of dipyridamole
(50 pg/min i.v.) on spontaneous chemoreceptor discharge (ct/s)
(recordings from 3 chemoreceptor units). The horizontal bar
indicates the duration of the infusion and the black rectangle the
discharge averaged in the 2 min that preceded the infusion. In the
lower part the dose-response curves to adenosine (i.e.) obtained
before (filled circles) and during (filled squares) a dipyridamole
infusion are shown. Values (ct/s) for the pre-injection (15 s) control
periods are as follows: adenosine 1 |ig 2.7 before dipyridamole,
2.6 during dipyridamole infusion; 10 pg 2.0 before, 2.5 during;
100 pg 3.8 before, 3.3 during; 200 pg 3.4 before, 4.5 during;
























Comparison between the effects of adenosine, adenine, inosine,
guanosine, cytidine and uridine in two cats (recordings from a total
of 5 - 7 chemoreceptor units). Averaged values (ct/s) for the pre-
injection (15 s) control periods for 10 and 100 pg respectively are
as follows: adenosine 3.4, 3.0; adenine 2.3, 2.1; inosine 3.5, 3.2;
guanosine 6.3, 7.8; cytidine 3.1, 2.7; uridine 1.5, 1.2.
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excitatory response evoked by ACh was enhanced, and the chemo-
inhibitory response evoked by dopamine was also increased. These
single dose results are not so reliable as dose-response curve studies
(but see Section II, Methods and Materials). In order to investigate
further whether adenosine influenced the responses evoked by those
substances, dose-response curves to NaCN (1-5 |ig i.e.), ACh
(10-50 |ig i.e.) and dopamine (1-5 ug i.e.) obtained before and during
adenosine infusions (10 ng/min i.e.) were performed in one experiment
and the results are shown in Figure 3.16. The excitatory responses
evoked by NaCN were not consistently changed during infusion of
adenosine as compared with the pre-infusion responses, whereas both
the chemoexcitatory responses evoked by ACh and the chemoinhibitory
responses evoked by dopamine were enhanced during adenosine infusions.
Theophylline and aminophylline
Methylxanthines, particularly theophylline and aminophylline,
have been considered as adenosine antagonists (for a review see e.g.
Fredholm, 1980). It was decided to study the effects of theophylline
and aminophylline on chemoreceptors and to determine whether these
substances influenced the chemoreceptor responses to adenosine.
Theophylline (1 mg) was injected i.e. in five cats and caused
a decrease in spontaneous chemoreceptor discharge, an effect which
lasted about 30 s. The integrated response (Alx) showed that the
depression was significantly greater (P <0.05) than that caused by
injecting Locke solution (Figure 3.17). Although theophylline transiently
decreased spontaneous chemoreceptor discharge, it did not prevent the
excitatory action of adenosine, and as can be seen in Figure 3.18, the































Effects of adenosine (100 jag- i.e.) on the chemoreceptor responses
evoked by NaCN, C02-equilibrated Locke solution (C02), acetyl¬
choline (ACh) and dopamine (DA) before (□) and after (□) adenosine
injections. Averaged values (ct/s) for the pre-injection (10-15 s)
control periods are as follows: NaCN before 5.5 ± 1.6, after 3.8 ± 0.6;
C02 before 5.1 ± 1.4, after 5.3 ± 1.5; ACh before 3.9 ± 1.8, after










Dose-response curves to NaCN, ACh and dopamine (DA) i.e. obtained
before (filled circles) and during (filled squares) an adenosine infusion
(10 pg/min i.e.) in one experiment (recordings from a single chemo-
receptor unit). Lines were fitted to the data by the method of least
squares. Averaged values (ct/s) for the pre-injection (10-15 s)
control periods are as follows: NaCN before adenosine infusion 1 |ig
3.5, 2.5 |ig 2.1, 5 ug 3.1; during infusion 1 |ig 4.0, 2.5 ug 3.7,
5 |ig 2.1; ACh before 10 ug 4.1, 25 ug 3.1, 50 ug 2.3; during infusion
10 |ig 2.2, 25 ug 5.1, 50 ug 6.8; DA before 1 ug 0.7, 2.5 ug 0.7,
5 ug 2.1; during infusion 1 ug 3.6, 2.5 ug 3.4, 5 ug 2.9.
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left which is indicative of an increase in the responses after theo¬
phylline; the response to adenosine 100 |ig was statistically significantly
greater after theophylline than it was before (P <0.05, n=4).
Injections of lower doses of theophylline (100 - 200 ng i.e.) did
not cause any significant effect on the spontaneous discharge (P >0.05,
n=3 pairs), and the excitatory effect of adenosine (1- 100 |ig) was
unaltered by these doses (P >0.05, n=3 pairs).
Aminophylline (1 mg i.e.) was injected in one cat and the effect
of adenosine (1- 100 |ig) tested before and after the injection.
A transient depressant effect similar to that seen with theophylline
was observed, and the excitatory action of adenosine was also un¬
diminished after aminophylline.
Neither theophylline (Figure 3.17) nor aminophylline caused any
marked changes in blood pressure and the highest dose of adenosine
studied (100 ug) did not alter arterial blood pressure when injected
post-theophylline.
Imidazole
The effect of imidazole, a stimulator of phosphodiesterases
(Butcher and Sutherland, 1962; Huang and Kemp, 1971) was also
investigated on spontaneous chemoreceptor discharge. Imidazole
(10 - 400 tig i.e.) was tested in two experiments. High doses (400 |ig)
inhibited markedly chemoreceptor discharge. Recordings from a single
chemoreceptor unit showed a reduction from 0.48 ct/s to 0 ct/s in the
10 to 60 s that followed the injection of imidazole; the discharge
recovered in the next 60 - 80 s. Lower doses (10 ug) increased
transiently chemoreceptor discharge from 6.4 ct/s (recordings from
2-3 chemoreceptor units obtained in another experiment) to 8.4 ct/s in
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FIGURE 3.17
Effect on spontaneous chemoreceptor discharge (ct/s) of injecting
theophylline 1 mg i.e. (■■■) compared with that of injecting Locke
solution (0.3 ml) (—) in five cats. Discharge was averaged over 10 s
periods following the injection. The upper panel shows the effect
on arterial blood pressure of injecting (arrow) 1 mg of theophylline
in one experiment.
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FIGURE 3.18
Dose-response data for adenosine obtained before (•) and after
(■) theophylline (1 mg i.e.) in four experiments. Doses (|ig i.e.)
are plotted on a logio scale and chemoreceptor responses expressed
as the mean £ Ex for the four experiments + s.e. mean. Lines were
fitted to the data by the method of least squares. Averaged values
± s.e. mean (ct/s) for the pre-injection (15 s) control periods are as
follows: 1 |ig 4.5 ± 1.0 before theophylline, 6.5 ± 1.4 after;
10 |ig 5.5 ± 1.4 before, 7.8 + 1.7 after; 50 |ig 3.5 ± 1.1 before,
5.2 ± 1.4 after; 100 |ig 3.9 ± 1.7 before, 5.1 ± 2.0 after.
* P <0.05 (paired t^test).
80.
a-flupenthixol
The effects of adenosine on chemoreceptor discharge were studied
in two cats before and after injecting a-flupenthixol (0.2 mg/kg i.e.),
a dopamine antagonist. Figure 3.19 illustrates the chemoinhibitory
responses to dopamine (5 jig i.e.) obtained before and after
a-flupenthixol and the chemoexcitatory responses to adenosine (10-
100 jig i.e.) observed before and after a-flupenthixol. As can be
seen, a-flupenthixol antagonized the inhibition caused by dopamine
but potentiated the chemoexcitatory responses induced by adenosine.
Cyclic AMP and dibutyryl cyclic AMP
Adenosine increases the concentration of cyclic AMP in many
preparations both in vitro and in vivo (for a review see Daly, 1977).
In order to know whether cyclic AMP and dibutyryl-cyclic AMP have
any effect on arterial chemoreceptors, the substances were administered
i.e. Figure 3.20 shows dose-response curves to both cyclic AMP
(10 - 800 |ig) and dibutyryl-cyclic AMP ( 10 - 800 ug) obtained in the
same cat together with responses to adenosine (10- 100 jig i.e.). As
can be seen both cyclic AMP and dibutyryl-cyclic AMP increased
spontaneous chemoreceptor discharge but both these substances were
less effective than adenosine.
Adenosine analogues : N6-methyladenosine , 3'-deoxyadenosine ,
2'-chloroadenosine and 2'-deoxyadenosine
Chemoreceptor responses to adenosine analogues were compared
with those to adenosine in four cats and the results are summarized
in Figure 3.21. N6-methyladenosine and 2'-chloroadenosine which
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Effects on chemoreceptor discharge of injecting i.e. dopamine (DA)
and adenosine before (BEF.) and after a-flupenthixol in two cats.
Averaged values (ct/s) for the pre-injection (10-15 s) control
periods are as follows: DA 10.2 before a-flupenthixol, 14.9 after
a-flupenthixol; adenosine 10 ug 10.7 before, 18.9 after; 100 ag
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FIGURE 3.20
Effects of cyclic AMP (cAMP) and dibutyryl-cyclic AMP (Db-cAMP)
on spontaneous chemoreceptor activity compared with adenosine.
Recordings from a single chemoreceptor unit. Lines for cAMP and
Db-cAMP were fitted to the data by the method of least squares.
Values (ct/s) for the pre-injection (15 s) control periods are as
follows: adenosine 10 ug 0.1, 100 ug 0.2; cAMP 10 jig 0.3,
200 |ig 0.1, 400 |ig 0.1, 800 ug 0.1; Db-cAMP 10 ug 0.1,



































Effects of adenosine analogues on spontaneous chemoreceptor
discharge and their comparison with adenosine in four cats. Data
were pooled and shown as mean ± s.e. mean. At the bottom averaged
values (ct/s) ± s.e. mean for the pre-injection (15 s) control periods
are shown.
* P <0.05 (paired t-test compared with any of the other responses).
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their effects were very similar to adenosine; 3'-deoxyadenosine which
acts in both R and P-sites (Londoa and Wolff, 1977) but has higher
affinity for R-site also increased chemoreceptor discharge, whereas
2' -deoxyadenosine which acts only on P-site had little or no effect
on spontaneous discharge.
Adenosine and hypoxia
It has been shown in a number of tissues (e.g. heart)
that hypoxia can release considerable amounts of adenosine (see e.g.
Berne, 1980). Two different experimental protocols were designed
to test the effect of hypoxia in the presence of a high concentration
of adenosine and the effect of adenosine in the presence of hypoxia on
arterial chemoreceptor discharge. In the first experimental protocol
after 2 min of infusing adenosine (100 ag/min i.e.) a hypoxic stimulus
(10% 02 + 90% N2) was applied, and a marked increase in chemoreceptor
discharge occurred additional to the increase caused by adenosine
(see Figure 3.22). After withdrawing the hypoxic stimulus, chemo¬
receptor discharge returned to about the same level as before. This
suggests that, if adenosine is involved in the hypoxic stimulation of
the carotid body chemoreceptors, other substances besides adenosine
are responsible for the chemoexcitation.
The second experimental protocol is illustrated in Figure 3.23.
Adenosine (50 ug/min i.e.) was infused in the presence of hypoxia
and as can be seen it still increased chemoreceptor activity. This
seems to indicate that the adenosine receptor is not fully saturated by












Effect of hypoxic stimulation (ventilation with 10% 02 + 90% N2) on
chemoreceptor discharge (ct/s) in the presence of A) adenosine
(100 ng/min i.e.) (recordings from a single chemoreceptor unit).
The black rectangle represents the discharge averaged 60 s before
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FIGURE 3.23
Effect of an adenosine infusion (50 |ig/min) on chemoreceptor
discharge (ct/s) before (A) and (B) in the presence of hypoxic
stimulation (10% 02 + 90% N2). Recordings from a single chemo¬
receptor unit. The left side of the figure shows the response to an
adenosine infusion recorded before hypoxic stimulation. The black
rectangles represent the pre-infusion (control) discharge averaged
in the 30 s (left) and 60 s (right) that preceded the adenosine
infusion or the hypoxic stimulation.
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DISCUSSION
The results of this section show that the predominant effect
of injecting or infusing adenosine close-arterial to the cat carotid
chemoreceptors is an increase in spontaneous chemosensory discharge
frequency. Adenine nucleotides (AMP, ADP and ATP) injected under
the same conditions and in equivalent amounts caused similar effects
on spontaneous chemoreceptor discharge.
When ATP was injected in the presence of adenosine or adenosine
in the presence of ATP, their chemoexcitatory actions are reduced,
which can be taken to indicate that ATP and/or adenosine activate
carotid body chemoreceptors through a mechanism similar to that used
by adenosine and/or ATP. Further support for the idea that both
substances act by a similar mechanism is that the effects of lower doses
are potentiated, and those of higher doses antagonized by dipyridamole.
An issue of considerable debate has been whether prior
degradation of the adenine nucleotides to adenosine is necessary
before they can activate the receptor, or whether the receptor will
accept a variety of different polyphosphate side chains on the 5'
position. This problem was investigated with the methylene isosters
of 5'-ATP, the a-g-methylene ATP and the g-y-methylene ATP. The
phosphorous methylene bond is considered to be stable to metabolic
transformations involving either hydrolysis or phosphate transfer
( Yount , 1975). The a-g-methylene ATP was found to decrease rather
than increase chemoreceptor discharge and g- y-methylene ATP increased
chemoreceptor discharge, though less effectively than ATP. This
suggests that even though the g,y bond in the ATP analogue is
stable, cleavage could still occur at the a,g position yielding the easily
metabolized compound 5'-AMP. However, when the bond in the a, g
88.
position is stabilized the compound does not increase chemoreeeptor
discharge, actually decreased discharge an effect associated with an
increase in B.P. Similar types of activity for the ATP analogues in
comparison with ATP were found in the brain (Phillis, Edstrom,
Kostopoulos and Kirkpatrick, 1979). The results obtained with the
ATP analogues taken together with the longer delay to onset of the
chemoreceptor responses seen with ATP as compared with adenosine
suggests that the ATP effect might depend on its previous hydrolysis
to adenosine.
The increase caused by a- g-methylene ATP on B.P. suggests
that ATP itself has a vasoconstrictor effect and this being consistent
with a recent report by Chiba, Ohhashi and Azuma (1980). These
authors described that in isolated fragments from the common carotid
and internal carotid arteries of dogs, ATP has a potent vasoconstrictor
effect.
As mentioned in Section I, General Introduction, a number of
authors reported that ATP causes chemoreceptor activation (Jarisch,
Landgren, Neil and Zotterman, 1952; Dontas, 1955; Anichkov and
Belen'kii, 1963; Krylov and Anichkov, 1968; Roumy and Leitner,
1977). These findings were confirmed in the present work, and
evidence was now produced suggesting that the chemoreceptor excita¬
tion by ATP depends on its previous hydrolysis to adenosine.
The present work also confirmed the results of Joels and Neil
( 1968) suggesting that cyclic AMP stimulates carotid body chemo-
receptors. These results were obtained in vascularly isolated carotid
bodies. In this preparation these authors described that ATP reduces
chemoreceptor discharge evoked by continuous perfusion of NaCN or
dinitrophenol whereas ADP and AMP had little or no effect. In the
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present work ADP and AMP were as effective as ATP. Since effects
of ATP on responses evoked by NaCN, C02, ACh or dopamine were not
investigated it is not possible to compare the present results with
those obtained by Joels and Neil (1968) in vascularly isolated carotid
bodies.
The vascular effect
Adenosine can cause vasodilation in a number of mammalian
organs, including the heart, skeletal muscle, brain (see e.g. Berne,
Foley, Watkinson, Miller, Winn and Rubio, 1979) and we cannot,
therefore, preclude the possibility that adenosine was changing blood
flow in the carotid body and thereby, perhaps, altering chemoreceptor
discharge, even though it had little overall effect on the systemic
blood pressure. When the vasodilator effect of adenosine was
potentiated by dipyridamole, a drug which potentiates the vasodilator
properties of exogenous adenosine (Bretschneider, Bernard, Kochsiek
and Scheler, 1959), a decrease rather than an increase in chemo¬
receptor discharge was observed; this is consistent with the effect
of other potent vasodilators (e.g. sodium nitrite, sodium nitroprusside -
Docherty, 1980) which also cause decreases in discharge following
their intracarotid injections, albeit more delayed. Moreover, if chemo¬
receptor activation by adenosine has been a result of its vasodilator
properties, the effect should have been blocked by theophylline (Berne,
Rubio and Curnish, 1974; Wahl and Kuschinsky, 1976) rather than
potentiated as was observed.
The increase in spontaneous chemoreceptor discharge by dipyridamole
(i.e.) is compatible with a role for endogenous adenosine on carotid body
chemoexcitation. Further support for such a role could be obtained by
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using adenosine deaminase inhibitors such as deoxycoformycin
which also potentiates the effects of endogenous adenosine in other
tissues (e.g. central nervous system, see Phillis, Edstrom, Kostopoulos
and Kirkpatrick, 1979).
The adenosine receptor
The receptor for adenosine appears to be specific since adenine,
the purine nucleosides inosine and guanosine, and the pyrimidine
nucleosides cytidine and uridine were virtually ineffective on the
chemoreceptors.
The adenosine receptor seems to be externally located since the
adenosine uptake blocker, dipyridamole, potentiated the chemoreceptor
activation induced by adenosine. It is at present impossible to know
whether the receptor is located on the sensory nerve endings, glomus
type I and/or type II cells or, and indeed if adenosine receptors may
be present, in all these structural components. The potentiation
observed in the responses evoked by ACh and dopamine, which some
authors used to consider as acting mainly on the sensory nerve
endings (see Eyzaguirre and Monti-Bloch, 1980) could be construed
as evidence that this structural component might be involved in the
adenosine effect. Since the location of the ACh receptors in the
carotid body structures remains to be established any conclusions
of evoked responses have to be somewhat tentative (see Eyzaguirre
and Monti-Bloch, 1980; Eyzaguirre and Fidone, 1980).
It is unlikely that the effect results from direct activation of the
sensory nerve fibres because adenosine does not change either amplitude
or duration of the compound action potential in the frog-sciatic nerve
(Ribeiro ana Dominguez, 1978) or of action potentials of unmyelinated
fibres in the brain (Stone, 1980).
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Direct activation of nerve endings by adenosine has been reported.
For example, Siggins, Gruol, Padjen and Forman (1977) found that
adenosine depolarizes neurones of explanted amphibian sympathetic
ganglia, and Bleehen and Keele (1977) described algogenic actions of
adenosine on the human blister base.
An adenylate cyclase-cyclic AMP system is apparently located in
the sinus nerve endings (Fitzgerald, Rogus and Dehghani, 1977) and
it may be that adenosine interacts with this in a manner similar to
that described for the brain in vivo (e.g. Davies, Taylor, Gregson and
Quinn, 1980). On the other hand both cyclic AMP and Db-cyclic AMP
increased chemoreceptor activity. The effect of cyclic AMP might
depend on its being hydrolysed to adenosine (Mah and Daly, 1976)
as appears to happen with ATP in the present work. However, this is
not probably the case for Db-cyclic AMP which has a high liposolubility
( Henion, Sutherland and Pasternak, 1967) and hence can easily cross
cell membranes. Its small effect may reflect that the concentration used
to modify intracellular concentration in the carotid body is too small and
not steady. It would be interesting to apply it to an in vitro carotid
body preparation.
In many preparations exogenous adenosine decreases release of
neurotransmitters [e.g. ACh (Ginsborg and Hirst, 1972; Ribeiro and
Walker, 1975; Vizi and Knoll, 1976; Gustafsson, Hedqvist, Fredholm
and Lundgren, 1978); noradrenaline (Hedqvist and Fredholm, 1976;
Verhaeghe, Vanhoutte and Shepherd, 1977; Wakade and Wakade, 1978);
dopamine (Michaelis, Michaelis and Myers, 1979); y-aminobutyric acid
[Hollins and Stone, 1980b)]. It is perhaps not too surprising that
adenosine decreases the output of substances which are released in a
calcium-dependent manner, because adenosine depresses uptake of
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calcium by synaptosomes depolarized by potassium (Ribeiro, Sa-Almeida
and Namorado, 1979). If adenosine exerts a similar action in the
carotid body, its excitatory effect could be interpreted as being the
consequence of decreased release of an inhibitory transmitter and/or
modulator. Dopamine (Chiocchio, Biscardi and Tramezzani, 1966;
Zapata, Hess, Bliss and Eyzaguirre, 1969) and the enkephalins (met- and
leu-ENK) (Lundberg, Hokfelt, Fahrenkrug, Nilsson and Terenius,
1979; Wharton, Polak, Pearse, McGregor, Bryant, Bloom, Emson,
Bisgard and Will, 1980) appear to be present in the cat carotid body and
both exogenous dopamine (Zapata, 1975; Docherty and McQueen, 1978)
and the enkephalins (see Section V) depress spontaneous chemoreceptor
activity. Osborne and Butler (1975) suggested that tonically released
dopamine may suppress chemoreceptor discharge, and although evidence
which is not in agreement with their hypothesis has been obtained (e.g.
Docherty and McQueen, 1978), the present effect of adenosine could
be explained in terms of adenosine inhibiting the release of dopamine,
or some other substance which is tonically active in inhibiting discharge
(? enkephalins). In support of a decrease on the release of dopamine
by adenosine are the present results in which a-flupenthixol potentiated
the chemoexcitatory responses to adenosine.
Adenosine does not operate through a theophylline-sensitive
receptor since theophylline in fact potentiated rather than reduced
responses to adenosine.
Theophylline appears unable to prevent activation of P2-purinergic
receptors. These receptors, as so far described, seem to be localized
post-junetionally (see Burnstock, 1978). De Mey, Burnstock and
Vanhoutte ( 1979) found that in the canine saphenous vein theophylline
antagonizes the inhibitory effect of ATP on neurogenic responses, but
not its direct contractile effect. According to these authors this
suggests the presence of both inhibitory pre-synaptic (Px) and
excitatory post-synaptic (P2) receptors. In the present study the
excitatory effect of adenosine was unaffected by low doses of theo¬
phylline (0.1-0.2 mg) but potentiated by a slightly higher dose (1 mg),
a finding which is compatible with a P2-excitatory post-junctional
effect. However, the potentiation might also have resulted from theo¬
phylline antagonizing a chemodepressant component of the adenosine
response, which might normally be masked by the excitatory component.
Such a chemodepressant component would result from adenosine
decreasing a tonically released excitatory transmitter - e.g. ACh
(see Osborne and Butler, 1975) or another excitatory influence which
cannot be antagonized by theophylline. In the brain adenosine decreases
the release of dopamine through a theophylline-insensitive receptor
(Michaelis, Michaelis and Myers, 197 9). Other possibilities to explain
the potentiation are: (1) that both adenosine and theophylline have
in common the ability to increase the cyclic AMP concentration, e.g.
theophylline by inhibiting phosphodiesterases (e.g. Butcher and
Sutherland, 1962), adenosine by activating the adenylate cyclase
(see Daly, 1977); and (2) the potentiation might result from theo¬
phylline inhibiting adenosine uptake as has been observed in rat brain
synaptosomes (Bender, Wu and Phillis, 1981).
Other classifications of adenosine receptors have been proposed.
Londos and Wolff ( 1977) postulated the existence of an adenosine
receptor with a P-site internally located and particularly sensitive to
2'-deoxyadenosine (a P-site agonist) and a R-site externally located
and predominantly sensitive to R-site agonists such as N6-methyl-
adenosine and 2'-chloroadenosine. Substances such as 3'-deoxyadenosine
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act in both R- and P-sites but has a higher affinity for R-site.
The present results are compatible with a R-site adenosine receptor
in carotid body since only R-site agonists (N 6-methyladenosine or
2'-chloroadenosine) or with higher affinity for R-site (3'-deoxyadenosine)
were effective. According to the same authors the P-site would be
responsible for inhibition of adenylate cyclase and consequent decrease
in cyclic AMP whereas R-sites would be associated with stimulation of
adenylate cyclase and subsequent increase in cyclic AMP.
In summary, adenosine and adenine nucleotides increase chemo-
receptor discharge. The effect of adenine nucleotides seems to depend
on their previous hydrolysis to adenosine. Adenosine appears to
operate through a specific adenosine receptor, externally located,
theophylline-insensitive and the R-site kind of receptor.
SECTION IV
The Effects of Peptides
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INTRODUCTION
Evidence has been produced showing that neuropeptides such
as met-ENK, leu-ENK, SP and YIP, or closely related immunoreactive
substances are present in the cat carotid body (Lundberg, Hokfelt,
Fahrenkrug, Nilsson and Terenius, 1979; Cuello and McQueen, 1980;
Wharton, Polak, Pearse, McGregor, Bryant, Bloom, Emson, Bisgard
and Will, 1980; Fitzgerald, Raff, Garger, Fechter, Anand and Said,
1981).
It has also been shown that met-ENK (McQueen, 1981), SP
(McQueen, 1980) and VIP (Fitzgerald, Raff, Garger, Fechter, Anand
and Said, 1981) can affect spontaneous chemoreceptor discharge when
injected close-arterial to the cat carotid body. The opportunity was
taken to investigate further the action of various polypeptides,
including some of those identified as being present in the carotid body
on the cat carotid chemoreceptors. During studies on the enkephalins
the effects on morphine were also investigated in order to have some




As illustrated in Figure 4.1, met-ENK caused a dose-related
decrease in spontaneous chemoreceptor discharge with a rapid onset,
the effect commencing within 1 to 2 s of beginning the injection.
The inhibition was followed by a gradual return, reaching control
(pre-injection) levels within 30 - 45 s following low doses of met-ENK,
but taking up to 5 min to recover after high doses. The inhibitory
effect was consistent, as can be gauged from the standard errors
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(Figure 4.1), and there was no evidence of tachyphylaxis occurring
when doses were administered at 7 min interval. Intravenous injections
of met-ENK (10-100 jig) also inhibited chemoreceptor discharge,
although to a lesser extent and after a longer delay than the same doses
by intracarotid injection.
Low doses of met-ENK had little or no effect on arterial blood
pressure, whereas higher doses (i.e. or i.v.) caused a fall in B.P.
(see Figure 4.1).
Leucine-Enkephalin
The effect of leu-ENK on the spontaneous chemoreceptor dis¬
charge is illustrated in Figure 4.2. The discharge was averaged in
15 s periods and the response was followed over a 90 s post-injection
period. As can be seen leu-ENK (0.1- 100 jig i.e.) caused a dose-
dependent decrease in spontaneous chemoreceptor discharge with a
rapid onset.
As with met-ENK, no tachyphylaxis was observed and low doses
of leu-ENK had no appreciable effect on B.P.
Comparison of the depressant effects of
methionine-, and leucine-enkephalin
Comparison between the depressant effects of met-ENK and
leu-ENK was carried out in two cats. Figure 4.3 shows dose response
curves (0.1- 100 jag i.e.) obtained for both substances in the same
animals. The inhibitory effects on spontaneous chemoreceptor dis¬
charge caused by both substances were similar when the substances
were administered in the same doses. As the molecular weights of
both met-ENK (m.w. — 556) and leu-ENK (m.w. - 574) are of the same
order, the substances seem to be equipotent.
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FIGURE 4.1
Effects on spontaneous chemoreceptor discharge (ct/s) of injecting
Locke solution (0.3 ml i.e.) n=5 (i) and met-ENK 0.01 |ig n=2 (ii),
0.1 ug n=5 (iii), 1 yg n=5 (iv), 10 yg n=5 (v), 100 yg n=5 (vi).
Discharge was averaged over 15 s periods following the injection.
Data from n experiments were pooled and are shown as the mean ±
s.e. mean. The panel on the right shows an arterial blood pressure
trace after injecting (arrow) 100 yg of met-ENK in one experiment.
B.P. calibration, 0-100-200 mmHg.
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FIGURE 4.2
Effects on spontaneous chemoreceptor discharge (ct/s) of injecting
(i.e.) Locke solution (0.3 ml) n=4 (i) and leu-ENK 1 jig n=3 (ii);
10 ug n=4 (iii); 100 |ig n=2 (iv). Discharge was averaged over 15 s
periods following the injection. Data from n experiments were pooled
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FIGURE 4.3
Chemoreceptor responses to doses of met-ENK in comparison with
those to leu-ENK. Each point is the average from two experiments.
Straight lines were fitted to the data by the method of least squares.
Averaged values (ct/s) for the control (100%) periods are as follows:
met-ENK 0.1 ug 1.5; 1 |ig 2.2; 10 ug 4.4; 100 ug 2.7;
leu-ENK 0.1 ug 2.7; 1 ug 8.2; 10 ug 7.9; 100 ug 3.2.
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g-endorphin
The effects of g-endorphin on chemoreceptor activity were
studied in three experiments. There was no appreciable difference
between the actions of human and porcine g-endorphin, so, results
have been expressed simply as responses to g-endorphin.
Injections of g-endorphin (0.1-50 tig i.e.) caused a biphasic
response on spontaneous chemoreceptor discharge, an increase
followed by a decrease (see Figure 4.5). The response lasted for about
3 min following the highest dose studied (50 |ig) and was associated
with a very slight fall in systemic blood pressure (Figure 4.4).
Discharge was averaged over the 60 s period immediately following
g-endorphin injection and compared with the averaged pre-injection
(control) discharge (Figure 4.5). The results showed that the
decrease in discharge was variable and from consideration of discharge
during the second min following the injection (Figure 4.5) fairly long-
lasting.
In one experiment, g-endorphin was also infused (3 gg/min i.e.)
for 5-10 min but only slight changes were detected in spontaneous
chemoreceptor discharge and B.P. Blood gas tensions and pH were
not modified by the infusion.
Morphine
The overall effect of morphine on spontaneous chemoreceptor
discharge was inhibitory, although the lowest dose studied, 0.1 (ig,
caused a slight increase in discharge (see Figure 4.6). Higher doses
(100 (ig) were associated with an inhibition of discharge which began
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FIGURE 4.4
Effect of injecting (arrow) 3-endorphin (50 ug i.e.) on:
A) systemic arterial blood pressure; B) spontaneous ehemoreceptor
discharge averaged over 15 s periods. Recordings obtained from
a single chemoreceptor unit. The black rectangle represents the
discharge averaged in the 30 s that preceded injection. B.P. calibra¬
tion is 0-100-200 mmHg.
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FIGURE 4.5
Effect of ^-endorphin on spontaneous chemoreceptor discharge
averaged over the first (A) or second (B) min following g-endorphin
injection. Discharge was expressed as a percentage of the pre-injection
frequency and plotted against dose of g-endorphin (log10 scale),
straight lines being fitted to the responses (filled circles) by the
method of least squares. Open circles illustrate the effect of injecting
the drug vehicle (0.5% bovine serum albumin); the pre-injection
(control) discharge frequency (100%= 1.5 ct/s) was determined by
averaging spontaneous discharge during the 30 - 60 s immediately
preceding each injection, and is represented. Recordings from a single
chemoreceptor unit.
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FIGURE 4.6
Effects on spontaneous chemoreceptor discharge (ct/s) of injecting
i.e. Locke solution (0.3 ml) n=4 (i), and morphine 0.1 pg n=4 (ii);
1 |ig n=3 (iii); 10 jig n = 3 (iv); 100 ug n=4 (v) ; 1000 pg n=3 (vi).
Discharge was averaged over 15 s periods following the injection.
Data from n experiments were pooled and are shown as the mean ±
s.e. mean. The panel on the right shows an arterial blood pressure
trace after injecting (arrow) 1000 |ig of morphine in one experiment.
B.P. calibration, 0-100-200 mmHg.
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Responses to morphine were rather variable, as can be seen
from the standard errors, but there was no evidence of tachyphylaxis
and responses to a low dose of morphine injected before and after
the highest dose were very similar. The higher doses of morphine
caused a fall in systemic blood pressure (B.P.) (see Figure 4.6).
The overall effect was similar to that evoked by g-endorphin (see above).
Naloxone
Naloxone (0.2 mg i.e.) caused a slight increase in chemoreceptor
discharge (Figure 4.7) and, after a delay of 15 to 45 s, a rise in
B.P. lasting for at least 30 min. Additional doses of naloxone (0.4,
0.8 and 1.6 mg i.e. at 7 min intervals) had no further effect on
chemoreceptor discharge or B.P.
When naloxone (0.2 mg i.e.) was injected during experiments in
which met-ENK and/or morphine had previously been administered,
there was also an increase, albeit somewhat variable, in spontaneous
chemoreceptor discharge (Figure 4.7) and a rise in B.P.
Responses to met-ENK (1 ug i.e.), leu-ENK (1 ug i.e.) and
g-endorphin (10 ug i.e.) obtained before and after injecting naloxone
(0.4 mg i.e.) are shown in Figure 4.8. As can be seen the responses
were attenuated after naloxone. Further reduction in the inhibition
of the opiates was obtained when the substances were injected 5 to 20
min after injecting naloxone (5 mg i.v.).
Quantitative data confirmed these observations and are shown for
g-endorphin in Figure 4.9, for leu-ENK in Figure 4.10 and for met-ENK
in Figure 4.11.
In order to characterize the opiate receptor, more detailed analysis
was carried out for data obtained before and after naloxone from met-
ENK and morphine experiments.
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FIGURE 4.7
a . Illustrates the effect of naloxone (0.2 mg i.e.) on spontaneous
chemoreceptor discharge in an experiment, b. Is the averaged
spontaneous chemoreceptor discharge from three experiments in which
the same dose of naloxone, 0.2 mg i.e. , was injected following prior
administration of met-ENK and/or morphine. Discharge was averaged
over 15 s periods following the injection and expressed as the per¬
centage of the averaged discharge + s.e. mean in the 15 s pre-
injection control period. Averaged values (ct/s) ± s.e. mean for the
control 100% period is given.
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FIGURE 4.8
Responses to met-ENK, leu-ENK and B-endorphin (B-END) obtained
before and after injecting naloxone 0.4 mg i.e. and again after




Chemoreceptor discharge following injection of ^-endorphin 10 jig
i.e. A) before and B) 5 min after naloxone (0.4 mg i.e.). Pooled
data from three experiments, discharge expressed as a percentage
of the pre-injection frequencies and shown as the average ± s.e. of
mean in 15 s intervals during the 150 s post-injection period. The
averaged control values were 4.8 ± 2.0 ct/s before and 2.7 ± 1.6 ct/s
after naloxone.
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FIGURE 4.10
Effects of leu-ENK before and after naloxone (200 |ig i.e.) on
spontaneous chemoreceptor discharge. Pooled data from n experiments,
discharge expressed as a percentage of the pre-injection frequencies
is shown as the mean in 15 s intervals during the 90 s post-injection
period. Averaged pre-injection (control) values are given.
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Comparison of responses to met-ENK and to morphine obtained
before and after injecting naloxone (0.2 mg i.e.) showed that, apart
from a slight initial inhibitory effect, the inhibitory action of morphine
was virtually abolished, and there was evidence of an overall increase
in discharge. The chemoinhibitory effect of met-ENK was reduced
by naloxone (see Figure 4.11).
Dose-response data were obtained by expressing the number of
impulses in the post-injection period as a percentage of the number of
impulses which would have been expected to occur in the same period
had the pre-injection control discharge (averaged over 15 to 30 s)
continued unaltered. It can be seen from Figure 4.11 that naloxone
antagonizes the responses to met-ENK both for 60 s and 150 s post-
injection periods. After intracarotid injection of naloxone (0.2 mg)
morphine tended to increase discharge over these periods, this effect
being inversely related to dose.
Evoked responses
Injections (i.e.) of ACh (50 ug), C02-equilibrated Locke
solution (0.3 ml), NaCN (5 ug) and dopamine (5 pg) were made
before and 5 to 20 min after a series of injections of either met-ENK
or morphine, and during infusions of met-ENK (50 ug/min) and
B-endorphin (5 ug/min). The results obtained before, during and
after morphine, met-ENK and B-endorphin are summarized in Table
4.1'. As can be seen the stimulant effects of ACh, C02 and NaCN
were slightly and somewhat variably reduced after met-ENK whereas
the inhibitory effect of dopamine was potentiated. Following morphine
administration, responses to ACh and NaCN were reduced slightly,
whereas those to C02 and dopamine were potentiated.
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FIGURE 4.11
a) Pooled data showing the effects of met-ENK 100 jig (n=3) and
morphine 1000 ug (n=2) on spontaneous chemoreceptor discharge
before (—) and after (—) injecting naloxone 0.2 mg i.e. Black
rectangles represent the control discharge (100%), values for met-
ENK being 3.7 ± 1.8 ct/s before and 3.1 ± 0.9 ct/s after naloxone,
the corresponding values for morphine being 3.7 ± 1.7 and 4.9 ± 2.4
ct/s. b) is a plot of the total discharge over the 60 s post-injection
period, expressed as a percentage of the total discharge which would
have occurred in the same period if control discharge had continued
unaltered (100% - dotted line), against log10 dose of met-ENK (pooled
data from three experiments) or morphine (data from a single experi¬
ment) before (—) and after (—) naloxone 0.2 mg i.e. Lines were
fitted by the method of least squares. c) is similar to b) but the
plot is of total discharge in the 150 s post-injection period and this
includes the delayed inhibition seen with morphine.
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Responses were also obtained before and during infusions of
met-ENK (50 gg/min i.e.) and g-endorphin (5 |ig/min i.e.), the
dose of met-ENK being sufficient to inhibit spontaneous discharge
throughout the infusion period. The effects of ACh and C02 were
slightly potentiated whereas the response to NaCN was slightly reduced
(Table 4.1). Since spontaneous discharge was suppressed it was not
possible, under these conditions, to investigate the effect of met-ENK
on the inhibitory response evoked by dopamine. The results obtained
before, during and after an infusion of 8-endorphin are also shown
in Table 4.1. It was found that responses to the stimulants were
reduced by g-endorphin in the concentration studied whereas the
inhibitory effect of dopamine was potentiated. The influence of
g-endorphin on responses evoked by dopamine and, to a lesser extent
NaCN, was still evident 15 min after infusion had finished.
In a separate experiment the influence of g-endorphin (5 ug/min)
on the inhibition evoked by an injection of met-ENK (10 ug i.e.) was
studied. The effect of met-ENK was found to be very slightly enhanced
(discharge, averaged over 150 s after the met-ENK injection and
expressed as a percentage of the pre-injection discharge frequency
[100%], was 71% before the infusion, 64% during the infusion and 73%
15 min after the infusion of g-endorphin).
Responses to ACh, NaCN, C02 and DA were not appreciably
affected by naloxone (0.2 mg i.e.).
Methionine-enkephalin and substance P
It has been shown that SP influences chemoreceptor discharge
(McQueen, 1980) and the present experiment was carried out to
determine whether any interaction occurs on simultaneous infusion of
TABLE4.1:Effectsofmorphine,methionine-enkephalin(me -ENK)a dg-end rphinov k d responses Intracarotidinje ti nof:AChC02-LockeNa NDopamine (50pg)0.3ml)n~ A.Followingmorphineinjecti ns83±193411563 B.Followingmet-ENKinjecti ns77±1626306245 C.Duringmet-ENKinfusions137±222984- (50pgmin-1i.e.) D.uringaninfusioofg-endorphi855248190 (5pgmin-1i.e.) Pooleddatafr mnexperimentsshowingch m receptorres ons s(AE),Afoll wi g injectionsofmorphi eandBfoll winginjectionsfmet-ENK.Ther sultarxpressed meanperc nt ges±s. .meanofthrespo sessamdoad inisteredbeformor hin ormet-ENK(i. .pre-injectionresponse=100%) Injectionswerealsomaddur ginf sionsofm t-ENKang-endorphire p nsevoked comparedwithpre-infusionvalues(CandD).
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met-ENK and SPclose-arterial to the carotid body. The results
obtained are shown in Figure 4.12. Locke solution infusions (0.1 ml/
min) caused small oscillations (slight increases and decreases) in
spontaneous chemoreceptor discharge, SP had a biphasic action
(decrease followed by increase) and met-ENK reduced discharge, an
effect which was most pronounced in the early part of the response;
when the met-ENK infusion was stopped discharge increased above
pre-infusion control levels. The delayed increase in discharge seen
with SP was accompanied by a rise in end-tidal C02; there was no
change in end-tidal C02 during or after met-ENK infusion.
SP and met-ENK were infused concurrently in equimolar con¬
centrations, it being so arranged that met-ENK began to act before
SP reached the carotid artery (see Figure 4.12). The pattern of
response was very similar to that obtained with met-ENK alone,
except that no post-infusion overshoot occurred. There was a rise
in end-tidal C02 towards the end of the infusion. Both peptides caused
hypotension, and when given together the overall effect on B.P. was
approximately additive.
The inhibitory effect of opiates on carotid body
chemoreceptors is not mediated by adenosine
It has been suggested that the inhibition of neurotransmitter
release produced by opiates may be mediated by the initial release of
adenosine (e.g. Stone and Perkins, 1979). The idea was advanced on
the grounds that adenosine mimicks the effect of morphine, and
theophylline antagonizes the actions of both adenosine and morphine.
It was decided, therefore, to investigate whether theophylline and
naloxone influenced the responses to opiates and adenosine respectively,
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FIGURE 4.12
The left-hand side of the figure shows chemoreceptor discharge
(ct/s) averaged over 60 s periods after starting intracarotid infusions
(horizontal bar) of (a) Locke solution via lingual and thyroid catheters;
(b) SP 25 ug/min via the lingual, Locke solution via the thyroid
catheter; (c) met-ENK 10 ug/min via the thyroid, Locke solution via
the lingual; (d) met-ENK 10 ug/min via the thyroid, SP 25 ug/min
via the lingual. The accompanying blood pressure records are shown
on the right-hand side of the figure, the time scale being common to
both sides. The catheter dead-space needed to be cleared before the
peptides arrived in the carotid artery, a process which took 1-2 min
after starting the infusion, except in (d) where the thyroid catheter
was fully primed with met-ENK so that the action of this peptide had
begun before SP reached the carotid artery.
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as well as to study the effects of infusing simultaneously adenosine
and met-ENK.
Figure 4.13 illustrates the affect of an infusion of adenosine
compared with an infusion of met-ENK and thereafter in the same cat
the effects of both substances when the infusions were carried out
simultaneously. As can be seen, adenosine alone had an excitatory
effect, met-ENK an inhibitory effect, and when both were infused
simultaneously a summation was observed.
Four experiments were performed to investigate the influence
of naloxone (400 ug i.e.) on chemoreceptor responses to adenosine
and morphine. The adenosine results were pooled and are shown in
Figure 4.14. No statistically significant difference was detected
between the pre- and post-naloxone response (P <0.05). In two of
these experiments morphine (100 ug i.e.) was injected before and
after naloxone (Figure 4.14). A chemodepressant effect of morphine
was obtained in accordance with previous observations (see above) and
this effect was converted to an excitatory one by naloxone.
The influence of theophylline (1 mg i.e.) on the responses to
morphine and met-ENK was also investigated in two experiments. As
can be seen from Figure 4.15 theophylline had little or no effect on the
inhibitory response to met-ENK. The total area of inhibition of
spontaneous chemoreceptor discharge caused by met-ENK (10 ug i.e.)
was slightly greater after theophylline than before the injection of
this substance (see Figure 4.15). A small change occurred with
morphine. For example, morphine 10 ug i.e. decreased spontaneous
chemoreceptor discharge to 64% of the pre-injection (control) discharge
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FIGURE 4.13
From left to right effects of infusing (bars between arrows) adenosine
(50 ug/min) via lingual catheter (A), met-ENK (100 ug/min) via
thyroid catheter (B) and concurrently adenosine (50 |ig/min) via
the lingual + met-ENK (100 |ig/min) via thyroid catheters (C). The
catheters were fully primed with adenosine or met-ENK. The horizontal
bars indicate the duration of infusions, and the black rectangles the





























A) Effects of morphine (100 |ig i.e.) on chemoreceptor discharge before
and after naloxone (NX 0.4 mg i.e.) in one experiment. Discharge
was averaged over 10 s periods following the injection. B) Dose-
response data for adenosine obtained before (•) and after (■) administra¬
tion of NX (0.4 mg i.e.) in four experiments. Doses (ug i.e.) are
plotted on a logio scale and chemoreceptor responses expressed as the
mean AIx for the four experiments; vertical lines show s.e. mean.
A Zx was calculated as the response during the 30 s following the in¬
jections. Lines were fitted to the data by the method of least squares.
Averaged values (ct/s) for the pre-injection (15 s) periods ± s.e. mean
were as follows: adenosine 1 |ig 4.5 + 2.1 before NX, 5.7 ± 2.6 after NX;
adenosine 10 |ig 4.2 ± 1.4 before, 6.7 ± 1.5 after; adenosine 100 |ig
















Effect of met-ENK 10 ug i.e. on spontaneous chemoreceptor discharge
before (A) and after (B) theophylline, 1 mg i.e. Discharge was
averaged over 10 s periods following the injections and expressed as
a percentage of the averaged discharge in the 20 s pre-injection control
period. Data from one experiment. Average values (ct/s) for the




The effects of VIP were studied in two cats.
Injections of VIP
Figure 4.16 illustrates the effect of injecting VIP (3.2 |ig i.e.)
on spontaneous chemoreceptor discharge and results from different
injections are summarized in Figure 4.17. Low doses caused a
decrease in discharge whereas higher doses increased it. The effects
were fairly long-lasting, as can be seen from the discharge recorded
in the second min following the injection (see Figure 4.17). Higher
doses caused a fall in B.P. followed by a rise (Figure 4.1).
Infusions of VIP
Infusion of VIP at a rate of 0.5 ug/min i.e. for 5 to 10 min
caused a sustained increase in discharge and a fall in B.P. (see
Figure 4.18). The increase in chemoreceptor discharge was associated
with a slight fall in B.P. The control B.P. was rather low, and to
preclude the possibility that the increase in chemoreceptor discharge
was secondary to the systemic vascular effects of VIP, the infusion
was repeated later in the same experiment when mean systemic B.P.
was over 100 mmHg and dextran was infused to prevent the fall in
B.P. Under these conditions discharge still increased, although the
increase was a little less than that obtained at the lower pressure.
Measurement of arterial blood gases and pH showed that the increase
in chemoreceptor discharge was not secondary to changes in arterial
blood gas tensions. Values for pH, Pa02 and PaC02 were respectively
7.31, 107 Torr and 34 Torr during the infusion compared with pre-
infusion sample values of pH 7.28, Pa02 105 Torr and PaC02 36 Torr.
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FIGURE 4.16
Effects of injecting VIP (3.2 |ig i.e.) on A) systemic arterial blood
pressure and B) spontaneous chemoreceptor discharge (ct/s).
Discharge averaged over 15 s periods following the injection.
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FIGURE 4.17
Effect of VIP on spontaneous chemoreceptor discharge averaged
over the first (A) or second (B) min following VIP injection (100% =
5.6 ct/s). Recordings from 3 to 4 chemoreceptor units. For further
details see legend of Figure 4.5.
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Evoked responses during infusion of VIP
Responses to ACh, C02 and NaCN were determined before,
during and after infusions of VIP (0.5 ug/min). Results obtained
from two experiments were pooled and it was found that responses to
the stimulants were reduced by VIP (ACh 50%, NaCN 57%, C02 65%
in relation to the control responses taken as 100%), whereas the
inhibitory effect of dopamine was only slightly reduced to 90% of the
control during the infusion, although there was a further reduction
to 75%, after infusion. Responses to ACh and C02 recovered within
15 min, whereas the NaCN and dopamine responses did not.
In one experiment it was investigated the influence of a VIP
infusion (0.5 lig/min) on the inhibition evoked by met-ENK (10 |ig
i.e.). Before the VIP infusion chemoreceptor discharge averaged
over the immediate 60 s post-injection period was reduced to 27% of
the pre-injection control frequency, and over the second min it was
reduced to 89% of control. Corresponding values during VIP infusion
were 46% in the first min and 100% in the second, meaning that the
inhibition caused by met-ENK was reduced during the VIP infusion.
Cholecystokinin octapeptide
The effects of CCK-8 on chemoreceptor activity were examined
in two experiments.
Injections of CCK-8
Injections of CCK-8 (0.1- 100 |ig i.e.) caused a somewhat
variable short-lasting biphasic effect on discharge, generally an
initial decrease followed by an increase (see Figure 4.19). Higher
doses caused a rise in B.P. The quantitative evidence shown in
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FIGURE 4.18
Effects on spontaneous chemoreceptor discharge of infusing during
the period represented by the horizontal bar, VIP 0.5 ug/min i.e.
Discharge was averaged over 60 s intervals, commencing 60 s before
starting infusion, and plotted on the same time scale as the B.P.
trace. The catheter was primed with polypeptide solution (i.e. there
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FIGURE 4.19
Effect of injecting CCK-8 (100 ug i.e.) on A) systemic arterial blood
pressure and B) spontaneous chemoreceptor discharge (ct/s). Dis¬
charge averaged over 15 s periods following the injection.
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Figure 4.20 A and B confirms that responses were somewhat variable
and short-lived.
Infusions of CCK-8
In one experiment CCK-8 was infused at a rate of 1 ug/min,
in another the rate was 10 ug/min (Figure 4.21). There was little
effect on spontaneous discharge with either dose; but a marked and
sustained increase in B.P. was detected after the first min post-
infusion .
Evoked responses during infusion of CCK-8
Responses to ACh, NaCN and dopamine were reduced during
infusion of CCK-8 at a rate of 1 ug/min. The response to C02 was
unaffected (Figure 4.22). Although the ACh effect returned to pre-
infusion levels within 15 min of finishing the infusion, responses to
NaCN and dopamine remained depressed. In a second experiment
during which CCK-8 was infused at 10 |ig/min, responses were some¬
what similar, except that a sustained potentiation of the dopamine-
induced chemoinhibition was observed ana there was a decreased response
to CO2 in the post-infusion period, although not during the infusion
(Figure 4.22).
DISCUSSION
In this section it is shown that the polypeptides investigated can
modify carotid chemoreceptor activity in the cat. Spontaneous chemo-
receptor discharge was decreased by intracarotid injections of met-ENK,
leu-ENK and 3-endorphin and by low doses of VIP, whereas it was
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FIGURE 4.20
Effects of injecting CCK-8 on spontaneous chemoreceptor discharge
in two experiments. Data were pooled and discharge was averaged
over the first (A) or second (B) min following CCK-8 injection (100% =
1.9 ct/s). Figure details as for Figure 4.5.
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FIGURE 4.21
Effect on spontaneous chemoreceptor discharge of infusing CCK-8
10 |ig/min i.e. during the period represented by the horizontal bar.
Discharge (ct/s) was averaged over 60 s before starting infusion,
and plotted on the same time scale as the B.P. trace. The catheter
was primed with polypeptide solution (i.e. there was no dead-space
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FIGURE 4.22
Responses (AZx) to ACh (50 ng i.e.), NaCN (2.5 |ig i.e.), C02 (0.3
ml C02-equilibrated Locke solution) and dopamine (DA, 5 |ig i.e.)
were obtained (a) before a 10 min infusion of CCK-8 into the second
carotid catheter, (b) during the infusion and (c) 5-15 min after
finishing the infusion and are shown as percentages (pre-infusion
response = 100%). Data from a single experiment. For Locke solution
the data shown are averages from two experiments.
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Both met-, and leu-ENK inhibited spontaneous chemoreceptor
discharge by acting on naloxone-sensitive receptors in the carotid
body. 3-endorphin and morphine also acted at these receptors, but
they were less potent than the enkephalins and caused a more
variable inhibition which tended to be biphasic.
Injection of the specific opiate antagonist naloxone (see Sawynok,
Pinsky and Labella, 1979 for a review) slightly increased chemoreceptor
discharge, an effect which does not appear to be due to reversal of
residual enkephalins, 0-endorphin or morphine chemodepression
because it was also observed when none of the substanceshad been ad¬
ministered. This may mean that there is some tonic inhibition of
chemoreceptor discharge by an opioid; alternatively, the effect could
be secondary to changes (e.g. in B.P.) induced by naloxone acting
elsewhere. The dose of naloxone (200 pg i.e.) is adequate for
reversing the fall in B.P. caused by morphine in cats (Feldberg and
Wei, 1977; McQueen, personal communication) and for antagonizing
the action of enkephalins in the cat substantia gelatinosa (Duggan,
Hall and Headley, 1977). In the present experiments naloxone reduced
the chemoreceptor inhibition caused by the enkephalins and, to a
greater extent, that caused by g-endorphin and morphine. It is
known that inhibition of neuronal firing caused by morphine is more
readily antagonized by naloxone than is that caused by opioid peptides
(North, 1979). Increasing the dose of naloxone to 0.8 mg i.e. produced
a greater decrease of the enkephalin-induced inhibition of chemo¬
receptor discharge, and virtually abolished the morphine effect.
Higher doses of naloxone could have been studied, but they might have
exerted non-specific actions, or reversed the anaesthetic (Furst,
Foldes and Knoll, 1977; Arndt and Freye, 1979; Sawynok, Pinsky and
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Labella, 1979). It seems reasonable to conclude that chemoreceptor
inhibition results from actions of opioid peptides, g-endorphin and
morphine on a naloxone-sensitive receptor in the carotid body, whereas
the slight chemoexcitation seen after naloxone does not. The latter
effect may result from actions at opiate receptors which are insensitive
to naloxone in the doses used, or to direct or indirect actions on non-
opiate receptors.
The greater potency of naloxone as an inhibitor of morphine and
g-endorphin in comparison with its effects against the enkephalins
may reflect differences in the potencies of morphine and g-endorphin
compared with the enkephalins and this may be due to different
populations of opiate receptors. According to Lord, Waterfield, Hughes
and Kosterlitz ( 1977) it is possible to distinguish at least two categories
of opiate receptors: |i receptors which are characterized by their
high affinity for morphine and related alkaloids as well as for the
antagonist naloxone, whereas <5 receptors preferentially recognize the
enkephalins and are relatively resistant to naloxone. Confirmation of
this idea comes from Fields, Emson, Leigh, Gilbert and Iversen (1980)
who have shown that in the primary afferent tissue (dorsal root) and
dorsal horn morphine has a higher affinity for g-sites whereas met-,
and leu-ENK have greater affinity for 6-sites. They also suggested
that separate pre- and post-synaptic populations of opiate receptors
exist, with a relatively greater proportion of 6-type receptors on
post-synaptic elements of the dorsal horn. Interpreting the present
results in the light of these findings one might suggest that in the
carotid body g and 6 receptors appear to be present and <5 receptors
could be responsible for the greater part of the inhibition observed, and
that this might result from an action on the post-synaptic component of
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the sensory synapse. The jj receptors at which morphine and
naloxone might act could be associated with pre-synaptic elements in
the carotid body. Taking the speculation further one might suggest
that the effect of morphine arises from a modification (? decrease)
of transmitter release from the pre-synaptic component (e.g. dopamine,
ACh) by depressing calcium uptake (see e.g. Guerrero-Munoz, Cerreta,
Guerrero and Way, 1979), and the effects of the enkephalins may
result from a hyperpolarization of sensory nerve endings.
Low doses of morphine tended to increase spontaneous chemo-
receptor discharge, an effect which was potentiated and also obtained
with higher doses of morphine, as well as low doses of the enkephalins,
after naloxone. Landgren, Liljestrand and Zotterman (1952) found
that an intracarotid injection of 3 mg morphine hydrochloride in cats
caused a moderate increase in small action potentials (probably ehemo-
receptors) recorded from the sinus nerve, and Eyzaguirre and Zapata
(1968a) showed that morphine caused a transient increase in discharge
recorded from the in vitro carotid body preparation. Whether the
excitation seen in the present study resulted from an action on naloxone-
insensitive opiate receptors, or to direct or indirect actions on non-
opiate receptors, e.g. morphine/opioid peptides, might influence
substances in the carotid body, as occurs in other tissues [e.g. ACh
(Paton, 1957), noradrenaline (Szerb, 1961; Snyder and Childers,
1979), 5-HT, or dopamine (Loh, Brase, Sampath-Khanna, Mar, Way and
Li, 1976)].
The polypeptides (the enkephalins, g-endorphin, VIP and CCK-8)
influenced arterial blood pressure and this confirmed that, in the doses
studied, they were biologically active. As stated above in relation to
adenosine the possibility that the effects of polypeptides on chemoreceptor
133.
activity were secondary to vascular changes either within the carotid
body, or systemically, needs to be considered. The rapid onset of
the peptide effects (within 1 - 2 s of injection), the fact that effects
on chemoreceptor discharge occurred before changes in blood pressure
were seen and persisted when such changes were prevented makes
it unlikely that vascular effects were responsible for the greater part
of the responses observed (see also Section VI, General Discussion
and Conclusions).
According to several authors (Hornbein, Griffo and Roos, 1961;
Biscoe, Purves and Sampson, 1970; Acker, Keller, Lubbers, Bingmann,
Schulze and Caspers, 1973; McQueen, 1977) the carotid body chemo-
receptors are relatively unaffected by sustained changes in arterial
blood pressure or in total carotid body flow within the physiological
range (60 - 160 mmHg). Moreover, Acker and Lubbers (1977) could
not find any consistent relationship between local blood flow and Pa02.
Summarizing this point, one might say that it is unlikely that
vascular effects are responsible for the greater part of the chemo¬
receptor effects of these substances, but it would be interesting to
investigate their effects on the in vitro carotid body preparation
(Eyzaguirre and Lewin, 1961) which would eliminate the vascular
complications.
Although met-ENK and morphine were able to inhibit spontaneous
chemoreceptor discharge, they only slightly reduced excitatory
responses evoked by ACh and NaCN, and potentiated dopamine-induced
inhibition. These were long-term effects since the responses were not
studied until 5-20 min after injections of met-ENK or morphine. When
responses were studied during infusions of met-ENK and g-endorphin
the excitatory effect of NaCN was reduced whereas the responses to ACh
and C02 were potentiated by met-ENK but reduced by g-endorphin.
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Responses evoked by ACh, NaCN and C02 were also studied
during infusions of VIP and CCK-8, when the levels of these substances
in the carotid body were assumed to be relatively steady, showed that
the excitatory action of NaCN and ACh was reduced, and that caused
by C02 was reduced by VIP, but unaffected by CCK-8.
Dopamine-induced chemoinhibition was potentiated by 3-endorphin,
largely unaltered by VIP, reduced by low concentrations of CCK-8
and potentiated by higher concentrations.
These single-dose studies are difficult to interpret (see Section II,
Methods and Materials), particularly since polypeptides may alter blood
flow through the carotid body, but the point is that the peptides so
far studied influence evoked responses.
The chemoinhibitory effect of low doses of the enkephalins was
very similar to that obtained with dopamine (5 ug i.e.), although it
should be noted that the enkephalins are 10 - 100 times more potent on
a molar basis. However, despite the similarities, it is unlikely that the
enkephalins act directly, or, by releasing dopamine within the carotid
body, indirectly at a dopamine receptor, because a-flupenthixol blocks
the inhibitory action of exogenous dopamine (Docherty and McQueen, 1978)
without affecting the inhibitory response to met-ENK (McQueen, 1981).
SP is present in the cat carotid body glomus type I cells and
carotid sinus nerve (Cuello and McQueen, 1980) and causes an increase
in chemoreceptor discharge when injected i.e. (McQueen, 1980). It
may be that the enkephalins are acting to inhibit the release of SP
within the carotid body in the same way as has been shown to occur
in the central nervous system (Jessel and Iversen, 1977). During the
present study it was investigated whether any interaction occurred in
the carotid body between SP and met-ENK. SP has been suggested to
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be a transmitter at the central nerve terminals of chemoreceptor
afferent fibres of cats (Gillis, Helke, Hamilton, Norman and Jacobowitz,
1980) and rats (Helke, O'Donohue and Jacobowitz, 1980; Jacobowitz and
Helke, 1980). It is also known that met-ENK (also present in the cat
carotid body, see Section I, General Introduction) can inhibit the
release of SP from cultured sensory neurones (Mudge, Leeman and
Fishbach, 1979) and probably in the central nervous system (Jessel
and Iversen, 1977). The present results showed that SP was unable
to overcome the chemoinhibitory effect of met-ENK, something it might
have been expected to do if release of endogenous SP is crucial for
chemoexcitation, and can be prevented by met-ENK. However, much
may depend on the type of fibre being recorded and the background
level of activity; SP is particularly associated with C fibres (Hokfelt,
Johansson, Kellerth, Ljungdahl, Nilsson, NygSrds and Pernow, 1977)
and it could be that A fibres were being recorded which are, perhaps,
affected by met-ENK, but not SP. In the absence of conduction
velocity experiments this must remain speculation, but also is unknown
whether following injection of SP the concentration in the carotid body
was physiological. As far as the other polypeptides were concerned,
the inhibition evoked by met-ENK was largely unaffected by B-endorphin
but reduced by VIP.
In contrast to what has been suggested for the smooth muscle
(Sawynok and Jhamandas, 1976) and the brain (Stone and Perkins,
1979) adenosine does not appear to be the mediator of carotid chemo¬
inhibitory action of opiates because: (1) adenosine did not mimick the
action of morphine or the enkephalins. These substances cause a
rapid and potent inhibitory action on chemoreceptor activity whereas
adenosine causes a rapid increase on chemoreceptor discharge;
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(2) naloxone antagonized the inhibitory action of opiates but did
not cause substantial modifications in the excitatory action of adenosine;
(3) theophylline did not cause substantial changes in the inhibitory
action of opiates and potentiated the adenosine chemoexcitatory action
(see also Section III).
The effects of polypeptides such as 3-endorphin, VIP and
CCK-8 on chemoreceptor discharge may not seem very impressive when
compared with those of ACh, NaCN, C02 or dopamine, but it has to
be remembered that the polypeptides have relatively high molecular
mass (see Section I, General Introduction). For example, the excitatory
response to ACh can be elicited by 180 nmoles (50 ug) (see e.g.
McQueen, 197.7), that to VIP involved only 1 nmole (3.2 |ig). Further¬
more, although the peptide effects were generally less intense they
tended to be longer lasting than those associated with classical neuro¬
transmitters. The prolonged action may be related to various factors,
such as molecular size, tissue penetration, dissociation from receptors,
activation of 'second messengers', or to peptide synthesis and in-
activation.
Evidence from other parts of the nervous system suggests that
some neuropeptides may function as neurotransmitters (see e.g.
Hokfelt, Johansson, Ljungdahl, Lundberg and Schultzberg, 1980),
but the question of what physiological role the neuropeptides play in
the nervous system is still very much a matter for debate (see Bishop
and Polak, 1978; Guillemin, 1978; Hokfelt, Johansson, Ljungdahl,
Lundberg and Schultzberg, 1980; Snyder, 1980). At the carotid body,
various exogenous neuropeptides alter chemoreceptor activity and
several of these are known to be present in the structure. However,
on its own this information is not enough to reach a conclusion regarding
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the role of the peptides in the carotid body. They may function as
neurotransmitters, neuromodulators, cotransmitters, neurohormones,
trophic factors, or as agents modifying the vasculature, they might
be influenced by each other, by carotid body amines, by circulating
hormones (e.g. ACTH, ^-endorphin) or by other substances.
In conclusion, the present results provide pharmacological
evidence for the presence of opiate receptors in the cat carotid body.
What type of receptors they are (e.g. Lord, Waterfield, Hughes and
Kosterlitz, 1977), in which structural elements are located, what the
endogenous ligand is and where it originates, as well as the circum¬
stances under which it is released, all need to be investigated before
one can determine whether the enkephalins or other opioid peptides
have a role as neurotransmitters or neuromodulators (Kosterlitz and
Hughes, 1975; Snyder and Childers, 1979) in the cat carotid body
chemoreceptors. In relation to the other polypeptides studied, e.g.
S-endorphin, VIP and CCK-8, the absence of drugs which can selec¬
tively affect their actions (e.g. by destruction of nerve cells, blockade
of receptors, inhibition of enzymatic destruction, interference with
biosynthesis) makes the proposals of their roles in chemosensory
transmission still more difficult, but their long-lasting effects and
increased delay to onset a chemoreceptor response, seem to suggest
that they act as neurohormones rather than as neurotransmitters in
the carotid body.
SECTION V
The Effects of Ouabain
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INTRODUCTION
The carotid body chemoreceptors are highly sensitive to
metabolic inhibitors (see e.g. Heymans, 1955; Comroe, 1964).
In spite of that, little is known about the actions on arterial chemo¬
receptors of ouabain, a drug which has many similarities with metabolic
inhibitors. In the paper by McLain (1970), it is reported that ouabain
in vivo increases the total neural traffic recorded from the carotid
sinus nerve; this includes chemo and baroreceptor activity. Other
observations have been reported by Joels and Neil (1968) who found,
using vascularly isolated cat carotid bodies, that ouabain decreases
chemoreceptor activity evoked by nitrogenated solutions, and by
Eyzaguirre, Baron and Gallego (1977) who described that in vitro
ouabain depolarizes some carotid body type I cells.
The opportunity was taken to investigate further the effects of
ouabain on cat carotid body chemoreceptors and whenever possible
those effects have been quantified.
RESULTS
Injections of ouabain
The effects on spontaneous chemoreceptor discharge of different
doses of ouabain (0.625- 200 ug i.e.) are summarized in Figure 5.1.
In three cats successive (cumulative) injections of ouabain were made
every 15- 25 min: in two of the cats only the lowest and the highest
doses (50 - 200 ug) were used. Ouabain caused a dose-related increase
in discharge (Figure 5.1), which was followed, the higher doses, by
a gradual decline in discharge and the chemoreceptors became un¬
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FIGURE 5.1
Effects of intracarotid injections of ouabain on spontaneous chemo-
receptor discharge (ct/s). Each point is the average ± s.e. mean
from two to three experiments. Averaged values (ct/s) ± s.e. mean
for the pre-injection (control) discharge are as follows: 0.625 ug
2.4 ± 0.1, n=2; 1.25 ug 2.8 + 0.9, n=3; 5 ug 5.6 + 2.9, n=3;
10 ug 2.2 + 0.5, n=3; 20 ug 4.0 + 0.7, n=3; 50 ug 6.3 ± 1.2, n=2;
100 ug 9.4 + 4.2, n=2; 200 ug 23.5 ± 10.1, n=2.
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Difficulties associated with interpreting the results from these
pilot experiments in which ouabain was injected led to the use of
ouabain infusions as described in the next part of this section.
Infusions of ouabain
A typical response of chemoreceptors to ouabain infusion in a
cat with the ganglioglomerular (sympathetic) nerves intact is shown
in neurogram form in Figure 5.2, and in graphical format in Figure
5.3. Results from another six experiments in which ganglioglomerular
nerves were also kept intact were pooled and are shown in Table 5.1.
Ouabain solution (30 |ig/ml) was infused into the common carotid
artery via the superior thyroid artery at a rate of 0.1 ml (3 ug) /min.
NaCN (5 ug) was injected before starting ouabain infusion, via the
superior thyroid and lingual catheters; the responses were
compared (Table 5.2) in order to determine whether catheter position
affected chemoreceptor discharge. No significant differences were
detected in relation to Ax, and duration of the response; the mean
time to onset of response was greater by 0.7 s for the thyroid catheter,
though this was not statistically significant (P >0.05, paired t_-test)
("see Table 5.2).
Infusion of the drug vehicle (Locke solution, 0.1 ml/min), via
the superior thyroid artery (control experiment) did not cause sub¬
stantial changes in the frequency of spontaneous chemoreceptor discharge
(Figure 5.3). Thus, marked changes in the discharge after starting
ouabain infusion were attributable to ouabain; not the drug vehicle.
Ouabain infusion caused the frequency of spontaneous chemoreceptor
discharge to increase slightly in the first 20 min of the infusion in the
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Effect of an infusion of ouabain (OUAB. inf.) (3 |ig/min i.e.) on
the frequency of spontaneous chemoreceptor discharge. Neurograms
were recorded at the times indicated. The broken line at the bottom
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FIGURE 5.3
Effect of a ouabain infusion (3 jig/min) i.e.) on spontaneous chemo-
receptor discharge in a cat with the ganglioglomerular nerves intact.
The ordinates are the computed averages of the number of spikes
recorded continuously during periods of 30 to 60 s. The abscissae
are the times the averaging began. ( ▲ ) Locke infusion (0.1 ml/min);
( • ) discharge before or after ouabain infusion; ( o ) and during
ouabain infusion. The duration of ouabain infusion is indicated by
the horizontal bar. The upper part shows the mean arterial blood
pressure (B.P.) recorded concurrently. B.P. calibration 0-100-200
mmHg. The mean values (3 determinations) for Pa02, PaC02 and pH
determined before and during ouabain infusion (at about the peak
discharge) are as follows: before, Pa02 94 Torr; PaC02 31.3 Torr;
pH 7.37. During Pa02 95 Torr; PaC02 29.5 Torr and pH 7.34.
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continued to rise and 3 to 5 min later a sudden and marked increase
occurred. The ouabain-induced increase in the spontaneous discharge
was followed by a decline and a return to a level of the same order
or slightly below that recorded before starting ouabain infusion. The
discharge remained at such a leyel despite stopping the infusion.
Chemoreceptor discharge was followed post-mortem in five animals
in which death was caused by infusing ouabain. During the 10 to 40
min that followed the cardiac arrest, chemoreceptors continued to
discharge though the frequency tended to decay during these periods.
Figure 5.3 also shows the mean femoral arterial blood pressure
recorded simultaneously with the chemoreceptor discharge. The
overall effect was an increase in B.P. which began to be apparent a
few min (5 to 10 min) after starting the ouabain infusions. The
averaged ± s.e. mean B.P. recorded at the time of the peak discharge
for the seven experiments was 175 + 12 mmHg, the control (obtained
before starting ouabain infusion) being 142 ± 11 mmHg (see Table 5.1).
The difference, 33 ± 8.3 mmHg was statistically significant (P <0.05,
paired t-test).
Under the present experimental conditions (extracellular
recordings) no substantial modification of either the amplitude or
duration of the action potentials was detected after starting ouabain
infusions.
The effects of ouabain were not a consequence of changes in
Pa02, PaC02 or pH of the blood since no substantial changes in these
parameters occurred during ouabain infusions compared with the pre-
infusion (control) levels (see Table 5.3).
In the experiment illustrated in Figure 5.4 chemoreceptor dis¬
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FIGURE 5.4
Effects of ouabain (3 [ig/min i.e.) on spontaneous chemoreceptor
discharge in a cat with the ganglioglomerular nerves intact.
Chemoreceptor discharge was evaluated by counting either a single
chemoreceptor unit (black) or several units (3-5) (upper line)
from a multi-unit recording. The horizontal bar indicates the
duration of infusion. Note that the pattern of the increased dis¬
charge is similar either counting a single or several units but the
single unit stopped firing earlier than the other units and ceased
entirely.
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units were counted separately from the same multi-unit recording.
As can be seen the general pattern of chemoreceptor discharge was not
markedly different counting either the single or multiple units, although
the single unit stopped firing earlier and it stopped discharging sooner
than the other units.
Ouabain reduces carotid blood flow and increases vascular
resistance (Treat, Ulano and Jacobson, 1970). According to these
authors this vasoconstrictor effect is only observed during infusion
of ouabain. After cessation of ouabain infusion, blood flow and
resistance return toward initial control values, although ouabain is
still present in the general circulation. Confirmation of a direct effect
of ouabain on vascular beds has also been obtained by others (e.g.
Ribeiro, 1976). In an attempt to test whether the action of ouabain
on chemoreceptor activity could be related to such a mechanism, two
experiments were performed in which the ouabain infusion (3 ug/min
i.e.) was stopped after 10 min. The results from one of these experi¬
ments are shown in Figure 5.5. The excitatory action of ouabain was
still apparent after stopping the infusion, the effect being similar to
that observed in experiments in which ouabain was infused for longer
periods. Figure 5.5 also shows the effect of another two infusions,
each of 10 min duration, the first separated from the second by 20 min
and the third from the second by 10 min. The second infusion induced
a short-lasting increase in the chemoreceptor discharge and the third
caused little or no effect on discharge. Following the latter infusion
no chemoreceptor responses were obtained to further ouabain infusions
or to substances such as NaCN (5 ug i.e.), CO2-equilibrated Locke
solution (0.3 ml i.e.), ACh (50 tag i.e.) or dopamine (5 ug i.e.) (see




Effect on spontaneous chemoreceptor discharge (ct/s) of three con¬
secutive ouabain infusions (3 ug/min i.e.) during periods of 10 min
indicated by the horizontal bars, in a cat with the ganglioglomerular
(sympathetic)nerves intact.. Recordings from 2 to 3 chemoreceptor
units. Note the increase in the discharge after stopping the first
ouabain infusion, the decrease in the intensity and duration of the
excitation during the second infusion and the absence of effect during
the third infusion of ouabain.
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TABLE 5.2: Comparison of the chemoreceptor responses evoked
by NaCN (5 |ig) injected into the common carotid
artery via either the lingual or superior thyroid




Control Effect of NaCN :
'
Delay to
X A x A Ex Duration onset
(ct/s) (ct/s) (counts) (s) (s)
1.7 28.2 161 5.3 2.6
±0.4 ±6.3 ±62 ±0.4 ±0.4
1.3 27.9 153 5.3 3.3
+0.5 ±10.6 ±65 ±0.3 ±0.4
Data from five experiments expressed as mean ± s.e. mean.
The injections were performed at different times and the tip of
the lingual catheter was about 1 cm and that of the superior thyroid
catheter was about 4 cm below the carotid bifurcation (for further
details see Section II, Methods and Materials).
TABLE 5.3: Effects of ouabain infusion (3 ug/min i.e.) on blood










Data from seven experiments expressed as mean ± s.e. mean.
•'The blood samples for these determinations were taken
during the peak discharge which was usually observed
within 15 to 25 min after starting ouabain infusions.
Atmospheric pressure: 724-762 mmHg.
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Does the decay phase of the ouabain response result from
exhaustion of chemoreceptors?
To test this possibility an experiment was designed in which
Locke solution (0.1 ml/min i.e.) was infused, and the animal made
hypoxic by breathing 10% 02 : 90% N2. As a result of this procedure
chemoreceptor discharge increased markedly (Figure 5.6). The peak
discharge occurred about 5 min after switching to the hypoxic gas
mixture and remained elevated throughout the period of hypoxic
stimulation (30 min). Thereafter hypoxia was intensified by ventilating
the cat with 100% N2 for 90 s; a further increase in the discharge
was then observed (Figure 5.6). On switching to breathing 02 (100%)
for the next 60 s it was observed that chemoreceptor discharge returned
to a level below that recorded before starting the hypoxic procedure.
This protocol was an attempt to mimick the evolution of the discharge
during ouabain infusion. After chemoreceptor discharge returned to
a steady level, which occurred after 10 min of air-breathing, an
infusion of ouabain (3 ug/min) was initiated. The glycoside caused
an increase in discharge (Figure 5.6) with the same pattern as that
described previously (see e.g. Figure 5.3).
The effect of ouabain during hypoxia
The effect of ouabain (3 ug7min i.e.) during hypoxic stimulation
(15% 02 + 85% N2) is illustrated in Figure 5.7. An infusion of Locke
solution was used as control and the hypoxic stimulation applied in its
presence. Within 5 min of switching to the hypoxic gas mixture
chemoreceptor discharge increased to a level where it remained more
or less steady throughout the hypoxic stimulation period (30 min).
Thereafter the discharge returned to the pre-hypoxia levels. Hypoxic
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LOCKE 0.1 ml/min OUABAIN 3og/min
Time (min)
FIGURE 5.6
Effect on chemoreceptor discharge of hypoxic stimulation (breathing
10% 02 + 90% N2) followed by 100% N2 and then hyperoxia (100% 02)
in the presence of a Locke solution infusion (0.1 ml/min i.e.). After
discharge returned to a steady level on breathing air, ouabain (3 |ig/
min i.e.) was infused. The duration of the Locke solution and ouabain
infusions is indicated by the horizontal bars.
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Effect of a ouabain infusion (3 ug/min i.e.) on chemoreceptor dis¬
charge evoked by hypoxic stimulation (15% 02 ) is illustrated
in the right hand side of the figure. The left hand side shows the
effect of a hypoxic stimulus (15% 02 + 85% N2) on spontaneous chemo¬
receptor discharge in the presence of a Locke solution infusion (0.1
ml/min i.e.). The duration of both Locke solution and ouabain infusions
is indicated by the horizontal bars. Note that the increase in chemo¬
receptor discharge caused by hypoxic stimulus during which ouabain
was infused (right hand side of the figure) was less intense than that
observed during the previous hypoxic stimulation (left hand side).
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stimulus was again applied and when a steady chemoexcitatory effect
was obtained an infusion of ouabain was begun. Under these con¬
ditions ouabain caused a slight increase in the discharge in the first
10 min after starting the infusion followed by a short-lasting peak
(~ 120 s) and a decay in chemoreceptor discharge to a level slightly
below that recorded before starting ouabain infusion.
The influence of the ganglioglomerular (sympathetic) nerves
on the effects of ouabain on chemoreceptors
Results from experiments in which the influence of the ganglio¬
glomerular (sympathetic) nerves was studied on the chemoreceptor
action of ouabain are summarized in Table 5.1. Ouabain was admin¬
istered in two different ways: i.v. or i.e. close to the carotid body
from which nerve activity was being recorded. For each route of
administration a comparison was made between cats with intact and cut
ganglioglomerular (sympathetic) nerves. It is evident that the mean
dose of ouabain infused i.e. needed to increase maximally chemoreceptor
discharge in cats with ganglioglomerular (sympathetic) nerves cut is
significantly greater (P <0.05, t-test) than in cats with the ganglio¬
glomerular (sympathetic) nerves intact (Table 5.1). Such a
difference, however, was not detected when ouabain was infused i.v.
and recordings obtained from intact and denervated carotid bodies
in some experiments (Table 5.1).
The carotid body chemosensory activation by
ouabain and its cardiotoxic actions
The doses of ouabain that caused maximal chemoreceptor discharge
are shown in Table 5.1. Comparing these doses with that needed to
cause ventricular extrasystoles when administered i.e. (64 + 5 |ig/kg,
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n=3) or i.v. (69 ± 2 ug/kg, n=6, Peres-Gomes and Ribeiro, 1979),
it is evident that when ouabain is administered i.e. a significant
difference (P <0.05) exists between chemoreceptor activation and
cardiotoxic doses, whereas little or no difference is apparent between
chemoreceptor activation and cardiotoxic effect when ouabain is given i.v.
Evoked responses
Injections (i.e.) of NaCN (5 ug), CO2-equilibrated Locke solution
(0.3 ml), ACh (50 |ig) and dopamine (5 ug) were made, before and
during ouabain infusions (3 ug/min i.e.). The times in Figures 5.8,
5.9, 5.10 and 5.11 at which injections of these substances
were performed are approximate, i.e. the injections were made at some
time during the 10 min periods over which the chemoreceptor discharge
was averaged. Since no substantial differences were detected in the
responses evoked by those substances between cats with ganglio-
glomerular (sympathetic) nerves cut or intact, responses evoked in
both populations were pooled.
Sodium cyanide
The chemoexcitatory responses evoked by NaCN were enhanced
during the increase in spontaneous chemoreceptor discharge caused
by ouabain and decreased during the phase in which discharge
returned to levels recorded before starting ouabain infusion (control)
or to levels below control (Figure 5.8).
CO ^-equilibrated Locke solution
An increase in the chemoexcitatory responses evoked by C02
was also observed during increase in spontaneous chemoreceptor
discharge induced by ouabain and this was followed by a marked
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decrease (P <0.05) or even absence of responses to C02 during the
subsequent decline in chemoreceptor discharge (Figure 5.9).
Acetylcholine
In the case of ACh its chemoexcitatory action was potentiated
during the increase in spontaneous chemoreceptor discharge induced
by ouabain and decreased during the subsequent decline of the chemo¬
receptor discharge. However, the decrease in the ACh responses was
not so accentuated as in relation to those induced by both NaCN and
CO2 (see Figure 5.10).
Dopamine
The chemoinhibitory action evoked by dopamine was enhanced
during the increase in spontaneous chemoreceptor discharge induced
by ouabain and was decreased during the subsequent decline of the
chemoreceptor discharge observed during ouabain continuous infusion
(Figure 5.11).
Adenosine
In the heart, adenosine potentiates the cardiotoxic effects of
cardiac glycosides (e.g. Rand, Stafford and Thorp, 1955). In order
to investigate whether ouabain influenced the responses to adenosine,
injections of submaximal doses of adenosine (20 and 50 |ig i.e.) were
made during a ouabain infusion (25 ag/min i.e.) and compared with
the effect of adenosine (100 ag i.e.) administered before commencing
ouabain infusion. Figure 5.12 illustrates the effects of ouabain and
the responses evoked by adenosine. Ouabain itself increased chemo¬
receptor discharge within the usual pattern of the ouabain infusions
but the time to reach the peak was decreased ( ~ 12 min) as compared with
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FIGURE 5.8
Effects on chemoreceptor discharge of injections of NaCN (5 jig i.e.)
during ouabain infusions (3 |ig/min i.e., n = 10) performed in five to
ten cats. In the lower part the chemoreceptor discharge (ct/s) is
shown averaged over 10 min periods during the ouabain infusion.
The black rectangle represents averaged chemoreceptor discharge
before starting ouabain infusions and the horizontal bar indicates the
duration of ouabain infusions. The times given for the injections of
NaCN are approximate.
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FIGURE 5.9
Effects of injecting C02-equilibrated Locke solution (0.3 ml i.e.)
during ouabain infusions (3 ug/min i.e., n=8). In the upper part
each point is the mean of five to eight experiments. In the lower
part the chemoreceptor discharge (ct/s) averaged in 10 min periods
during ouabain infusions (3 |ig/min i.e., n=8) is shown. The times
at which the injections of C02 were made are approximate. For further
details see legend of Figure 5.8.
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FIGURE 5.10
Effect of injecting ACh (50 ug i.e.) during ouabain infusions (3 gg/
min i.e.). In the upper part each point is the mean of five to eight
experiments. Note that the responses evoked between 40 and 50 min,
and between 50 and 60 min are not significantly different from the
control. In the lower part the chemoreceptor discharge (ct/s)
averaged in 10 min periods during ouabain infusions (3 |ig/min i.e.,
n=8) is shown. The times at which the injections of ACh were made
are approximate. For further details see legend of Figure 5.8.
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FIGURE 5.11
Effects of injecting dopamine (DA 5 ug i.e.) during ouabain infusions
(3 ug/min i.e.). In the upper part each point is the mean of three
to five experiments. In the lower part the chemoreceptor discharge
(ct/s) averaged in 10 min periods during ouabain infusions (3 |ig/min
i.e., n=5) is shown. The times at which the injections of DA were
made are approximate. For further details see legend of Figure 5.8.





Effect of adenosine injections (i.e.) on chemoreceptor discharge
(ct/s) (recordings obtained from a single chemoreceptor unit) before
and during a ouabain infusion (25 ug/min i.e.). A. Response to
adenosine (100 |ig) before starting ouabain infusion; B. Response
to adenosine (20 ng) administered 5 min; and <0. Response to adenosine
(50 |ig) administered 7 min after starting ouabain infusion. Note that
the response to adenosine (50 ng) was greater than that obtained with
100 (jg before starting ouabain infusion. The arrows indicate the
times of injections. The horizontal bar represents the duration of the
ouabain infusion.
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The response to adenosine (20 |ig i.e.) at 5 min and at 7 min (50 Mg
i.e.) was potentiated (Figure 5.12). No responses were evoked by
adenosine during the decline of the response to ouabain infusion.
Leucine-enkephalin
In one experiment leu-ENK (10- 100 |ig i.e.) was administered
after a series of successive ouabain injections 1, 10 and 100 gg i.e.
The injections of leu-ENK were performed during the increase in
chemoreceptor discharge induced by ouabain 100 ng i.e. The
injections, 10 |ig and 100 |ig, were made 5 and 10 min respectively
after ouabain injection. Both injections of leu-ENK caused inhibition
in the chemoreceptor discharge evoked by ouabain.
This experiment had only a qualitative purpose, that to test
if inhibitory responses could still be evoked by the enkephalins in
the presence of ouabain.
Dihydro-ouabain
Ouabain in low concentrations stimulates and high concentration
inhibits Na + , K+-ATPase whereas the ouabain analogue dihydro-ouabain
has been considered to be a pure Na + , K+-ATPase inhibitor (e.g.
Ghysel-Burton and Godfraind, 1979). In order to determine whether
the effect or part of the effect of ouabain might be attributed to its
Na+, K+-ATPase stimulating properties it was decided to investigate
the response of chemoreceptors to dihydro-ouabain.
Two experiments were performed, dihydro-ouabain was infused
i.e. close to the carotid body at two different rates 3 jjg/min i.e. and
9 ug/min i.e. The low dose had little or no effect on chemoreceptor
discharge as compared with ouabain (3 |ig/min) infusions. However,
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when administered at a rate of 9 ug/min i.e. (see Figure 5.13) its
activation of chemoreceptor discharge followed a pattern similar to
that observed during ouabain infusions.
Physostigmine and mecamylamine
Ouabain releases ACh from both central and peripheral nervous
systems (see Section I, General Introduction). In order to investigate
whether endogenous ACh would be responsible for the increase in
chemoreceptor discharge caused by ouabain, three experiments were
designed. In one experiment physostigmine (a potent anticholinesterase,
effective against both acetylcholinesterase and pseudocholinesterase;
see e.g. Koelle and Gilman, 1949) was used. The effect of ouabain
(3 |ig/min i.e.) was investigated in a cat pretreated with atropine
(1 mg/kg i.v.) and physostigmine (1 mg/kg i.e.) (see Figure 5.14A).
Ouabain increased chemoreceptor discharge in a manner similar to
that usually obtained, and the increase was followed by a subsequent
decline in the discharge.
In another two experiments mecamylamine was used.
Mecamylamine is a potent ganglion blocking drug (e.g. Stone, Torchiana,
Navarro and Beyer, 1956) which can reduce or abolish the increase in
chemoreceptor activity evoked by ACh in the eat carotid body in vitro
(Eyzaguirre and Zapata, 1968b) or in vivo (Sampson, 1971; Nishi and
Eyzaguirre, 1971; McQueen, 1977)..
In the experiments with mecamylamine, the appropriate volume of
dextran solution (25% dextran, 5% glucose in distilled water) required
to maintain B.P. at the control level was administered i.v. This
treatment prevented the fall in B.P. which would otherwise have
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FIGURE 5.13
Effect of infusing dihydro-ouabain (9 ag/min i.e.) on spontaneous
chemoreceptor discharge (ct/s), in a cat with the ganglioglomerular
(sympathetic) nerves intact. Recordings from 1 to 2 chemoreceptor
units. Discharge was averaged over 5 min periods during 50 min.
The horizontal bar indicates the duration of the infusion.
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interpretation of results difficult, because severe hypotension causes
increase in background discharge. Figure 5.14B illustrates one of
the experiments performed to explore whether mecamylamine influences
the action of ouabain. Mecamylamine in the dose given (5 mg/kg i.e.)
was able to antagonize the responses to ACh (25 - 250 ug i.e.), but the
chemoexcitatory effect of ouabain and the general pattern of its responses
(Figure 5.14B) was similar to that described previously in the absence
of mecamylamine (see e.g. Figure 5.3).
q-flupenthixol
In two experiments ouabain (3 ug/min i.e.) was infused after
injecting the dopamine antagonist ct-flupenthixol in a dose of 200 |ig/
kg i.e., which was able to antagonize the inhibitory response to dopamine
(2.5 pg i.e.) converting it into an excitation. One experiment is
illustrated in Figure 5.15, the chemoreceptor response to ouabain peaked
earlier and the general picture of the response was attenuated in
relation to both its intensity and duration.
DISCUSSION
The results obtained show that ouabain alters activity of the
carotid body chemoreceptors. The effect can be divided into two main
phases: increase in spontaneous discharge followed by a return of
chemoreceptor discharge to or slightly below the pre-injection (control)
levels. During the chemoexcitatory phase responses evoked by NaCN,
CO2-equilibrated Locke solution and ACh were increased as was the
chemoinhibitory response evoked by dopamine. During the decline that
follows the ouabain chemoreceptor excitation the responses evoked by
these substances were reduced. Thus it might be concluded that the
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Time (min) after starting infusion
FIGURE 5.14
Effects of ouabain (3 (ig/min i.e.) on chemoreceptor discharge in two
different cats. A. Response to ouabain infusion after pretreatment
with physostigmine (1 mg/kg i.e.). Recordings obtained from 2 to 3
chemoreceptor units. B^. Response to ouabain after pretreatment
with mecamylamine (5 mg/kg i.v.). Recordings obtained from 4 to 6
chemoreceptor units. The infusion of ouabain started at time o .














Effect of ouabain (3 ug/min i.e.) on chemoreceptor discharge (ct/s)
after injecting crflupenthixol (200 ug/kg i.e.). Recordings from two
chemoreceptor units. The black rectangle represents the discharge
averaged before starting ouabain infusion. The horizontal bar
indicates the period during which ouabain was infused.
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effect of ouabain on chemoreceptors comprises a 'sensitizing' followed
by a 'desensitizing' phase.
The increase observed in ehemoexcitatory responses evoked by
NaCN, C02 or ACh might depend on the increase in background
discharge induced by ouabain, but seems probable that at least part
of the effect is a consequence of a ouabain-sensitizing process taking
place at the carotid body. For example when chemoreceptor discharge
returned to the pre-infusion (control) level the evoked responses were
greatly diminished and eventually abolished.
As mentioned previously (Section I, General Introduction), a
number of authors have reported effects of ouabain on arterial chemo¬
receptors. McLain (1970) described an increase in the total spontaneous
neural traffic (baro- and chemoreceptors) recorded from the cat
carotid sinus nerve after injecting ouabain i.v. or i.m. Joels and Neil
(1968) found that ouabain inhibits chemoreceptor discharge evoked by
perfusion of vascularly isolated cat carotid bodies with either nitrogenated
solutions or ACh. Other cardiac glycosides increase spontaneous chemo¬
receptor activity (Schmitt, Giith and Muller-Limmroth, 1958). The
excitation of spontaneous chemoreceptor discharge has been confirmed
in the present work. A decrease in the excitatory action of ouabain
on chemoreceptor responses evoked by NaCN, C02 and ACh was also
obtained in the present study during the declining phase that followed
the initial increase in chemoreceptor discharge during ouabain infusion.
It is not possible to make a direct comparison between the present
results and those of Joels and Neil (1968) because, (1) the duration
of the ouabain infusions in their experiments is not given, and (2)
the experimental conditions were different, which may explain why
Joels and Neil (1968) did not report any chemoexcitatory action of ouabain.
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The easiest way to explain the present results is in terms of
Biscoe's hypothesis (Biscoe, 1971), i.e. the sensory nerve ending
behaves as a chemoreceptor. The idea was put forward on the grounds
that, "the membrane potential of all nerve cells is determined by ionic
concentration gradients that are controlled by the sodium pump. The
metabolic energy on which the pump depends for its level of activity
is derived from oxygen, in aerobic systems. Thus given an excess
of other requirements, the ambient oxygen tension could control the
rate of the sodium pump, which in turn would affect the potassium
gradient and so the membrane potential. A fall in oxygen tension
could slow the pump down, allowing a loss of potassium, which would
cause depolarization and which in turn could be sufficient to initiate
action potentials in the afferent fiber. With large nerve fibers or
cells the effects on the potassium potential would normally be of little
account. However, it is possible that because of their very high
surface-to-volume ratio the membrane potential of very small fibers
will be extremely sensitive to oxygen tension. The electrogenic
property of the sodium pump, if taken into account, would reinforce
the depolarizing effect of a reduction in pump activity".
It is known that raising the extracellular potassium concentration
in the carotid body increases the nervous chemoreceptor activity
(Acker, 1978). However, in vitro the glomus cell membrane seems to
be rather insensitive to changes in extracellular K+ (Eyzaguirre and
Fidone, 1980). Ouabain inhibits the sodium pump (Repke and Portius,
1963). Two phases in the action of ouabain have been postulated.
For instance, Baker and Willis ( 1972) refer the existence of a primary
phase that is concentration-dependent but does not follow simple first
order kinetics and is a consequence of Na+, K+-ATPase inhibition and
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a secondary phase that results from uptake of ouabain by nerve
endings ana its interaction with the movements of Ca2+ inside and
outside the cells.
In relation to the present results, the 'sensitizing' phase of
ouabain would represent inhibition of the Na+, K+-pump and the
'desensitizing' phase could be related to paralysis of the Na+, K+-
pump. The direct sensory nerve ending activation hypothesis is
supported by the observation that in the 'sensitizing' phase responses
to both ACh and dopamine were potentiated. Furthermore, direct
excitation of carotid body baroreceptors by ouabain has been suggested
by Quest and Gillis (1974) and most of the arguments used to explain
how ouabain causes such activation, i.e. by reducing the threshold
for excitation of sensory receptors in particular those related to C
fibres, could also apply to the present findings. However, afferent
chemoreceptor activity seems to be conducted by one third of C fibres
and two thirds of A fibres (Fidone and Sato, 1969), making more
probable that the present recordings were obtained from A fibres.
Whether the ouabain effect differs according to the fibre affected cannot
be determined from the present observations.
The difficulty in obtaining full recovery after ouabain is probably
related to its mechanism of action and binding of ouabain. Assuming
that Na+, K+-ATPase inhibition is responsible for its excitatory action
after using high doses, it might be accepted that what has been
described for other tissues may also be applied to the present findings.
The ouabain-Na + , K+-ATPase complex is extremely stable (Peters,
Raben and Wassermann, 1974). It cannot be dissociated within 30 min.
The decay phase of the ouabain response does not seem to result
from an exhaustion mechanism because mimicking the pattern of the
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ouabain response by applying first partial hypoxia (10% 02 + 90%N2)
and then severe hypoxia (100% N2) did not prevent further chemoreceptor
responses (Figure 5.6). However, one could argue that higher doses
of ouabain paralyse the Na + , K+-ATPase. This could trigger a bio¬
chemical mechanism, which eventually might exhaust the mechanisms
involved in the increased discharge evoked by ouabain.
For example, Fidone, Gonzalez and Yoshizaki (1981) described
that in the rabbit superfusing the carotid body in vitro with no Ca2 +
and high Mg2 + a nearly complete block of 3H-dopamine release occurred,
yet only about a 50% reduction in nervous activity was observed.
The carotid body type I cell has been classified as being in the
APUD cell series (Pearse, 1969) and within the paraneurone group
(Kobayashi, 1977) (see Section I, General Introduction). It contains
amines, peptides and ATP (see e.g. Fujita and Kobayashi, 1979). The
amine so far identified and being an effective depressant at the carotid
body is dopamine (for a review see Fidone, Gonzalez and Yoshizaki,
1980). The peptide-like substances so far identified as being present
are met-ENK, leu-ENK, SP and VIP. The enkephalins depress chemo¬
receptor discharge (see Section IV); SP causes a delayed increase
in discharge (McQueen, 1980) and VIP in low doses depresses and in
high doses increases chemoreceptor discharge (see Section IV). ATP
and its closely related nucleoside, adenosine, increase chemoreceptor
discharge (see Section III). Classifying the actions of all those
substances according to speed of onset and duration of the response
it is possible to distinguish two groups: one with rapid onset (1 to 5 s)
and a short-lasting effect, namely the enkephalins and adenosine, and
another with delayed onset and a long lasting effect exemplified by
SP and VIP. The latter, appear to have properties usually associated
with neurohormones and the former group more those of neurotransmitters.
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It is well documented that ouabain can release the classical
neurotransmitters (ACh and NA) both in vitro (for reviews see
Vizi, 1979; Gillis and Quest, 1980) and in vivo (Ribeiro and Peres-
Gomes, 1977) as well as adenosine (Shimizu, Creveling and Daly, 1970;
Daval, Barberis and Gayet, 1980; Hollins and Stone, 1980a; Hollins,
Stone and Lloyd, 1980). Thus the possibility of ouabain releasing
all these substances (i.e. 'classical' neurotransmitters, peptides,
adenosine) from the carotid body has to be considered, meaning that
its effect might result from release of inhibitory and excitatory neuro¬
transmitters or neuromodulators in the carotid body. From the present
results it is not possible to establish the importance of these factors.
For example, ACh appears not to be any more important than other
stimulatory influences since no substantial changes were seen in the
pattern of the ouabain response either after physostigmine or mecamyl-
amine. Dopamine might be involved because in the cats pretreated with
the dopamine antagonist a-flupenthixol, ouabain caused a less exuberant
increase in chemoreceptor discharge and the peak occurred earlier.
Sensitization to exogenous ACh, dopamine and adenosine was also
detected. Whether these actions mean involvement of the same endogenous
substances as well as those of peptides deserve further investigation.
In the case of adenosine, it will be necessary to determine the effect
of ouabain in the presence of an adenosine uptake blocker (e.g.
dipyridamole) or after pretreatment with adenosine deaminase inhibitors
such as deoxycoformycin. In the case of the enkephalins it would be
interesting to know whether naloxone modifies the response to ouabain.
The chemoinhibition induced by leu-ENK is still present during the
ouabain excitatory phase. Interactions with other peptides also present
in the carotid body such as SP and VIP might also be of interest.
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An efferent pathway has been postulated (see Biscoe, 1971; Osborne
and Butler, 1975) so ouabain might interfere with the release of
substances involved in that pathway. What transmitters are released
or how ouabain affects this component is impossible to determine as
its physiological relevance has not yet been established (but see
Section 1, General Introduction).
The metabolic inhibitors have amongst other actions, the ability
to inhibit the sodium pump. For instance, at the neuromuscular
junction 2-4-dinitrophenol (Beani, Bianchi and Ledda, 1966) or hypoxia
(nitrogen atmosphere) (Hubbard and Ldyning, 1966) increase the
frequency of miniature end-plate potentials in a manner similar to
that caused by ouabain. The same is in general observed with
procedures that interfere with the regeneration of ATP. Although
in the present study ouabain appears to mimick, at least in part, the
hypoxic response, striking differences were noted: (1) the response
of chemoreceptors to hypoxic stimulation can be maintained throughout
the period of stimulation, whereas during ouabain infusion chemo-
receptor discharge begins to fall shortly after peak discharge is
reached; (2) after hypoxic stimulation is stopped and discharge
returned to the pre-infusion levels responses evoked by substances
such as NaCN, C02, ACh and dopamine are not substantially altered,
whereas after ouabain infusion that lasted about the same time as
hypoxic stimulation the responses to those stimulants were markedly
reduced or absent. A reason for these differences may be, as Birks
and Cohen ( 1968) pointed out for the neuromuscular junction, from
ouabain acting specifically on the Na + , K+-ATPase which behaves
as the ouabain receptor, whilst the metabolic inhibitors and/or hypoxia
act indirectly by interfering with the synthesis of ATP.
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The persistence of chemoreceptor discharge after death seems
to indicate that part of the chemoreceptor discharge is independent,
at least for 10 to 40 min, of a number of factors such as the profound
change in B.P., alterations in arterial blood gases (Pa02, PaC02)
and pH, as well as becoming unresponsive to the 'classical' chemo¬
receptor stimulants NaCN, C02 and ACh. Alternatively the absence
of chemoreceptor response might result from the chemoreceptors
adapting to different stimuli in consequence of ouabain action.
According to Nakaiima and Onodera (1969) an electrogenic sodium
pump could be responsible for adaptation processes at the sensory
receptors. An adaptation to hypercapnia has been reported by
McCloskey ( 1968) and Gray (1968). Thus, the persistence of the
discharge after cardiac arrest might correspond to the existence of
an interaction with an adaptative process.
Another possibility is that a metabolite capable of activating
chemoreceptors is being released, by whatever leakage process, after
death. For instance, at the central nervous system, in vivo, Ribeiro
and Peres-Gomes ( 1977) were able to detect by bioassay a considerable
output of an ACh-like substance, until 60 min after cardiac arrest,
in the cerebrospinal fluid. The appearance of ACh seems to be
independent of the cause that induced cardiac arrest (e.g. ouabain
infusion i.v. or intracerebroventricular; electrical stimulation,
aconitine or potassium chloride directly applied to the external surface
of the cardiac ventricles). If the same applies to the carotid body
then one could reviv^ the metabolite hypothesis advanced by Neil (1951)
and Landgren and Neil (1951), which had its origin with Bogue and
Stella ( 1935) on the grounds of similar observations to those presently
described, i.e. the prolongation of the chemoreceptor discharge after
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death. This hypothesis, however, has been refuted by Daly,
Lambertsen and Schweitzer ( 1954) and Paintal (1967) on the grounds
that chemoreceptors are highly sensitive to falls in 02 and that dis¬
charge of chemoreceptors falls within 2 to 3 min after circulatory
arrest (see e.g. Paintal, 1971).
In conclusion, ouabain affects chemoreceptor activity first
increasing spontaneous chemoreceptor discharge and sensitizing
chemoreceptors to the action of substances such as NaCN, C02, ACh,
dopamine and adenosine: this can be considered a 'sensitizing' phase.
Secondly, during the decline of chemoreceptor discharge that follows
the 'sensitizing' phase ouabain alters chemoreceptor activity in a
manner that the chemoreceptors usually become much less responsive
or even unresponsive to ouabain itself, NaCN, C02, ACh, dopamine
and adenosine and this can be named 'desensitizing' phase. As
ouabain inhibits Na+, K+-ATPase and it is likely that the structural
components of the carotid body contain that ATPase, the ouabain
effect is perhaps the net effect on all the components, i.e. on the
glomus type I and type II cells, sensory nerve endings and nerve
endings with motor-like function. Sympathetic nerve endings appear
to be affected as can be concluded from differences observed between
cats with ganglioglomerular (sympathetic) nerves intact and cut
during i.e. infusions. Sensory nerve endings, in particular those
originating from C fibres should also be activated. Whether the trans¬
mitters or any other substances released by ouabain from type I cells
should also be considered in the ouabain effect is at present impossible
to know.
SECTION VI
General Discussion and Conclusions
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I. The results obtained with purines and peptides suggest the
following main conclusions:
1. Substances present in the cat carotid body such as ATP/adenosine
and the peptides, met-ENK, leu-ENK, and VIP are effective when
injected close arterial to the carotid body. These substances can
be grouped with others which are also present in the carotid body
and also affect chemosensory discharge (e.g. catecholamines,
5-HT, ACh, SP).
2. The effect these substances produced when injected i.e. can be
divided on the basis of the speed of onset and duration of the
responses into (a) rapid onset and short-lasting (adenosine and
the enkephalins) and (b) slower onset and long-lasting (VIP).
Both adenosine and the enkephalins caused quite clear effects,
the former activated the chemoreceptors and the latter inhibited
them. The effects of B-endorphin, VIP and CCK-8 were not so
clear cut and tended to be biphasic.
3. Considering those substances in molecular terms, adenosine and
the enkephalins are relatively small molecules compared with
S-endorphin, VIP or CCK-8. In this respect adenosine and the
enkephalins are closer to neurotransmitters and VIP, B-endorphin
and CCK-8 to neurohormones.
4. The effects on chemosensory discharge of the different substances
present in the cat carotid body following i.e. injection in the cat
can be distinguished into: (a) inhibitory, obtained with dopamine
and the enkephalins; (b) excitatory, obtained with ACh and ATP/
adenosine; (c) biphasic, obtained with VIP and SP.
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5. g-endorphin and CCK-8 are present in various parts of the body
but it is not yet established whether or not they are present in
the carotid body, and have biphasic actions on chemoreceptor
activity.
II. Another important conclusion relates to ouabain, which can both
excite and inhibit chemoreceptor activity. Two phases can be detected,
a 'sensitization' followed by a 'desensitization' phase. These effects
are probably related to the well-established properties of ouabain in
various tissues, namely its ability to modify Na+, K+-ATPase.
Some of the substances mentioned above have been suggested as
being involved in sensory transmission. For example, ATP was suggested
as a sensory transmitter of both central and peripheral sensory nerve
endings (Holton and Holton, 1953; 1954). The enkephalins may be the
endogenous ligands for the opiate receptor and as such they have been
considered as participants in the analgesia processes (see e.g. Kosterlitz
and Hughes, 1975). SP has been frequently proposed as a sensory
(? pain) transmitter (see e.g. Nicoll, Sehenker and Leeman, 1980).
Interactions between the enkephalins and SP and between VIP
and ACh or in general terms between peptides and the'classical' trans¬
mitters as well as between ATP/adenosine and the 'classical' transmitters
have been considered in the recent literature in order to explain both
central and peripheral excitation and/or inhibition. Thus, electro¬
physiological evidence is compatible with three actions of opioid peptides
and adenosine at the present time. Firstly, there is a presynaptic
action to depress the release of certain neurotransmitters (a neuro¬
modulator effect). The mechanism underlying this might involve the
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decrease in uptake of calcium ions by the nerve endings. Secondly,
opioid peptides and adenosine can interfere directly with the post¬
synaptic actions of certain neurotransmitters, altering their ability to
change ionic conductances (a cotransmitter effect). The third action
is a direct 'postsynaptic' action on some cells (a neurotransmitter
effect). When this action occurs, as in the case of the opioid peptides,
it may be predominantly inhibitory. The present evidence, however,
does not allow one to conclude which one of these is the most important
action underlying the acute effects of the purines or opioid peptides on
the activity of the carotid body chemoreceptors.
The opioid peptides may be divided into two independent groups
which act in different systems (see Kosterlitz, 1979). The first is
represented by the short-chain peptides met-ENK and leu-ENK and they
are distributed unevenly throughout the brain, spinal cord and peripheral
nervous system (e.g. Elde, Hokfelt, Johansson and Terenius, 1976;
Hughes, Kosterlitz and Smith, 1977). The second group is represented
by the long-chain peptide g-endorphin, present in the hypothalamus-
pituitary axis and extending into the midline regions of the diencephalon
and anterior pons (e.g. Bloom, Rossier, Battenberg, Bayon, French,
Henriksen, Siggins, Segal, Browne, Ling and Guillemin, 1978; Watson,
Barchas and Li, 1977). On this basis, according to Kosterlitz (1979),
only the enkephalins should be considered as neurotransmitters in the
peripheral nervous system. In certain stress conditions g-endorphin
may be released into the blood stream, but its concentration is unlikely
to be high enough to affect peripheral tissues; if such an effect were
to occur, it should be classified as a hormonal action (see Kosterlitz, 1979).
The evidence that adenosine is a neurotransmitter in the brain is
still unclear and the fact that it has multiple metabolic roles make it
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difficult to identify a potential neurotransmitter function for this
substance (see e.g. Snyder, Bruns, Daly and Innis, 1981). However,
adenosine has important roles in many functions of the central and
peripheral nervous systems. The electrophysiological expression of the
changes it produces is a reduction of spontaneous and evoked neuronal
activity (see e.g. Ribeiro, 1979) and the biochemical expression is the
inhibition of adenylate cyclase via a 'high' affinity receptor and its
excitation via a 'low' affinity receptor. The first is localized intra-
cellularly and the latter extracellularly (see e.g. Daly, Bruns and
Snyder, 1981; Stone, 1981).
On the other hand, adenosine is released into the circulation by
a number of physiological and pathophysiological processes (e.g.
ischaemia; see Winn, Rubio and Berne, 1979), and a correlation between
adenosine concentration and oxygen supply in rat brain has been
suggested (Rubio, Berne, Bockman and Curnish, 1975). In the
present work low doses of adenosine modified chemoreceptor discharge,
and it seems reasonable to speculate that adenosine might influence
events taking place in the carotid body by acting as a neuromodulator,
cotransmitter or neurotransmitter.
In cells such as those in the adrenal medulla and the SIF cells,
which have several similarities to those of the carotid body type I cells
ATP, peptides and classical transmitters coexist, can be released
together, and may interact postsynaptically (e.g. Burnstock, Hokfelt,
Gershon, Iversen, Kosterlitz and Szurszewski, 1979; Viveros, Diliberto,
Hazum and Chang, 1979; Wilson, Klein, Chang, Gasparis, Viveros and
Yang, 1980; Costa, Guidotti, Hanbauer, Hexum, Saiani, Stive and Yang,
1981). If the same occurs in the carotid body their physiological action
is probably composite. However, at present it is not possible to
180.
ascertain in which of the carotid body structures these substances act,
i.e. type I cells, type II cells, sensory nerve endings, efferent
terminals, or whether all these components are influenced through
postsynaptic or presynaptic receptors. In physiological conditions the
sympathetic nerve endings that regulate carotid body flow may also be
affected.
The classical pharmacological criteria, based on the notion of
specific drug receptors, namely supported by the use of specific
agonists and antagonists, appear to apply particularly to the enkephalins
which act through a naloxone-sensitive receptor. Theophylline in the
doses studied did not behave as an adenosine antagonist. No specific
antagonists are available for the other neuropeptides. It is generally
recognised that antagonists are necessary to characterize the receptor,
but in the absence of specific antagonists much emphasis has recently
been put on radioligand binding studies at neurotransmitter receptors
since they can provide discrimination at the molecular level, permitting
the differentiation of multiple receptor subtypes (see e.g. Daly, Bruns
and Snyder, 1981; Snyder, Bruns, Daly and Innis, 1981).
The vascular effect
The fact that the neuropeptides studied so far, as well as adenosine
(for adenosine see also Discussion in Section III), can affect the
vasculature could be taken to imply that the role of endogenous carotid
body peptides and adenosine is to modify blood flow. However, it is
not known whether endogenous peptides or adenosine do actually change
carotid body flow, and 'classical' neurotransmitters, such as ACh,
noradrenaline and dopamine, have marked effects on blood vessels when
injected. This has not prevented these latter substances from being
considered as putative neurotransmitters in the carotid body (see e.g.
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Biscoe, 1971). So, by the same token the vascular effects caused by
exogenously applied neuropeptides or adenosine should not exclude them
from consideration as putative neurotransmitters in the carotid body.
Ouabain also affects the vasculature and, hence, some of the above
arguments could also apply. But the fact that this substance affects
neural tissues implies that in its action on chemoreceptors other
mechanisms are involved, namely those related to changes in transmitter
output!s) and nerve depolarization.
Cyclic AMP
Despite the presence of various substances in the carotid body
affecting different receptors, they may eventually influence a common
mechanism (e.g. adenylate cyclase) within the carotid body. This
common mechanism can be affected by drugs such as ouabain or by
potassium, electrical depolarization, anoxia. The involvement of cyclic
AMP is supported by the presence in the carotid body sensory nerve
endings of an adenylate cyclase-cyclic AMP system (Fitzgerald, Rogus
and Dehghani, 1977) and the findings that isoprenaline stimulates
cyclic AMP formation in the rat carotid body in vivo (Mir, Pallot and
Nahorski, 1981) and stimulates spontaneous chemoreceptor discharge
through g-receptors (Folgering, Ponte and Purves, 1980).
A brief discussion postulating the involvement of cyclic AMP in
both activation and inhibition of chemoreceptor activity by the substances
investigated in the present work follows.
It is now well-established that cyclic AMP formed from ATP by
activation of the membrane-bound enzyme adenylate cyclase serves as
an intracellular messenger for the action of a number of circulating
hormones and neurotransmitters (for reviews see e.g. Greengard, 1976;
Daly, 1977; Nathanson, 1977). The enzymatic machinery involved in
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the process of cyclic AMP formation includes: adenylate cyclase,
cyclic nucleotide phosphodiesterase, cyclic AMP-dependent protein
kinase, phosphop rote in phosphatase, and the protein substrates for
phosphorylation (see Nathanson, 1977). The mechanism of action of
cyclic AMP in neuronal function involves the protein phosphorylation
which then regulates permeability to calcium (see e.g. Greengard, 1976).
Adenosine
Adenosine causes a great increase in cyclic AMP through two
mechanisms (1) by its incorporation into ATP thus increasing the
concentration of substrate available to adenylate cyclase (Shimizu and
Daly, 1970; Skolnick and Daly, 1975) and (2) through activation of a
specialized adenosine receptor linked with adenylate cyclase (e.g. Huang
and Daly, 1974; Londos and Wolff, 1977).
Dopamine
A dopamine-sensitive adenylate cyclase has been identified in
several mammalian nerve tissues including sympathetic ganglia (Kebabian
and Greengard, 1971) and other parts of the nervous system (central
and peripheral) as well as an adenylate cyclase-sensitive to noradrenaline
(see Nathanson, 1977).
The fact that sulpiride (a dopamine D2 antagonist) can antagonize
the ehemoinhibitory action of dopamine (McQueen, personal communication)
suggests the presence of D2 dopamine receptor which operates without
increasing the concentration of cyclic AMP (see e.g. Tsuruta, Frey,
Grewe, Cote, Eskay and Kebabian, 1981). However, whether such a
receptor exists in the carotid body remains to be established.
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iMorphine and the enkephalins
Morphine inhibits stimulation of adenylate cyclase by prostaglandins
in the brain (Collier and Roy, 1974) and this effect is antagonized by
naloxone. The same can also apply to the endogenous ligands for
morphine, the enkephalins (see Nathanson, 1977).
Substance P
Adenylate cyclase activity stimulated by SP has been found in both
rat and human-brain (Duffy, Wong and Powell, 1975).
Cholecystokinin
In some systems CCK may enhance adenylate cyclase. However,
in the pancreas it does not stimulate cyclic AMP formation even though
cyclic AMP derivatives do mimic the ability of CCK to enhance amylase
secretion (see e.g. Snyder, Bruns, Daly and Innis, 1981).
Vasoactive Intestinal Polypeptide
This peptide also stimulates adenylate cyclase and secretion in
several tissues such as intestinal smooth muscle (see e.g. Said, 1978).
Anoxia
Anoxia increases cyclic AMP and cyclic GMP (Kimura, Thomas
and Murad, 1974) and this might be achieved via release of adenosine
because theophylline antagonizes the increase caused by anoxia (see
Daly, 1977).
Ouabain
Ouabain and potassium increase both cyclic AMP and cyclic GMP
in the brain (Ferrendelli, Kinscherf and Chang, 1973; Kinscherf, Chang,
Rubin, Schneider and Ferrendelli, 1976).
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Some of the above substances modify the concentration
of cyclic AMP by interfering with adenylate cyclase. Other substances
which also change the concentration of cyclic AMP, but by interfering
with the phosphodiesterases, such as theophylline and imidazole, do
not show such a clear cut correlation between pharmacological and
biochemical effects (see e.g. Ginsborg and House , 1980). This might
suggest that it is the adenylate cyclase-cyclic AMP system that has to
be affected rather than simply the concentration of cyclic AMP.
r
Table 6.1 correlates presence of substances in the carotid body
with chemoreceptor activity and adenylate cyclase changes.
TABLE 6.1: Substances present in the cat carotid body and their
effects on chemoreceptor discharge : correlation with
their capacity to change the adenylate cyclase-cyclic
AMP system
Effect on the cat Effect on the
Chemoreceptor Adenylate Cyclase-
Discharge Cyclic AMP system
Dopamine I I





SP ; 1 f





means slight decrease ( +) or increase ( ; )
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The analysis of the above information suggests that in the
cat carotid body, stimulation of chemoreceptor activity results from
prior activation of an adenylate cyclase-cyclic AMP system, and
inhibition of this system leads to chemosensory inhibition.
Five criteria are generally regarded as necessary for establish¬
ing a substance as a neurotransmitter namely: (1) synthesis and
storage of transmitter in nerve terminals; (2) release of transmitter
during nerve stimulation; (3) postjunctional responses to exogenous
transmitter should mimic responses to nerve stimulation; (4) enzymes
that inactivate the transmitter and/or an uptake system for the
transmitter or its breakdown products; (5) antagonists should block
and ag^onists potentiate the responses to both exogenous transmitter
and nerve stimulation.
This list is, indeed, enormous compared with the progress made,
i.e. only requirements (1) and (3) are closer of being fulfilled in
the case of the carotid body. A more 'reasonable' requirement (Werman,
1980) is that at least two criteria have to be met, namely 'collectibility'
(the proof of the release of a given material in appropriate concentrations
on stimulation of the input nerve) and the criterion of 'identity of
action' [(the proof that the action of the substance on the postsynaptic
structure - nerve, muscle or gland cell) when present in the extra¬
cellular space in sufficient concentration is identical with that of the
physiological released material].
As a final comment, from studies on inputs (drugs) and outputs
(chemoreceptor discharge) attempts have been made to interpret what
happens in the 'black box' (the carotid body). As Crick ( 1979) pointed
out recently "the difficulty with the black-box approach is that unless
the box is inherently very simple", which is not the case with the carotid
186.
body, "a stage is soon reached when several rival theories all explain
the observed results equally well" (see e.g. the hypotheses listed by
Biscoe, 1976). "Attempts to decide among them often prove unsuccess¬
ful because as more experiments are done more complexities are revealed."
For example, until 1979/80 the carotid body was considered to contain
mainly amines (dopamine, noradrenaline, adrenaline, 5-HT) and ACh,
but after 1979/80 it was also shown to contain ATP stored with amines,
met-ENK, leu-ENK, SP, VIP. As Crick (1979) states, "at this point
there is no choice but to poke inside the box if the matter is to be
settled one way or the other". So, more extensive studies are needed
using more sophisticated methods which have proved useful in other
systems, such as microelectrophysiological techniques which certainly
help to provide accurate information concerning cellular function and
the mechanisms involved, i.e. to know more about pumps, ion channels,
drug receptors, enzymes and structural proteins of the cell membranes
of the carotid body components.
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The effects of ouabain on carotid chemoreceptor activity in the cat
By D. S. McQueen and J. A. Ribeiro. Department of Pharmacology, University of
Edinburgh, Edinburgh E11S 9JZ
It is not clear whether ouabain increases (e.g. McLain, 1970) or decreases (Joels &
Neil, 1968) chemoreceptor activity, so the present study was undertaken to investi¬
gate further its effects on the cat carotid chemoreceptors.
Experiments were performed on pentobarbitone-anaesthetized cats which were
artificially ventilated and paralysed with gallamine (3 mg kg-1 i.v.). Chemoreceptor
activity was recorded from the peripheral end of a sectioned sinus nerve and quanti¬
fied (McQueen, 1977); the ganglioglomerular (sympathetic) nerves were left intact.
Drugs were dissolved in Locke solution and either injected or infused into the
ipsilateral common carotid artery (i.e.).
Ouabain was given either as successive injections (0-625, 1-25, 2-5, 5, 10, 20, 40,
80 yg in volumes of 0-1 ml. i.e., every 20-25 min) or as a continuous infusion (3 yg
in 0-1 ml. min-1 i.e.). Its effect could be divided into two components, an initial
excitation followed by a decrease in chemoreceptor activity. Injections of ouabain
caused a dose-related increase in discharge lasting 1-2 min and a gradual increase in
spontaneous discharge. When about 80 yg had been injected spontaneous discharge
began to decrease, sometimes very rapidly, and further injections of ouabain were
less effective; ultimately discharge ceased entirely. Infusions of ouabain caused a
gradual increase in discharge frequency until about 20-30 yg had been infused when
discharge began to decrease, eventually ceasing. The depression lasted for at least
2-3 hr after stopping the infusion.
Responses to the stimulants NaCN (5 yg i.e. or 50 yg r.v.), C02 (0-3 ml. i.e. C02-
saturated Locke), acetylcholine (ACh, 50 yg i.e.) and to the inhibitor, dopamine
(5 ygi.c.), were determined after injections and during infusions ofouabain. Responses
to NaCN, C02 and ACh increased during the early excitatory period and were greatly
reduced during the later period when discharge was decreasing. The effect of dop¬
amine persisted during the excitatory period and was potentiated during the period
of reduced discharge.
These results indicate that ouabain can both increase and then reduce the activity of
the carotid chemoreceptors. During the excitatory phase chemoreceptor sensitivity
to stimulants is increased, whereas during the later phase of decreasing discharge
sensitivity to stimulants is reduced and that to inhibitors is increased.
This work was supported by an M.R.C. project grant. J.A.R. is on leave from the Instituto
Gulbenkian de Ciencia, Oeiras, Portugal.
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INHIBITORY ACTIONS OF METHIONINE-ENKEPHALIN AND
MORPHINE ON THE CAT CAROTID CHEMORECEPTORS
d.s. mcqueen & j.a. ribeiro1
Department of Pharmacology, University of Edinburgh. 1 George Square. Edinburgh EH8 9JZ
1 The effects of intracarotid injections of methionine-enkephalin (Met-enkephalin) and morphine on
chemoreceptor activity recorded from the peripheral end of a sectioned carotid sinus nerve have been
studied in cats anaesthetized with pentobarbitone.
2 Met-enkephalin caused a rapid, powerful, inhibition of spontaneous chemoreceptor discharge, the
intensity and duration of which was dose-dependent.
3 Morphine was a less potent inhibitor of spontaneous chemoreceptor discharge, and the inhibition
it evoked was rather variable and tended to be biphasic. Low doses of morphine caused a slight
increase in discharge.
4 Naloxone (0.2 mg i.e.) slightly increased spontaneous discharge, greatly reduced the chemo-
inhibition caused by morphine, and reduced the inhibitory effect of Met-enkephalin. A higher dose
of naloxone (0.8 mg) caused a substantial reduction of the Met-enkephalin effect.
5 Chemo-excitation evoked by intracarotid injections of acetylcholine. CO,-saturated Locke solu¬
tion. and sodium cyanide were only slightly and somewhat variably reduced following injections of
Met-enkephalin, whereas the inhibitory effect of dopamine was potentiated. Following morphine
administration, responses to acetylcholine and sodium cyanide were reduced slightly, whereas those
to CO, and dopamine were potentiated.
6 Responses to acetylcholine and CO, were slightly potentiated during infusion of Met-enkephalin
-(50 pg/min, i.e.) and the response to sodium cyanide was slightly reduced.
7 It is concluded that naloxone-sensitive opiate receptors are present in the cat carotid body: when
activated they cause inhibition of spontaneous chemoreceptor discharge. The physiological role of
these receptors and the identity of any endogenous ligand remains to be established.
Introduction
Methionine-enkephalin (Met-enkephalin) is a potent
inhibitor of spontaneous chemoreceptor discharge in
the cat (McQueen. 1979), and the present neurophar-
macological study was undertaken to investigate
further this action of Met-enkephalin. It was also con¬
sidered of interest to determine whether morphine has
the same effect as Met-enkephalin on the cat carotid
chemoreceptors.
Methods
Experiments were performed on ten cats weighing
between 2.1 and 3.5 kg. median weight 2.9 kg. They
were anaesthetized with pentobarbitone sodium (42
mg/kg i.p. initially, supplemented by i.v. adminis¬
tration of 10°o of the initial dose every 1 to 2 h).
1 Permanent address: Centro de Biologia. Institute Gul-
benkian de Ciencta. Oeiras. Portugal.
artificially ventilated and paralysed by gallamine
triethiodide (3 mg kg i.v.). Full details of the experi¬
mental techniques have been given previously
(McQueen. 1977; Docherty & McQueen. 1978).
Electrical activity of chemoreceptor units (1 to 5
units) was recorded from filaments of the peripheral
end of a sectioned sinus nerve, passed through a pulse
height (window) discriminator, and quantified with
the aid of a PDP-8 computer. The ganglioglomerular
(sympathetic) nerves were cut.
Drugs were dissolved in modified Locke solution
(McQueen. 1977). Drug solutions (0.1 ml) were
injected into the common carotid artery ipsilateral to
the sinus nerve from which activity was being
recorded, and washed in with 0.2 ml Locke solution
which had been bubbled with 5% CO,: 950o air in a
water bath at 37°C; injections were made over 2 s.
The catheter was introduced into the common carotid
artery via the lingual artery and advanced until its tip
lay about 2 cm caudal to the carotid bifurcation. In
0007-1188/80/130297-09 S01.00 © Macmillan Publishers Ltd 1980
























3.5±1.9 n = 2
2.1±0.6/? = 4
4.3±1.2n = 5














3.4± 1.5 n = 3
CD
o~
2.9± 1.6/7 = 3
2.9±1.0 n = 4
30 60 90 120 150
Time (s) after injection
30 60 90 120 150
ME 0.1pg i.e. Morphine 1000pg i.e.
Figure 1 The upper part illustrates the effects of various doses of methionine-enkephalin (ME) (a) and morphine
(b) on spontaneous chemoreceptor discharge. Discharge was averaged over 15 s periods following the injection and
expressed as a percentage of the averaged discharge in the 15 s pre-injection control period. Data from n experi¬
ments were pooled and are shown as the mean percentages: vertical lines show s.e. mean. Averaged values (ct/s)
+ s.e. mean for the control (100%) periods are given.
The neurograms in the lower part of the figure, taken from one experiment, show the early part of the somewhat
similar inhibition of chemoreceptor discharge caused by injecting (arrow) (a) ME 0.1 ug i.e. and (b) morphine 1000
pg i.e.
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some experiments a second catheter was positioned in
the common carotid artery, this time via the superior
thyroid artery, and used for the infusion of drug solu¬
tions (0.5 ml/min for 65 s; Braun, Unita).
Drugs used were: morphine sulphate, gallamine
triethiodide (May & Baker); sodium cyanide, acetyl¬
choline iodide (B.D.H.); methionine-enkephalin
(Uniscience); dopamine hydrochloride (Koch Light)
and naloxone hydrochloride (Endo), kindly given to
us by Professor W. Feldberg.
Results
Effect of methionine-enkephalin injections on spon¬
taneous chemoreceptor discharge
Met-enkephalin caused a dose-dependent reduction in
spontaneous chemoreceptor discharge with a rapid
onset, starting within 1 to 2 s of beginning the injec¬
tion. During the early part of the response there was
total inhibition of chemoreceptor discharge, then
spontaneous activity returned gradually, reaching
control (pre-injection) levels within 30 to 45 s follow¬
ing low doses of Met-enkephalin, but taking up to 5
min to recover after high doses (see Figure la). The
inhibitory effect was consistent, as can be gauged
from the standard errors, and there was no evidence
of tachyphylaxis occurring when doses were adminis¬
tered at 7 min intervals. The effect of Met-enkephalin
seemed to be potentiated slightly after morphine had
been injected. Intravenous injections of Met-
enkephalin (10 to 100 pg) also inhibited chemorecep¬
tor discharge, although to a lesser extent and after a
longer delay than the same doses by intracarotid
injection.
Low doses of Met-enkephalin had little or no effect
on blood pressure (BP), whereas higher doses (i.e. or
i.v.) caused a fall in BP (see Figure 2).
Effects of morphine injections on spontaneous chemo¬
receptor discharge
The over-all effect of morphine on spontaneous
chemoreceptor discharge was inhibitory, although the
lowest dose studied, 0.1 pg, caused a slight increase in
discharge (see Figure lb). Higher doses were associ¬
ated with an inhibition of discharge which began
within 1 to 2 s of starting the injection (Figure lb) and
was dose-related. The initial inhibition lasted for 15 to
45 s after which discharge returned towards pre-
injection control levels. There was then a delayed or
secondary inhibition of spontaneous discharge, an
effect which was most clearly seen after the highest
dose of morphine (see Figures lb, 3a).
Responses to morphine were rather variable, as can
be seen from the standard errors, but there was no
evidence of tachyphylaxis, and responses to a low
dose of morphine injected before and after the highest
dose were very similar. The higher doses of morphine
caused a fall in BP (see Figure 2).
Effects of naloxone
In an adequately anaesthetized cat, which had
received neither Met-enkephalin nor morphine, nalox¬
one (0.2 mg i.e.) caused a slight increase in chemo¬
receptor discharge and, after a delay of 15 to 45 s,
a rise in BP (Figure 2) lasting for at least 30 min.
Additional doses of naloxone (0.4, 0.8 and 1.6 mg i.e.
at 7 min intervals) had no further effect on chemo¬
receptor discharge or BP.
When naloxone (0.2 mg i.e.) was injected during
experiments in which Met-enkephalin and/or mor¬
phine had previously been administered, there was
also an increase, albeit somewhat variable, in spon¬
taneous chemoreceptor discharge (Figure 2) and a rise
in BP.
Comparison of responses to Met-enkephalin and to
morphine obtained before and after injecting nalox¬
one showed that, apart from a slight initial inhibition,
the inhibitory action of morphine was virtually abol¬
ished, and there was evidence of an over-all increase
in discharge. The chemo-inhibitory effect of Met-
enkephalin was much reduced (see Figures 2 and 3).
Dose-response data were obtained by expressing
the number of impulses in the post-injection period as
a percentage of the number of impulses which would
have been likely to occur in the same period had the
pre-injection control discharge (averaged over 15 to
30 s) continued unaltered, and plotting this value
against log10 dose. It can be seen from Figure 3 that
naloxone shifts the Met-enkephalin dose-response line
to the right, both for 60 s and 150 s post-injection
periods. After intracarotid injection of naloxone (0.2
mg), morphine tended to increase discharge over these
periods, this effect being inversely related to dose.
A higher dose of naloxone (0.8 mg i.e.) completely
abolished the inhibitory action of morphine (1 mg i.e.)
and greatly reduced the inhibitory reponse to Met-
enkephalin; over-all there was an increase in dis¬
charge following lower doses of Met-enkephalin (see
Figure 4).
Although naloxone reduced the hypotensive action
ofMet-enkephalin and morphine, slightly after 0.2 mg
i.e. (see Figure 2) and to a greater extent after 0.8 mg
i.e., falls in BP were still obtained even when the
chemo-inhibitory response had been abolished.
Evoked responses
Injections (i.e.) of acetylcholine (ACh, 50 pig), carbon
dioxide-saturated Locke solution (C02, 0.3 ml),
sodium cyanide (NaCN. 5 pig) and dopamine (5 pg)
300 d.s. McQueen & j.a. ribeiro















Figure 2 In (a) the effect of naloxone (0.2 mg i.e.) on spontaneous chemoreceptor discharge in an experiment
during which no methionine-enkephalin (Met-enkephaiin) or morphine had been administered is illustrated; (b) is
the averaged spontaneous chemoreceptor discharge from three experiments in which the same dose of naloxone
(0.2 mg i.e.) was injected following prior administration of Met-enkephalin and/or morphine. Details as for
Figure 1.
Met-enkephalin 100 pg i.e. (c) and morphine 1000 pg i.e. (d) were injected, at the arrows, before and after
naloxone (0.2 mg i.e.). Their effects on chemoreceptor discharge and BP are shown, and it can be seen that
chemoreceptor inhibition was greatly reduced by naloxone, whereas the hypotension was less affected by this dose
of naloxone.
were made before and 5 to 20 min after a series of
injections of either Met-enkephalin or morphine. The
results obtained (Table 1) showed that the stimulant
action of ACh, C02, and NaCN were slightly and
somewhat variably reduced after Met-enkephalin,
whereas the inhibitory effect of dopamine was poten¬
tiated. Following morphine administration, responses
to ACh and NaCN were reduced slightly, whereas
those to CO, and dopamine were potentiated.
Responses were also obtained before and during an
infusion of Met-enkephalin (50 pg/min i.e.), this dose
being sufficient to inhibit spontaneous discharge
throughout the infusion period. The effects of ACh
and CO, were slightly potentiated whereas the re¬
sponse to NaCN was slightly reduced (see Table 1).
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Figure 3 (a) Pooled data showing the effects of methionine-enkephalin (Met-enkephalin) 100 fig {n = 3) and
morphine 1000 fig (n = 2) on spontaneous chemoreceptor discharge before (—) and after (—) injecting naloxone
(0.2 mg i.e.). Black rectangles represent the control discharge (100%), values for Met-enkephalin being 3.7 ± 1.8 ct/s
before and 3.1 + 0.9 after naloxone, the corresponding values for morphine being 3.7 + 1.7 and 4.9 + 2.4 ct/s. See
Figure 1 for further details, (b) is a plot of the total discharge over the 60 s post-injection period, expressed as a
percentage of the total discharge which would have occurred in the same period if control discharge had continued
unaltered (100% = dotted line), against log10 dose of methionine-enkephalin (ME) (pooled data from three experi¬
ments) or morphine (data from a single experiment) before (—) and after (—) naloxone (0.2 mg i.e.). Lines were
fitted by the method of least squares, (c) is similar to (b), but the plot is of total discharge in the 150 s post-injection
period and this includes the delayed inhibition seen with morphine.
Since spontaneous discharge was suppressed it was
not possible, under these conditions, to investigate the
effect of Met-enkephalin on the inhibitory response
evoked by dopamine.
Responses to ACh, NaCN, C02 and dopamine
were not appreciably affected by naloxone (0.2 mg
i.e.).
Discussion
Our results indicate that enkephalin inhibited spon¬
taneous chemoreceptor discharge by acting on
naloxone-sensitive receptors in the carotid body.
Morphine also acted at these receptors, but it was less
potent than Met-enkephalin and caused a more vari¬
able inhibition which tended to be biphasic.
Although Met-enkephalin and morphine were able
to inhibit spontaneous chemoreceptor discharge, they
only slightly reduced excitatory responses evoked by
ACh and NaCN, and potentiated dopamine-induced
inhibition. These were long-term effects since the re¬
sponses were not studied until 5 to 20 min after injec¬
tions of Met-enkephalin or morphine. When re¬
sponses were studied during an infusion of Met-
enkephalin sufficient to reduce spontaneous chemore¬
ceptor discharge substantially, the excitatory effect of
NaCN was slightly reduced whereas responses to
ACh and C02 were potentiated. These single-dose
studies are difficult to interpret, particularly since







Figure 4 Effects of methionine-enkephalin (ME) on chemoreceptor discharge (plotted as a percentage of the total
discharge in the 150 s post-injection period/control discharge x 150 s) before (—) and after (—) injecting naloxone
(0.8 mg i.e.). Lines were fitted by the method of least squares. See Figure 3 for further details. Following this dose of
naloxone, low doses of Met-enkephalin no longer inhibited chemoreceptor discharge: the tendency was for dis¬
charge to be increased. This can be clearly seen in the neurograms which show the effect of Met-enkephalin (1 pg
i.e.), injected at the arrow, before and after naloxone (0.8 mg i.e.).
Table 1 Effects of methionine-enkephalin (Met-enkephalin) and morphine on evoked responses
Intracarotid injection of:
A Following morphine injections
B Following Met-enkephalin injections





















Pooled data from n experiments showing chemoreceptor responses (AIx) (A) following injections of morphine and
(B) following injections of Met-enkephalin. The results are expressed as mean percentages ± s.e. mean of the
response:; to the same doses administered before morphine or Met-enkephalin (i.«. pre-injection response = 100%).
Injections were also made 60 s after starting a 65 s infusion of Met-enkephalin and responses evoked compared
with pre-infusion values (C).
AXx = X:c (total spike count during response period, t s) — (ic.t) where x is the average pre-injection (control)
discharae in ct/s.
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Met-enkephalin may alter blood flow through the
carotid body, but the important point is that whereas
Met-enkephalin can reduce spontaneous chemorecep-
tor discharge, it has little effect on responses to
intense stimuli of short duration. In the present ex¬
periments, the local concentration of Met-enkephalin/
morphine may have been high enough to suppress the
resting discharge but not that evoked by ACh, NaCN
or C02.
Injection of the specific opiate antagonist, naloxone
(see Sawynok, Pinsky & Labella 1979 for a review),
slightly increased chemoreceptor discharge, an effect
that was not simply due to reversal of residual Met-
enkephalin or morphine chemo-depression because it
was also observed when neither substance had been
administered. This may mean that there is some tonic
inhibition of chemoreceptor discharge by an opioid;
alternatively, the effect could be secondary to changes
(e.g. in BP) induced by naloxone acting elsewhere.
The dose of naloxone used (0.2 mg) is adequate for
reversing the fall in BP caused by morphine in cats
(Feldberg & Wei, 1977; McQueen, unpublished
observations) and for reversing the action of enkepha¬
lins in the cat substantia gelatinosa (Duggan, Hall &
Headley, 1977). In the present experiments it reduced
the chemoreceptor inhibition caused by Met-
enkephalin and, to a greater extent, that caused by
morphine. It is known that inhibition of neuronal fir¬
ing caused by morphine is more readily antagonized
by naloxone than is that caused by opioid peptides
(North, 1979). Increasing the dose of naloxone to 0.8
mg caused an even greater reduction of the Met-
enkephalin-induced inhibition of chemoreceptor dis¬
charge, and virtually abolished the morphine effect.
Higher doses of naloxone could have been studied,
but we were concerned that they might have exerted
non-specific actions, or reversed the anaesthetic
(Furst, Foldes & Knoll, 1977; Arndt & Freye, 1979;
Sawynok et al., 1979). It seems reasonable to conclude
that most of the chemoreceptor inhibition results
from actions of Met-enkephalin and morphine on
naloxone-sensitive receptors in the carotid body.
Low doses of morphine tended to increase spon¬
taneous chemoreceptor discharge, an effect that was
potentiated and also obtained with higher doses of
morphine, as well as low doses of Met-enkephalin,
after naloxone. Landgren, Liljestrand & Zotterman
(1952) found that an intracarotid injection of 3 mg
morphine hydrochloride in cats caused a moderate
increase in small action potentials (probably chemore-
ceptors) recorded from the sinus nerve, and Eyza-
guirre & Zapata (1968) showed that morphine caused
a transient increase in discharge recorded from the in
vitro carotid body preparation. Whether the exci¬
tation seen in the present study resulted from an
action on naloxone-insensitive opiate receptors, or
was caused by morphine/Met-enkephalin influencing
substances in the carotid body, as occurs in other
tissues (e.g. ACh (Paton, 1957), noradrenaline (Szerb,
1961; Snyder & Childers, 1979), 5-HT, or dopamine
(Loh, Brase, Sampath-Khanna. Mar. Way & Li.
1976)), requires further investigation. So does the
biphasic nature of the inhibitory response to mor¬
phine; could vascular changes be responsible for the
transient return of discharge to control levels?
High doses of Met-enkephalin and morphine
caused a fall in BP, and it is possible that some of the
changes in chemoreceptor discharge might result from
changes in blood flow through the carotid body.
However, the fact that chemo-inhibitory actions of
Met-enkephalin and morphine, (a) started within 1 to
2 s of the injection, (b) occurred following low doses
which had no effect on BP and, (c) were greatly
reduced by naloxone in doses which only slightly
reduced the hypotensive effect, all argue against vas¬
cular effects contributing much to the inhibition, at
least as far as the early part of the response is con¬
cerned. Further information could be obtained by
studying the effect of Met-enkephalin on the in vitro
carotid body preparation (Eyzaguirre & Lewin. 1961),
which would eliminate the vascular complications.
The chemo-inhibitory effect of low doses of Met-
enkephalin was very similar to that obtained with
dopamine, (5 pg i.e.), although it should be noted that
Met-enkephalin is 10 to 100 times more potent on a
molar basis. However, despite the similarities, it is
unlikely that Met-enkephalin acts directly, or, by
releasing dopamine within the carotid body, indirectly
at a dopamine receptor, because a-flupenthixol blocks
the inhibitory action of exogenous dopamine
(Docherty & McQueen, 1978) without affecting the
inhibitory response to Met-enkephalin (McQueen,
1979).
Substance P is present in the cat carotid body
(Cuello & McQueen, 1980) and causes an increase in
chemoreceptor discharge on intracarotid injection
(McQueen, 1980). It may be that Met-enkephalin is
acting to inhibit the release of substance P within
the carotid body in the same way as has been shown
to occur in the CNS (Jessel & Iversen, 1977), the
mechanism probably involving an action of Met-
enkephalin on Ca2+ channels (Mudge, Leeman &
Fischbach, 1979).
It has been suggested that adenosine might be the
mediator of the neuro-inhibitory action of opiates
(Sawynok & Jhamandas 1976; Stone & Perkins.
1979). Both adenosine (see Ribeiro. 1978) and
morphine (Henderson, Hughes & Kosterlitz, 1975) de¬
crease transmitter release in the central and peri¬
pheral nervous systems, and adenosine (Ribeiro, Sa-
Almeida & Namorado, 1979), morphine (Guerrero-
Munoz, Cerreta, Guerrero & Way, 1979), and
^-endorphin (Guerrero-Munoz. Guerrero, Way & Li,
1979) decrease the uptake of calcium by synapto-
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somes; Ca2 + is known to be involved in transmitter
release (e.g. Katz & Miledi, 1968). Opioids might
depress chemoreceptor activity by inhibiting the entry
of Ca2+ needed for the release of putative sensory
excitatory transmitter(s). Whether adenosine is the
mediator of the Met-enkephalin or morphine-induced
inhibition, and whether Met-enkephalin interacts with
other substances in the carotid body (e.g. substance P,
noradrenaline, 5-hydroxytryptamine, dopamine, ACh)
requires investigation. Preliminary results (Cuello &
McQueen, unpublished observations) suggest that
enkephalin-like material is present in the carotid
body.
In conclusion, the present results provide pharma¬
cological evidence for the presence of an opiate recep-
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Comparison of the depressant effects of ieucine-
and methionine-enkephalin on spontaneous
chemoreceptor activity in cats
d.s. McQueen & j.a ribeiro1
Department of Pharmacology. University of Edinburgh.
Edinburgh. EHH VJZ.
There is evidence that methionine-enkephalin (met-
ENK) and leucine-enkephalin (leu-enkl are present
in cat carotid body type 1 cells (Lundberg. Hokfeit,
Fahrenkrug, Nilsson & Terenius, 1979; Wharton.
Polak. Pearse. McGregor, Bryant. Bloom. Emson.
Bisgard & Will, 1980). Intra-carotid injection of mct-
ENK decreases spontaneous chemoreceptor discharge
in cats (McQueen, 1979; McQueen & Ribeiro. 1980).
The present study was undertaken to investigate the
effects of leu-ENK on the carotid chemoreceplors and
to compare them with those of met-ENK.
Experiments were performed on cats anaesthetized
with pentobarbitone (42 mg/kg i.p.. supplemented
every 1-2 h). The animals were artificially ventilated
with air and paralysed by gallamine (3 mg/kg i.v ).
Chemoreceptor activity was recorded from the peri¬
pheral end of a sectioned sinus nerve (McQueen.
1977). In the majority of experiments the ganglioglo-
merular (sympathetic) nerves were cut. Drug solutions
were injected into the ipsilateral common carotid




Leu-ENK and met-ENK both decreased spon¬
taneous chemorcceptor discharge frequency in a dose-
dependent manner, being of similar potency (see
Figure I). The intensity and duration of the depres¬
sion evoked by both peptides were reduced after
naloxone (0 2 0.4 mg i.e.). Similar responses were
obtained in all the experiments, regardless of whether
or not the sympathetic nerve supply to the carotid
body had been cut.
These results suggest that leu-ENK and met-ENK
depress spontaneous chemoreceptor discharge by act¬
ing on opiate receptors in the carotid body. Since the
enkephalins have potent effects on chemoreceptor dis¬
charge and are present in the carotid body, they may
function there as neurotransmitters or neuromodula¬
tors. Further studies are needed to establish their
physiological roles in the carotid body and to identify
the opiate receptor(s) (Hughes. Kostcrlitz. McKnight.
Sosa. Lord & Waterfield. 1978).
1 On leave from Institute Gulbcnkian de Cicncia. Oeiras.
Portugal
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Figure I Effects of i.e. injections (arrows) of leu-ENK (10 pgi and mcl-ENK (HI ugl on spontaneous chemo¬
receptor activity before (a| and after (h) naloxone (04 mg i.e.leu-ENK was injected 5 min after naloxone and
mct-ENK 10 mm later The upper pari of each panel shows the femoral arterial U P (calibration (I I0O 200
mmHgl. and the lower part the neurogram.
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EFFECTS OF /^-ENDORPHIN, VASOACTIVE
INTESTINAL POLYPEPTIDE AND CHOLECYSTOKININ
OCTAPEPTIDE ON CAT CAROTID CHEMORECEPTOR
ACTIVITY
d. s. McQueen and j. a. ribeiro*
Department of Pharmacology, University of Edinburgh Medical School, 1 George Square. Edinburgh EH8 9JZ
(RECEIVED FOR PUBLICATION 17 DECEMBER 1980)
summary
The effects of /^-endorphin, vasoactive intestinal polypeptide (VIP) and cholecystokinin
octapeptide (CCK-8) on carotid chemoreceptor activity have been investigated in cats
anaesthetized with pentobarbitone. Spontaneous chemoreceptor discharge was decreased by
intracarotid injection of /^-endorphin and by low doses of VIP. whereas it was increased by
CCK-8 and higher doses of VIP, these effects being relatively long-lasting and often associated
with changes in systemic blood pressure. The chemoexcitation evoked by acetylcholine and
sodium cyanide was reduced during intracarotid infusion of any of the three peptides studied,
and that caused by CO,-saturated Locke solution was reduced by /7-endorphin, largely
unaltered by VIP and variably affected by CCK-8. The inhibitory effect of /^-endorphin was
greatly reduced by naloxone, implying that it probably involved actions at naloxone-sensitive
opiate receptors in the carotid body. Substance P was unable to overcome the chemoinhibitory
effect of methionine enkephalin. Possible functions of polypeptides in the carotid body are
discussed.
introduction
The ability of some polypeptides to modify spontaneous chemoreceptor discharge when
injected close-arterial to the cat carotid body has been described (McQueen, 1979, 1980).
Since then evidence has been presented which shows that substance P (SP), the enkephalins
and vasoactive intestinal polypeptide (VIP), or closely related immunoreactive substances,
are present in the cat carotid body (Lundberg, Hokfelt, Fahrenkrug, Nilsson & Terenius,
1979; Cuello & McQueen, 1980; Wharton, Polak, Pearse, McGregor, Bryant, Bloom,
Emson, Bisgard & Will, 1980).
The present neuropharmacological study was undertaken to investigate further the
actions of various polypeptides, including those identified as being present in the carotid
body, on the cat carotid chemoreceptors with a view to obtaining some insight into the
physiological role of these substances in the carotid body.
methods
Experiments were performed on nine cats weighing between 3-0 and 4-4 kg. median weight 3-5 kg. They
were anaesthetized with pentobarbitone sodium (42 mg. kg"1 i.p.), supplemented as required during
the experiments, artificially ventilated with air and paralysed with gallamine (3 mg.kg"1 i.v.). Full
details for most of the experiment procedures have been given previously (McQueen. 1977; Docherty
& McQueen, 1978) and only a brief description follows.
The lingual and superior thyroid arteries ipsilateral to the sinus nerve from which recordings were
* On leave from Instituto Gulbenkian de Ciencia. Oeiras, Portugal.
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obtained were both cannulated. the catheter tips being positioned in the common carotid artery; blood
pressure was recorded from a femoral artery. Electrical activity of chemoreceptor units (1-5 units)
was recorded from filaments of the peripheral end of a sectional sinus nerve, stored on FM tape, passed
through a pulse height (window) discriminator and quantified with the aid of a PDP-8 computer. The
ganglioglomerular (sympathetic) nerves were cut.
Drugs were dissolved in either modified Locke solution (see McQueen, 1977) or 0-9°0 w/'v aqueous
sodium chloride solution, except //-endorphin which was initially dissolved in 0-5°o aqueous bovine
serum albumin solution^then diluted with saline. Injections were made in a volume of 01 ml into
the lingual catheter and washed in with 0-2 ml Locke solution which had been bubbled with 5%
CO,:95% air in a water bath at 37 °C: they were made over a 2 s period. Infusions were made into
the common carotid artery via the thyroid catheter at a rate of 01 ml. min-1, using a Unita pump
(Braun), and lasted for 5-10 min; the catheter dead-space was 0-2 ml.
Drugs used were: pentobarbitone sodium, gallamine triethiodide (May & Baker), acetylcholine
iodide, sodium cyanide (B.D.H.), dopamine hydrochloride (Koch Light), substance P. methionine
enkephalin formate (Sigma), cholecvstokinin octapeptide non-sulphated (Peninsula Labs), naloxone
hydrochloride (Endo), human //-endorphin (Aalton Bio Reagents, Dublin), porcine /(-endorphin
(kindly given to us by Dr D. Smyth. National Institute for Medical Research. London) and vasoactive




In three experiments the effects of //-endorphin on chemoreceptor activity were examined.
Since there was no appreciable difference between the actions of human and porcine
//-endorphin, results have been expressed simply as responses to //-endorphin.
Injections of ft-endorphin. Injections of //-endorphin (0-1—50 //g i.e.) caused a decrease in
spontaneous chemoreceptor discharge (see Fig. 1B and C). The response lasted for about
3 min following the highest dose investigated (50 pg) and was associated with a very slight
fall in systemic blood pressure (Fig. I A). Discharge was averaged over the 60s period
immediately following //-endorphin injection and expressed as a percentage of the averaged
pre-injection (control) discharge (Fig. 1 D). The results showed that the decrease in discharge
was dose-dependent and, from consideration of discharge during the second minute
following the injection (Fig. 1 E), fairly long-lasting. The reason for the somewhat variable
nature of the response, reflected in the scatter of points about the lines, was that responses
to //-endorphin were often bi- or triphasic; there was an initial decrease followed by a return
to control level, or to discharge frequencies greater than control, then a delayed decrease
in spontaneous discharge (see Fig. 2A). The overall effect was similar to that evoked by
morphine (McQueen & Ribeiro, 1980).
Following administration of the opiate antagonist naloxone (0-4 mg i.e.) //-endorphin
caused only a slight decrease in spontaneous chemoreceptor discharge, the main effect being
a rather variable increase in discharge (Fig. 25) which was not abolished by additional doses
of naloxone.
Infusions offi-endorphin. Infusion of //-endorphin at a rate of 5 //g/min for 5-10 min resulted
in very slight changes in spontaneous chemoreceptor discharge and systemic blood pressure
(Fig. 3 A). Blood gas tensions and pH were unaffected by the infusion.
Evoked responses during infusion of f-endorphin. The increases in chemoreceptor discharge
evoked by ACh, C02 and NaCN, together with the decrease caused by dopamine, were
determined before, during, and after an infusion of //-endorphin at a rate of 5 //g,min. The
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Fig. 1. The left-hand side of the figure shows the effect of injecting (arrow)/?-endorphin (50 // g i.e.) on: A. systemic
arterial blood pressure: B. spontaneous chemorecejjtor discharge averaged over a 15 s periods and expressed
as a percentage (control discharge. 1 -5 ct/s = 100°o); C, the single chemoreceptor unit from which the data in
B, D and E were obtained. The right-hand side of the figure shows the discharge averaged over the first (D)
or second (£) minute following/f-endorphin injection. Discharge was expressed as a percentage of the pre-injection
frequency and plotted against dose of/f-endorphin (log10 scale), straight lines being fitted to the responses (#)
by the method of least squares. O. illustrate the effect of injecting the drug vehicle (0-5°o bovine serum albumin):
the pre-injection (control) discharge frequency (100"o) was determined by averaging spontaneous discharge
during the 30-60 s immediately preceding each injection, and is represented by the dotted line.
results obtained are summarized in Fig. 4 and it was found that responses to the stimulants
were reduced by /^-endorphin in the concentration studied, whereas the inhibitory effect of
dopamine was potentiated. The influence of /(-endorphin on responses evoked by dopamine
and. to a lesser extent, NaCN. was still evident 15 min after the infusion had finished.
In a separate experiment the influence of /i-endorphin (5 //g/min) on the inhibition evoked
by an injection of methionine enkephalin (10 //g i.e.) was studied. The effect of methionine
enkephalin was found to be very slightly enhanced. (Discharge, averaged over 150 s after
the enkephalin injection and expressed as a percentage of the pre-injection discharge
frequency (100%) was 71% before the infusion. 64% during the infusion, and 73% 15 min
after the infusion of /(-endorphin.)
Vasoactive Intestinal Polypeptide {VIP)
In two experiments the effects of VIP were studied. Only a limited amount of VIP was
available, but the results obtained were quite clear.
Injections of VIP. VIP injections (0 05-6-3 pg i.e.) produced the type ofeffects seen in Fig.
5. Low doses caused a decrease in spontaneous chemoreceptor discharge whereas higher
doses increased discharge. The effects were fairly long-lasting, being evident in the second
minute following the injection (see Fig. 5£>). There was a good correlation between dose
and response, and higher doses caused a fall in b.p. followed by a rise (Fig. 5.4).
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Fig. 2. Chemoreceptor discharge following injection of /f-endorphin 10 /<g i.e., A. before and B. 5 min after
naloxone (0-4 mg i.e.). Pooled data from three experiments, discharge expressed as a percentage of the
pre-injection frequencies and shown as the average + s.E. ofmean in 15 s intervals during the 150 s post-injection
period. The averaged control values were 4-8 + 2-0ct/s before and 2-7+ 1 -6 ct/s after naloxone.
Infusions of VIP. Infusion of VIP at a rate of 0-5 //g/min for 5-10 min caused a sustained
increase in discharge and a fall in blood pressure (see Fig. 3 B). The chemoreceptor response
shown in Fig. 35, the biggest observed with the dose of VIP studied, was accompanied by
a slight fall in b.p. The control b.p. was rather low, and to preclude the possibility that the
increase in chemoreceptor discharge was entirely secondary to the systemic vascular effects
of VIP. the infusion was repeated later in the same experiment when mean systemic b.p.
was over lOOmmHg and dextran was infused to prevent the fall in b.p. Under these
conditions discharge still increased, although the increase was a little less than that obtained
at the lower pressure. Measurement of arterial blood gases and pH (see Fig. 3, legend)
showed that the increase in chemoreceptor discharge was not secondary to changes in
arterial blood gas tensions.
Evoked responses during infusion of VIP. Responses to ACh. C02 and NaCN were
determined before, during and after infusions of VIP at a rate of 0-5 //g/min. The results
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Fig. 3. Effects on spontaneous chemoreceptor discharge of infusing, during the periods represented by the
horizontal bars. A. //-endorphin 5 /rg/min i.e.: B, VIP 0-5 /tg/'min i.e.; C. CCK-8 10 //g/min i.e. Discharge (ct/s)
was averaged over 60 s intervals, commencing 60 s before starting an infusion, and plotted on the same time
scale as the b.p. trace. Just before the end of the VIP infusion in B. an arterial blood sample was taken and
gave values of pH 7-31. Pa co, 107 mmHg, co. 34 mmHg compared with pre-infusion sample values of pH
7-28. co. 105 mmHg, cQ, 36 mmHg. These results were obtained from three separate experiments, and
it should be noted that the catheters were primed with polypeptide solution (i.e. there was no dead-space to
be cleared after starting an infusion).
obtained from two experiments were pooled and are summarized in Fig. 4. It was found
that responses to the stimulants were reduced by VIP. whereas the inhibitory effect of
dopamine was only slightly reduced during the infusion, although there was a further
reduction after infusion. Responses to ACh and CO., recovered within 15 min, whereas the
NaCN and dopamine responses did not.
In one experiment the influence of a VIP infusion (0-5 //g/min) on the inhibition evoked
by methionine enkephalin (10 //g i.e.) was studied. Before the VIP infusion chemoreceptor
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Fig. 4. Responses (A£x) to ACh (50 //g i.e.). NaCN (2-5 //g i.e.), CO, (0-3 ml CO,-saturated Locke solution) and
dopamine (DA. 5 //g i.e.) were obtained; A, before a 10 min infusion of polypeptide into the second carotid
catheter; B. during the infusion; C. 5-15 min after finishing the infusion, and are shown as percentages
(pre-infusion response = 100%). In the case of /(-endorphin and CCK-8 data were from single experiments;
for VIP and Locke solution the data shown are averages from two experiments. Al.r = X.v-.r. t. where I.v is
the number of action potentials counted during the response of duration t s. a ' response' being defined as lasting
from the first substantial change from background discharge frequency (X ct/s) until return to background level.
discharge averaged over the immediate 60 s post-injection period was reduced to 27°0 of
the pre-injection control frequency, and over the second minute it was reduced to 89% of
control. Corresponding values during VIP infusion were 46% in the first minute and 100%
in the second, meaning that the inhibition caused by methionine enkephalin was reduced
during the VIP infusion.
Cholecystokinin octapeptide (CCK-8)
In two experiments the effects of CCK-8 on chemoreceptor activity were examined.
Similar effects were obtained in both experiments.
Injections of CCK-8. Injections of CCK-8 (0-1 — 100 pg i.e.) caused a somewhat variable
short-lasting biphasic effect on discharge, generally an initial decrease followed by an
increase (see Fig. 6). Higher doses caused a rise in b.p. The quantitative evidence shown
in Fig. 6C and D confirms that responses were somewhat variable and short-lived.
Infusions of CCK-8. In one experiment CCK-8 was infused at a rate of 1 /tg/min, in the
other the rate was 10 //g/min. There was little effect on spontaneous discharge with either
dose (Fig. 3C); arterial blood pressure rose.
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Fig. 5. The left-hand side of the figure shows the effect of injecting VIP (3-2 j/g i.e.) on: A. systemic arterial blood
pressure: B. spontaneous chemoreceptor discharge, control frequency (100°„) being 5-6 ct/s. The right-hand side
of the figure shows data obtained from the same experiment and illustrates discharge averaged over the first
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Fig. 6. The left-hand side of the figure shows the effect of injecting CCK-8 (100 //g i.e.) on: .4. systemic arterial
blood pressure: B. spontaneous chemoreceptor discharge, control frequency! 100" „) being 1 -9 ct s. The right-hand
side of the figure shows pooled data from two experiments, illustrating discharge averaged over the first (C)
or second (D) minute following CCK-8 injection. Figure details as for Fig. I.
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Fig. 7. The left-hand side of the figure shows chemoreceptor discharge (control (100°;,) values given in ct/s)
averaged over 60 s periods after starting intracarotid infusions (horizontal bar) of: A, Locke solution via lingual
and thyroid catheters: B. SP 25 //g/min via the lingual. Locke solution via the thyroid catheter; C. methionine
enkephalin 10 //g/min via the thyroid. Locke solution via the lingual; D. methionine enkephalin 10//g/min via
the thyroid. SP 25 //g/min via the lingual. The accompanying blood pressure records are shown on the right-hand
side of the figure, the time scale being common to both sides. The catheter dead-space needed to be cleared
before the peptides arrived in the carotid artery, a process which took 1-2 min after starting the infusion, except
in D where the thyroid catheter was fully primed with methionine enkephalin so that the action of this peptide
had begun before SP reached the carotid artery.
Evoked responses during infusion of CCK-8. Responses to ACh, NaCN and DA were
reduced during infusion ofCCK-8 at a rate of 1 //g/min. The response to CO., was unaffected
(Fig. 4). Although the ACh effect returned to pre-infusion levels within 15 min of finishing
the infusion, responses to NaCN and dopamine remained depressed. In a second experiment,
during which CCK-8 was infused at 10//g/min. responses were somewhat similar except
that a sustained potentiation of the dopamine-induced chemoinhibition was observed and
there was a decreased response to CO, in the post-infusion period, although not during the
infusion (Fig. 4).
Substance P and methionine enkephalin
Previous experiments had established that both these polypeptides can influence chemo¬
receptor discharge (McQueen. 1979; McQueen & Ribeiro, 1980) and the present experiment
was undertaken to determine whether any interaction occurs on simultaneous infusion of
both peptides close-arterial to the carotid body. The results obtained are shown in Fig. 7.
Locke solution caused a very slight increase in spontaneous chemoreceptor discharge. SP
had a biphasic action (decrease followed by increase) and methionine enkephalin reduced
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discharge, an effect which was most pronounced in the early part of the response; when
the methionine enkephalin infusion was stopped discharge increased above pre-infusion
control levels. The delayed increase in discharge seen with SP was accompanied by a rise
in end-tidal CO,; there was no change in end-tidal CO., during or after methionine
enkephalin infusion.
SP and methionine enkephalin were infused concurrently in equimolar concentrations,
it being so arranged that methionine enkephalin began to act before SP reached the carotid
artery (see Fig. 7). The pattern of response was very similar to that obtained with methionine
enkephalin alone, except that no post-infusion overshoot occurred. There was a rise in
end-tidal CO., towards the end of the infusion. Both peptides caused hypotension, and when
given together the overall effect on b.p. was approximately additive.
discussion
The present study showed that the polypeptides investigated can modify carotid chemo-
receptor activity in the cat. Spontaneous chemoreceptor discharge was decreased by
intracarotid injection of /(-endorphin and by low doses of VIP. whereas it was increased
by CCK-8 and higher doses of VIP. The chemo-excitatory effect of VIP has been reported
by Fitzgerald. Raff, Garger, Fechter, Anand & Said (1979). The effects of these peptides
on chemoreceptor discharge may not seem very impressive when compared with those of
ACh, NaCN, CO., or dopamine, but it has to be remembered that the polypeptides have
a relatively high molecular mass so that, for example, whereas the excitatory response to
ACh was elicited by 180nmol (50 //g), that to VIP involved only 1 nmol (3-2 //g).
Furthermore, although the peptide effects were generally less intense they tended to be longer
lasting than those associated with classical neurotransmitters. The prolonged action may
be related to various factors, such as molecular size, tissue penetration, dissociation from
receptors/activation of'second messengers', or to peptide inactivation. and needs to be
further investigated.
Responses evoked by ACh, NaCN, CO, and dopamine during polypeptide infusion, when
peptide levels in the carotid body were assumed to be relatively steady, showed that the
excitatory action of ACh and NaCN was reduced by all three peptides studied, and that
caused by CO, was reduced by both /(-endorphin and VIP. but unaffected by CCK-8.
Dopamine-induced chemoinhibition was potentiated by /(-endorphin, largely unaltered by
VIP and reduced by low concentrations ofCCK-8 but potentiated by higher concentrations.
Lack of sufficient peptide precluded full dose response studies (e.g. McQueen, 1977), but
although the results obtained with single submaximal doses may be less reliable, they do
indicate that polypeptides can influence evoked response when infused in fairly low
concentrations. It is particularly intriguing that polypeptides are sometimes stored with
putative neurotransmitters (see Pearse, 1969), for example VIP with ACh (Lundberg,
Hokfelt, Schultzberg, Uvnas-Wallensten, Kohler & Said, 1979), enkephalin with nor¬
adrenaline (Schultzberg, Lundberg, Hokfeit, Terenius, Brandt. Elde & Goldstein. 1978), SP
with 5-hydroxytryptamine (Hokfelt, Ljungdahl, Steinbusch, Verhofstad, Nilsson, Brodin,
Pernow & Goldstein, 1978) and CCK-8 with dopamine (Hokfelt, Johansson. Ljungdahl,
Lundberg & Schultzberg, 1980). All these putative neurotransmitters are present in the
carotid body (see Biscoe, 1972) and so, it appears, are several of the polypeptides. It will
be most interesting to determine whether similar dual localization of peptide and amine
occurs in the carotid body and whether the distribution of peptides and peptides/amines
within the carotid body is homogeneous, or whether different regions or nerve fibres (A
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and C, afferent, efferent) have different representation. It may transpire that all the different
substances in the carotid body, although activating different receptors, eventually influence
a common mechanism (e.g. adenylate cyclase) within the carotid body.
The action of /^-endorphin on the chemoreceptors was similar to that of morphine
(McQueen & Ribeiro, 1980), there being a tendency for inhibitory responses to be biphasic,
and greatly reduced by naloxone (0-4 mg i.e.). Following naloxone an overall increase in
discharge occurs (Fig. 2). These similarities might mean that both substances affect the same
receptors! with /^-endorphin being about twenty times more potent than morphine on a
molar basis. The enkephalins, in contrast, cause a much greater chemoinhibition which is
not so readily prevented by naloxone, and also have greater hypotensive effects
(McQueen & Ribeiro, 1980, 1981). Thus, the chemoinhibition caused by /^-endorphin
appears to result from actions on naloxone-sensitive opiate receptors, whereas the slight
chemoexcitation seen after naloxone does not. The latter effect may result from actions at
opiate receptors which are insensitive to naloxone in the doses used, or to direct or indirect
actions on non-opiate receptors.
The polypeptides influenced arterial blood pressure and this confirmed that, in the doses
studied, they were biologically active. The possibility that the effect of polypeptides on
chemoreceptor activity was secondary to vascular changes either within the carotid body,
or systemically, needs to be considered. The rapid onset of the peptide effect (within 1-2 s
of injection), the fact that effects on chemoreceptor discharge occurred before changes in
blood pressure were seen and persisted when such changes were prevented, and the
knowledge that chemoreceptor discharge appears to be largely independent of blood
pressure over the physiological range (Hornbein. Griffo & Roos, 1961; Biscoe, Purves &
Sampson, 1970; Acker, Keller, Lubbers. Bingman, Schulze & Caspers. 1973) and probably
carotid body blood flow (Acker & Lubbers, 1977) lead us to consider it unlikely that vascular
effects were responsible for the greater part of the responses observed.
The fact that most of the peptides affect the vasculature could be taken to imply that
the role of endogenous carotid body peptides is to modify blood flow. However, it is not
known whether endogenous polypeptides do in fact modify carotid body blood flow when
released, and many established neurotransmitters, such as ACh. noradrenaline and
dopamine, have marked vascular effects when injected. This, albeit together with other
evidence, has not prevented these latter substances, when present in the carotid body (e.g.
see Biscoe. 1972). from being considered as putative chemoreceptor neurotransmitters, so
by the same token the vascular effects caused by exogenous polypeptides should not exclude
them from consideration as putative neurotransmitters when found to be present in the
carotid body.
During the present study we investigated whether any interaction occurred in the carotid
body between SP and methionine enkephalin. These two peptides, or closely related
material, are present in the cat carotid body (see Introduction) and SP has been claimed
to be a neurotransmitter at the central nerve terminals of baro- and chemoreceptor afferent
fibres of cats (Gillis. Helke. Hamilton, Norman & Jacobowitz, 1980) and rats (Helke,
O'Donohue & Jacobowitz, 1980; Jacobowitz & Helke, 1980). It is also known that
methionine enkephalin can inhibit the release of SP from cultured sensory neurones (Mudge,
Leeman & Fishbach, 1979) and probably in the c.n.s. (Jessel & Iversen, 1977). Our results
showed that SP was unable to overcome the chemoinhibitory effect of methionine
enkephalin, something it might have been expected to do if release of endogenous SP is
crucial for chemoexcitation, and can be prevented by methionine enkephalin. However,
much may depend on the type of fibre being recorded and the background level of activity;
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SP is particularly associated with C fibres (Hokfelt, Johansson, Kellerth. Ljungdahl.
Nilsson, Nygards & Pernow, 1977) and it could be that A fibres were being recorded which
are, perhaps, affected more by methionine enkephalin than by SP. In the absence of
conduction velocity measurements this must remain speculation, and also we don't know
whether the concentration of injected SP in the carotid body was physiological. As far as
the other polypeptides were concerned, the inhibition evoked by methionine enkephalin was
slightly potentiated by /(-endorphin but reduced by VIP.
Evidence from other parts of the nervous system suggests that some polypeptides may
function as neurotransmitters (see Hokfelt etal. 1980), but the question ofwhat physiological
role the polypeptides play in the nervous system is still very much a matter for debate (see
Bishop & Polak, 1978; Guillemin, 1978; Hokfelt et al. 1980; Snyder, 1980). As far as the
carotid body is concerned, various exogenous polypeptides affect chemoreceptor activity
and several of these are known to be present in the structure. However, on its own this
information does not enable us to reach a conclusion regarding the role of the peptides in
the carotid body. Theymay function as neurotransmitters, neuromodulators, co-transmitters
affecting receptor sensitivity, neurohormones, trophic factors, or as agents modifying the
vasculature, and might be influenced by each other, by carotid body amines, by circulating
hormones (e.g. ACTH, /(-endorphin) or by other substances.
In conclusion, further studies are needed in order to determine the role of polypeptides
in carotid body chemoreception, and these will involve the use ofdrugs which can selectively
affect the peptidergic system (e.g. by destruction of nerve cells, blockade of receptors,
inhibition of enzymatic destruction, interference with biosynthesis) and also the correlation
of carotid body peptide release with chemoreceptor activity under various physiological
conditions. It will also be necessary to establish whether the polypeptides which appear to
be present in the carotid body are the endogenous physiologically active entities, or whether
they are converted to or derived from more active forms. Most of these ideals seem
unattainable at present because of lack of suitable drugs or techniques, but this situation
may change rapidly.
The authors gratefully acknowledge the technical assistance of Mrs S. Bond.
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Excitatory action of adenosine on cat carotid chemoreceptors
By D. S. McQueen and J. A. Ribeiro. Department of Pharmacology, University of
Edinburgh. 1 George Square. Edinburgh EH8 9JZ
There do not appear to be any reports concerning the-action of adenosine on cat
carotid chemoreceptors. In view of the suggestions that adenosine may play a role
in neurotransmission (e.g. Ribeiro, 1979), it seemed of interest to study the effect of
adenosine on cat carotid chemosensory activity.
Experiments were performed on pentobarbitone-anaesthetized cats (42 mg kg-1
i.p. supplemented every 1-2 h). The animals were artificially ventilated with air and
paralysed with gallamine (3 mg kg-1 i.v.). Chemoreceptor activity was recorded from
the peripheral end of a sectioned sinus nerve (McQueen, 1977); the ganglio-glomerular
(sympathetic) nerves were usually cut. Drug solutions were injected into the
ipsilateral common carotid artery (i.e.) over a 2 s period.
Adenosine (0-01-100 yg i.e.) caused a rapid and marked increase of spontaneous
ehemoreceptor discharge (e.g. Fig. 1). the intensity, duration and onset of which was
dose-dependent. Theophylline (0-1-1 mg i.e.), an adenosine antagonist (see Fredholm,
1980), decreased spontaneous chemoreceptor discharge but did not significantly alter
the excitatory action of adenosine.
I I
Fig. 1. Recording of a single chemoreceptor unit illustrating the response to adenosine
(1 /tg i.e.). Panel shows from above downwards: action potentials, injection marker and
10 s calibration.
Responses to the stimulants NaCN (2-5 or 5 pg i.e.), C02 (0-3 ml i.e. C02- saturated
Locke), acetylcholine (ACh. 50 yg i.e.) and to the inhibitor, dopamine (DA, 5 yg i.e.),
were determined before and after adenosine injections, and expressed as AXx
(McQueen. 1977). Responses to NaCN and CO, were slightly and variably decreased
after adenosine whereas both the excitatory response to ACh and the inhibitory
response to DA were increased.
These results indicate that adenosine increases spontaneous chemoreceptor activity
and facilitates the action of both ACh and DA on the carotid chemoreceptors.
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EFFECT OF ADENOSINE ON CAROTID CHEMORECEPTOR
ACTIVITY IN THE CAT
d.s. McQueen & j.a. ribeiro1
Department of Pharmacology, University of Edinburgh, 1 George Square. Edinburgh EH8 9JZ
1 The effects of intracarotid (i.e.) injections or infusions of adenosine on chemoreceptor activity
recorded from the peripheral end of a sectioned carotid sinus nerve have been studied in cats
anaesthetized with pentobarbitone.
2 Adenosine injections (0.1-100 pg) caused a rapid and marked increase of spontaneous
chemoreceptor discharge, the intensity, duration and onset of which was dose-dependent. Infusion
of adenosine, 50 pg/min, also evoked an increase in discharge which persisted for the duration of the
infusion.
3 Both theophylline (1 mg i.e.) and aminophylline (1 mg i.e.) caused short-lasting decreases in
spontaneous discharge but did not prevent the excitatory effect of adenosine. Theophylline
increased the excitatory action of adenosine.
4 Naloxone (400 pg i.e.) antagonized the depressant effect of morphine on chemoreceptor
discharge but not the excitatory action of adenosine.
5 It is concluded that exogenous adenosine can excite the cat carotid chemoreceptors, an effect
which is not prevented by theophylline in the doses studied. The physiological significance of the
findings is discussed.
Introduction
There do not appear to be any reports concerning the
action of adenosine on peripheral arterial
chemoreceptors. In view of the suggestions that
adenosine may play a role in neurotransmission (e.g.
Ribeiro, 1979), it seemed of interest to study the
effect of adenosine on cat carotid chemosensory ac¬
tivity. A preliminary account of some of this work has
been presented to the Physiological Society (Mc¬
Queen & Ribeiro, 1981b).
Methods
Experiments were performed on 20 cats of either sex
weighing between 2.4 and 3.4 kg (median 3.1kg).
The animals were anaesthetized with pentobarbitone
sodium (42 mg/kg i.p. initially, supplemented by i.v.
administration of 10% of the initial dose every 1 to
2 h), artificially ventilated and paralysed by gal-
lamine triethiodide (3 mg/kg i.v.). The ganglio-
glomerular (sympathetic) nerves were usually cut.
Full details of the experimental techniques, including
the recording of arterial blood pressure and monitor¬
ing and regulation of arterial blood gas tensions and
pH, have been given previously (McQueen, 1977;
Docherty & McQueen, 1978).
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Electrical activity of chemoreceptor units (1 to 6
units) was recorded from filaments of the peripheral
end of a sectioned sinus nerve, passed through a pulse
height (window) discriminator, and quantified with
the aid of a PDP-8 computer.
A catheter was introduced via the lingual artery
into the common carotid artery ipsilateral to the sinus
nerve from which activity was recorded and advanced
until its tip lay about 2 cm caudal to the carotid
bifurcation. In some experiments a second catheter
was positioned in the same common carotid artery,
this time via the superior thyroid artery, and used for
infusing drug solutions (0.1 ml/min).
Drugs were dissolved in modified Locke solution
(McQueen, 1977) or 0.9% w/v aqueous sodium
chloride (saline). Drug solutions (0.1 ml, except
adenosine 100 pg which was in 0.2 ml) were injected
into the common carotid artery and washed in with
0.2 ml Locke solution which had been bubbled with
5% C02: 95% air in a water bath at 37°C; injections
were made over 2 s.
Results obtained from different experiments were
pooled and expressed as the mean±s.e. mean of the
absolute values, which varied from experiment to
experiment according to the number of units re¬
corded. In order to determine whether changes ob¬
served were statistically significant, particularly when
such changes were small, responses to particular drug
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doses in the different experiments were compared
with the corresponding responses to the drug vehicle
in the same experiments using either the Wilcoxon
signed ranks test (when the number of pairs >7) or
Student's paired t test (for < 6 pairs, and assuming
Gaussian distribution). The null hypothesis was re¬
jected if P< 0.05 and the difference between groups
was considered statistically significant.
Drugs used were: adenosine, theophylline,
aminophylline (Sigma); morphine sulphate, pen¬
tobarbitone sodium, gallamine triethiodide (May &
Baker); naloxone hydrochloride (Endo).
Results
Injections of adenosine
The effects of intracarotid injection of different doses
of adenosine on spontaneous chemoreceptor dis¬
charge in one experiment are illustrated in Figure 1.
Discharge for each test was averaged over 10 s
periods starting 10s before and continuing for 60s
after the injection. As can be seen from either the
neurograms or the averaged discharge, the main
effect of adenosine was a dose-dependent increase in
the frequency of discharge. No tachyphylaxis to the
action of adenosine was observed. Thus, when in¬
jected at intervals of 5 min over a period of 1 h, there
was no diminution of the effect on spontaneous
chemoreceptor discharge.
Low doses of adenosine (0.001 to 0.01 pg) caused
a decrease in chemoreceptor discharge during the
first 10 s following the injection (see Figure 1), an
effect which appeared to be most pronounced for the
lowest dose. However, an inhibition of spontaneous
discharge was also usually associated with injection
































-10 0 20 40 60 -10 0 20 40 60 -10 0 20 40 60
Time (s) after injection
Figure 1 Effects of intracarotid (i.e.) injections of adenosine on the frequency of spontaneous chemoreceptor
discharge, (a) Neurograms taken from one experiment show the increase in the discharge of a single unit (insert, i)
caused by injecting (arrow) adenosine 0.1 (ii) and 1 pg (iii); in (i) the duration of the action potential is shown, the
trace being of 10 consecutive superimposed spikes, (b) Responses of the chemoreceptor unit to i.e. injection of (i)
0.3 ml of the Locke solution and to adenosine: 0.001 pg (ii); 0.1 pg (iii) and 1 pg(iv).The graphs show the amplitude
and duration of the responses averaged over 10 s periods following the injections.
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Figure 2 Effects on spontaneous chemoreceptor dis¬
charge of injecting Locke solution 0.3 ml (i) and
adenosine 0.1 jig (ii); 1 pg(iii); lOpg (iv) and lOOpg (v).
Discharge was averaged over 5 s periods following the
injection. Data obtained from tests in 8-10 cats were
pooled and presented as the mean with vertical bars
indicating s.e.mean. The lower panel shows the effect on
arterial blood pressure (BP) of injecting (arrow) lOOpg
of adenosine in one experiment. *P<0.05 compared
with Locke solution injections; *"P< 0.05 compared
with pre-injection control discharge; + R>0.05 com¬
pared with adenosine 100 pg.
(see Figures 1 and 2). so responses to the low doses of
adenosine were studied in five cats (results not
shown) and compared with responses to injections of
Locke solution (0.3 ml). There was no significant
difference (P> 0.05) between the responses to
adenosine and Locke solution in these experiments.
Data obtained from ten experiments were aver¬
aged over 5 s periods for 30 s after the injection,
pooled and plotted against time (Figure 2). This
quantitative evidence confirmed that the increase in
both amplitude and duration of the discharge were
dose-related. The peak of the discharge, averaged
over 5 s periods, for all doses (0.1-100 pg) occurred
between 5 and 10 s after the injections, and that
caused by 0.1 pg was not significantly different from
that caused by the highest dose studied, 100 pg
(P> 0.05, n= 8 pairs). Injections of Locke solution
were also made in these experiments and the results
obtained are summarized in Figure 2. They confirm
the transient inhibitory effect of Locke solution illus¬
trated in Figure 1. A significant decrease in discharge
occurred during the first 5 s following the injection
(P<0.05, n = 10, compared with the pre-injection
averaged discharge). This was less marked and not
statistically significant in the next 5 s (P> 0.05), and
thereafter discharge returned to the pre-injection
control levels.
Results from four experiments in which both aver¬
age discharge and maximum discharge, expressed as
ct/s, were obtained for different doses of adenosine
are compared and summarized in Table 1. The aver¬
age spontaneous chemoreceptor discharge was de¬
termined in the 15 s pre-injection control period
immediately preceding each injection and in the 15 s
post-control period commencing 45 s after the injec¬
tions. Responses to adenosine were evaluated by
determining the average discharge in the period dur¬
ing which discharge was increased above control
frequency. Apart from increasing the average dis¬
charge, adenosine also increased the maximum dis¬
charge frequency. This latter increase, however, was
not so marked as that averaged over the whole
period, showing that the overall increase in discharge
caused by adenosine resulted from a sustained in¬
crease throughout the response rather than from a
sudden transient increase, such as occurs with acetyl¬
choline (ACh) (cf. McQueen, 1977). The duration of
the adenosine response was dose-dependent, and the
delay to onset of the response was inversely related to
dose.
The effects obtained were not related to changes in
systemic blood pressure since adenosine in the doses
studied (0.001 to 100 pg) did not cause any consistent
or substantial changes in arterial blood pressure, as
can be seen from Figure 2. There were no changes in
arterial blood gas tensions or pH following administ¬
ration of adenosine.
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Theophylline (lmg) was given as an intracarotid
(i.e.) injection in five cats and caused a decrease in
spontaneous chemoreceptor discharge, an effect
which lasted for about 30 s. The integrated response
(AZx) showed that the depression was significantly
greater (P<0.05) than that caused by injecting
Locke solution. Although theophylline transiently
decreased spontaneous chemoreceptor discharge
(Figure 3), it did not prevent the excitatory action of
adenosine, and as can be seen in Figure 4, the log
dose-response curve to adenosine was shifted up¬
wards and to the left which is indicative of an increase
in the responses after theophylline; the response to
adenosine 100 pg was statistically significantly grea¬
ter after theophylline than it was before (P<0.05,
n= 4).
Injections of lower doses of theophylline
(100-200 pg) did not cause any significant effect on
the spontaneous discharge (P> 0.05, n= 3 pairs),
and the excitatory effect of adenosine (1-100 pg)
was unaltered by these doses (P> 0.05, n= 3 pairs).
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Figure 3 Effect on spontaneous chemoreceptor dis¬
charge of injecting theophylline 1 mg i.e. (heavy line,
) compared with that of injecting Locke solution
(0.3 ml) (thin line, ). Discharge was averaged over
10 s periods following the injection. *P<0.05, n— 5
pairs. The upper panel shows the effect on arterial blood
pressure of injecting (arrow) 1 mg of theophylline in one
experiment.













Figure 4 Dose-response data for adenosine obtained
before (•) and after (■) theophylline (1 mg i.e.) in four
experiments. Doses (pg i.e.) are plotted on a logio scale
and chemoreceptor responses expressed as the mean
A Zx for the four experiments; vertical lines show
s.e.mean. AZx was calculated as the response during the
30s following the injections. (A£x = Ix-x.t, where
Z x is the number of action potentials counted during the
response of duration ts, a 'response' being defined as
lasting from the first substantial change from back¬
ground discharge frequency (x ct/s) until return to back¬
ground level.) Lines were fitted to the data by the
mfethod of least squares. Averaged values ± s.e.mean
(ct/s) for the pre-injection (15 s) control periods are as
follows: adenosine lug 4.5 ±1.0 before theophylline,
6.5 ± 1.4 after theophylline; adenosine lOpg 5.5± 1.4
before, 7.8 ± 1.7 after, adenosine 50pg3.5 ±1.1 before,
5.2±1.4 after; adenosine lOOpg 3.9±1.7 before,
5.1 ±2.0 after. *P<0.05.
and the effect of adenosine (1-100 pg) tested before
and after the injection. A transient depressant effect
similar to that seen with theophylline was observed,
and the excitatory action of adenosine was also undi¬
minished after aminophylline.
Neither theophylline (Figure 3) nor aminophylline
caused any marked changes in blood pressure and the
highest dose of adenosine did not alter arterial blood
pressure when injected after theophylline.
Naloxone
Four experiments were performed to investigate the
influence of naloxone (0.4 mg i.e.) on chemoreceptor
responses to adenosine and morphine. The
adenosine results were pooled and are shown in
Figure 5. No statistically significant difference was
detected between the pre- and post-naloxone re¬
sponse (P> 0.05). In two of these experiments mor¬
phine (10- 100 pg i.e.) was injected before and after
naloxone (Figure 5). A chemodepressant effect of
morphine was obtained in accordance with previous
observations (McQueen & Ribeiro, 1980). This de¬
pressant effect of morphine was converted to an
excitatory one by naloxone.
Infusions of adenosine
Adenosine, infused at a rate of 50 pg/min for 2 min in
two cats, caused a sustained increase in chemorecep¬
tor discharge, which returned to pre-infusion control
levels within 30 s of stopping the infusion (Figure 6).
The peak response was significantly different from
the control, whether this was taken as the pre-
infusion discharge or the discharge averaged during
an infusion of a Locke solution (O.lml/min). The
infusion of Locke solution did not affect spontaneous
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Figure 5 (a) Dose-response data for adenosine ob¬
tained before (•) and after (■) administration of nalox¬
one (400 pg i.e.) in four experiments. Doses (pg i.e.) are
plotted on a logio scale and chemoreceptor responses
expressed as the mean AZx for the four experiments;
vertical lines show s.e.mean. AZx was calculated as the
response during the 30 s following the injections. For
details see Figure 4. Lines were fitted to the data by the
method of least squares. Averaged values (ct/s) for the
pre-injection (15s) periods±s.e.mean were as follows:
adenosine 1 pg 4.5 ± 2.1 before naloxone. 5.7 ± 2.6 after
naloxone; adenosine lOpg 4.2±1.4 before, 6.7±1.5
after; adenosine 100 pg 6.5 ± 1.3 before, 5.0 ± 1.9 after,
(b) Effects of morphine (lOOpg i.e.) on chemoreceptor
discharge before (i) and after (ii) naloxone (400 pg i.e.)
in one experiment. Discharge was averaged over 10 s
periods following the injection.




















Figure 6 Pooled data from 6 infusions of adenosine
(50 ng/min) in 2 cats showing the effect on spontaneous
chemoreceptor discharge. The broken line represents
the typical discharge during an infusion of Locke solu¬
tion (0.1 ml/min). The upper panel shows a blood pres¬
sure trace recorded during one of the adenosine infu¬
sions. * P <0.05.
associated with changes in arterial blood pressure, as
can be seen from Figure 6.
Discussion
The results show that the predominant effect of
injecting or infusing adenosine close-arterial to the
cat carotid chemoreceptors is an increase in spon¬
taneous discharge frequency.
In many preparations exogenous adenosine de¬
creases the release of neurotransmitters (e.g. ACh
(Ginsborg & Hirst, 1972; Ribeiro & Walker, 1975;
Vizi & Knoll, 1976; Gustafsson. Hedqvist, Fredholm
& Lundgren, 1978); noradrenaline (Hedqvist &
Fredholm, 1976; Verhaeghe, Vanhoutte &
Shepherd. 1977; Wakade & Wakade, 1978),
dopamine (Michaelis, Michaelis & Myers, 1979) y-
aminobutyric acid (Hollins & Stone, 1978)). If
adenosine exerts a similar action in the carotid body,
its excitatory effect could be interpreted as being the
consequence of decreased release of an inhibitory
transmitter and/or modulator. Dopamine (Chioc-
chio, Biscardi & Tramezzani, 1966; Zapata, Hess,
Bliss & Eyzaguirre, 1969) and enkephalins (Lund-
berg. Hokfelt. Fahrenkrug, Nilsson & Terenius,
1979; Wharton, Polak. Pearse, McGregor, Bryant,
Bloom, Emson, Bisgard & Will, 1980) appear to be
present in the cat carotid body and both exogenous
dopamine (Zapata, 1975; Docherty & McQueen,
1978) and the enkephalins (McQueen & Ribeiro,
1980; 1981a; McQueen, 1981) depress spontaneous
chemoreceptor activity. Osborne & Butler (1975)
suggested that tonically released dopamine may sup¬
press chemoreceptor discharge and although evi¬
dence which is not in agreement with their hypothesis
has been obtained (e.g. Docherty & McQueen.
1978), the present results could be explained in terms
of adenosine inhibiting the release of dopamine, or
some other substance which is tonically active in
inhibiting discharge (? enkephalins).
However, it has also been found that adenosine can
excite nerve cells. For example. Siggins, Gruol, Pad-
jen & Forman (1977) showed that adenosine de¬
polarizes neurones of explanted amphibian sym¬
pathetic ganglia, and Bleehen & Keele (1977) de¬
scribed algogenic actions of adenosine on the human
blister base. It appears that adenosine sensitizes the
carotid chemoreceptors to ACh and dopamine (Mc¬
Queen & Ribeiro, 1981b) which might be construed
as evidence that adenosine acts directly on the post¬
synaptic component of the carotid body chemosen-
sory synapse, i.e. on the sensory nerve ending. An
adenylate cyclase-cyclic AMP system is apparently
located in the sinus nerve endings (Fitzgerald, Rogus
& Dehghani, 1977) and it may be that adenosine
interacts with this in a manner similar to that de¬
scribed for the brain (e.g. Davies, Taylor, Gregson &
Quinn, 1980). Further investigation is needed to
explore this possibility.
Theophylline appears unable to prevent activation
of P2-purinoceptors. These receptors, as so far de¬
scribed, seem to be localized post-junctionallv (see
Burnstock, 1978). De Mey, Burnstock & Vanhoutte
(1979) found that in the canine saphenous vein,
theophylline antagonizes the inhibitory effect of ATP
on neurogenic responses but not its direct contractile
effect. According to these authors this suggests the
presence of both inhibitory presynaptic (Pt) and
excitatory postsynaptic (P2) receptors. In the present
study the excitatory effect of adenosine was unaf¬
fected by low doses of theophylline (0.1-0.2 mg) but
potentiated by a slightly higher dose (1 mg), a finding
that is compatible with a P2-excitatory post¬
junctional effect. However, the potentiation might
also have resulted from theophylline antagonizing a
chemodepressant component of the adenosine re¬
sponse, which might normally be masked by the
excitatory component, or from mechanisms having in
common the ability to increase the cyclic AMP con¬
centration (e.g. theophylline by inhibiting phos¬
phodiesterases, and adenosine by activating the
adenylate cyclase).
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It has also been proposed that the inhibitory action
of morphine may involve the release of adenosine as
an intermediary (Sawynok & Jhamandas. 1976;
Stone & Perkins, 1979), and it has been shown that
morphine and enkephalins can inhibit spontaneous
carotid chemosensory discharge in the cat (McQueen
& Ribeiro, 1980; 1981a; McQueen. 1981). How¬
ever, naloxone reduces the inhibitory effect of mor¬
phine without reducing the excitatory response to
adenosine, so the effects of adenosine do not appear
to result from actions on naloxone-sensitive opiate
receptors in the carotid body.
Adenosine can cause vasodilatation (see Berne,
Foley, Watkinson, Miller. Winn & Rubio, 1979) and
we cannot, therefore, preclude the possibility that
adenosine was changing blood flow in the carotid
body and thereby, perhaps, altering chemoreceptor
discharge, even though it had little overall effect on
the systemic blood pressure. However, other vas¬
odilators (e.g. sodium nitrite, sodium nitroprusside:
Docherty, 1980) tend to cause a delayed decrease in
discharge, which is the opposite of the main effect
obtained following adenosine injections in the pres¬
ent experiments. We consider it unlikely that vascu¬
lar effects are responsible for the greater part of the
response to adenosine, but would wish to investigate
this with in vitro carotid body studies.
Adenosine is released into the circulation by a
number of physiological and pathophysiological pro¬
cesses (e.g. ischaemia; see Winn. Rubio & Berne.
1979), and a correlation between adenosine concent¬
ration and oxygen supply in rat brain has been sug¬
gested (Rubio, Berne, Bockman & Curnish. 1975).
In the present study, low doses of adenosine modified
chemoreceptor discharge and it seems reasonable to
speculate that adenosine might influence events tak¬
ing place in the carotid body, perhaps by modulating
any putative transmitter(s) which may be released
within the carotid body complex, and/or by directly
activating sensory nerve endings.
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